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1 Summary 
Hematopoietic Stem Cells (HSCs) reside in specialized bone marrow (BM) 
microenvironments, which govern their cell fate. During homeostasis, some HSCs within 
this niche are kept dormant, preserving long-term self-renewal potential, while others self-
renew to replenish the hematopoietic system. The stem cell niche mediates signals 
inducing quiescence, proliferation or differentiation in HSCs. While HSCs themselves are 
well defined, the composition of the niche is still unclear. Various cell types like 
mesenchymal stem cells (MSCs), sinusoidal endothelial cells, osteoblasts and adipocytes 
have been implicated in homing, mobilization and maintenance of HSCs. The transcription 
factor Ebf2 is expressed in mesenchymal progenitors with osteoblastic and adipocytic 
differentiation potential. Noteworthy, HSCs localize to Ebf2-expressing cells in the bone 
marrow and deletion of Ebf2 in mice results in decreased frequencies of HSCs. 
 
In the present study, the contribution of individual mesenchymal cell lineages in Ebf2-
mediated niche function for HSCs was defined. Therefore, Ebf2 conditional knockout mice 
were generated and crossed with MSC (PrxCre), adipocyte (AP2Cre) and osteoblast (OsxCre) 
specific Cre lines. The results in this thesis confirm an important role for Ebf2 in HSC 
homeostasis, and more specifically that this potential resides in stromal cells with 
osteoblastic differentiation potential. A DNA microarray analysis of Ebf2-expressing cells 
revealed that genes involved in homing and proliferation of HSCs are downregulated in 
Ebf2-deficient cells, partly explaining the observed phenotype.  
In the thymus, we found Ebf2 expressed by mature mTECs and MTS-15+ fibroblasts, 
which are implicated in a functional microenvironment for lymphoid progenitors. 
Interestingly, we detected a significant reduction of CD4+ T cells in Ebf2-deficient mice. 
However, this phenotype was not detectable post-transplantation of Ebf2-/- thymic lobes 
under the kidney capsule of wild type mice. Therefore, we speculate that the loss of Ebf2 
in bone marrow stromal cells causes hematopoietic alterations at the level of a bone 
marrow derived early T cell progenitor.  
To study the role of Ebf2 in malignant hematopoiesis, human acute lymphocytic leukemia 
(ALL) and chronic lymphocytic leukemia (CLL) cells were co-cultured on feeder cells 
deficient for Ebf2 or ectopically expressing Ebf2. While some CLL patient samples showed 
higher survival rates and cell numbers on Ebf2-expressing feeders, no differences were 
observed for ALL cells. However, ALL cells cultured on Ebf2-expressing feeder layers 
reconstituted leukemias with the same frequency as non-cultured cells, providing evidence 
that Ebf2-expressing niche cells supported the survival of cancer stem cells in vitro. 
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Zusammenfassung 
Hämatopoetische Stammzellen (HSC) befinden sich im Knochenmark in speziellen 
Nischen, welche ihre biologische Aktivität regulieren. Bei Homöostase befindet sich ein 
Teil der Stammzellpopulation in einer regenerativen Ruhephase. Dadurch bleibt langfristig 
das Potential, selbsterneuernde Teilungen zu durchlaufen, erhalten. Andere Stammzellen 
hingegen proliferieren und differenzieren in spezialisierte Zellen des Blutes. Reguliert 
werden diese Prozesse nicht ausschließlich in Stammzellen selbst, sondern auch von 
ihrer Stammzellnische. Während die Organisationsstruktur hämatopoetischer Zellen gut 
verstanden ist, ist die zelluläre und molekulare Zusammensetzung ihrer Nische 
größtenteils unbekannt. Man geht heute davon aus, dass der Erhalt bzw. die Mobilisierung 
und Rückkehr von Stammzellen aus dem Knochenmark von mesenchymalen 
Stammzellen (MSCs), spezialisierten Endothelzellen, Osteoblasten und Adipozyten 
reguliert ist. Der Transkriptionsfaktor Ebf2 wird von einer Population mesenchymaler 
Vorläuferzellen, unreifen Osteoblasten und Adipozyten exprimiert. Interessanterweise 
findet man HSCs in unmittelbarer Nähe dieser Zellen und die gezielte Deletion von Ebf2 in 
Mäusen führt zum Verlust von HSCs im Knochenmark. 
Das Ziel dieser Arbeit besteht darin, die Beiträge verschiedener stromaler Zelltypen für die 
von Ebf2-vermittelte Nische für HSCs zu untersuchen. Dafür wurde ein Mausmodell mit 
konditional inaktivierbarem Ebf2-Gen hergestellt und mit mesenchymalen Stammzell-, 
Osteoblasten- und Adipozyten-spezifischen Cre-Linien verpaart. Wie sich herausstellte, 
führt die gezielte Inaktivierung von Ebf2 in Osteoblasten zum Verlust von HSCs im 
Knochenmark. Interessanterweise wurden in einer DNA-CHIP-Technologie Analyse Gene, 
welche für die Funktion von Stammzellen wichtig sind, in Ebf2-defizienten stromalen 
Zellen weniger stark exprimiert gefunden. 
Im Thymusstroma fanden wir Ebf2 von mTECs und MTS15+ Fibroblasten exprimiert. 
MTS15+ Zellen bilden im Thymus vermutlich eine Nische für unreife T-Zellvorläufer und 
die Deletion von Ebf2 in Mäusen resultiert in einer 40%igen Reduktion von CD4+ T Zellen 
im Thymus. Überraschenderweise konnte der Phänotyp nach Transplantation von Ebf2-/- 
Thymuslappen unter die Nierenkapsel von Wildtyp-Mäusen nicht mehr detektiert werden. 
Wir vermuten daher, dass der Verlust von Ebf2 in stromalen Zellen des Knochenmarks 
Veränderungen in knochenmarksständigen T Zell Vorläuferzellen zur Folge hat und dieser 
Defekt sich auch auf die T Zell Entwicklung im Thymus auswirkt. 
Zur Untersuchung der Funktion von Ebf2 in der malignen Hämatopoese wurden humane 
ALL und CLL Zellen mit Ebf2-defizienten und Ebf2 überexprimierenden adhärenten Zellen 
kokultiviert. Einige CLL Patienten Proben reagierten auf Ebf2 mit verbessertem 
Zellüberleben, während ALL Zellen keine Reaktion zeigten. Interessanterweise 
rekonstituierten nach Kokultur mit Ebf2-exprimierenden Zellen transplantierte ALL Zellen 
Leukämien mit gleicher Frequenz wie nicht kultivierte ALL Zellen. Dies weist darauf hin, 
dass Ebf2 Leukämiestammzellen in vitro unterstützt. 
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2 Introduction 
2.1 Hematopoiesis 
The investigation of the hematopoietic system and stem cell biology in general 
began in the 1950s when scientists tried to understand the radiation syndrome. 
Many victims that had survived the catastrophes of Hiroshima and Nagasaki died 
within two weeks after, without any visible signs of injury (USSBS, 1945). To 
understand the cause of the radiation syndrome, scientists irradiated mice and 
discovered that when they protected some skeletal elements with a lead shield the 
mice would survive even higher dose of radiation (Jacobson et al., 1949; Lorenz et 
al., 1951). Soon after, transplantation experiments with bone marrow were 
performed. When bone marrow from a wild type animal was transplanted into an 
animal that had received a lethal dose of radiation, the animal survived (Jacobson, 
1952). 
When lower doses of radiation were applied it became clear that the bone marrow, 
or the blood forming system is the most susceptible organ to radiation and the first 
to be destroyed by a certain (lethal) dosage. To determine how many bone marrow 
cells are required to rescue a lethally irradiated mouse, the animals were 
transplanted with different numbers of bone marrow cells (Makinodan, 1956; 
Nowell et al., 1956). Interestingly, animals that had received relatively low cell 
numbers and had died during the experiment displayed white cell bumps on their 
spleens. The number of bumps correlated with the number of bone marrow cells 
the animals had received. Surprisingly, genetic analyses revealed that the cells 
within a bump were of clonal origin. The existence of a blood forming stem cell 
was functionally proven by transplantation of a single bump of clonal origin into a 
lethally irradiated recipient when Becker and colleagues could show that all 
hematopoietic cells of the surviving recipient are genetically identical to those of 
the bump originally transplanted (Becker et al., 1963; Juraskova and Tkadlecek, 
1965; Siminovitch et al., 1963). 
The isolation of hematopoietic stem cells (HSCs) on a single cell level took almost 
another thirty years and required the development of the hybridoma technology 
(Kohler and Milstein, 1975) and fluorescence activated cell sorting (FACS; Hulett 
et al., 1969). Monoclonal antibodies against membrane bound proteins were 
generated and tested by FACS for their specificity to identify defined populations of 
hematopoietic cells (Bernard et al., 1984; Coffman and Weissman, 1981). These 
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were then characterized for their function and properties (Muller-Sieburg et al., 
1986; Whitlock and Witte, 1982). From the functional observations it took until 
1988 when Weissman and colleagues demonstrated they had identified a 
population highly enriched for HSCs. It requires only sixty of these cells to rescue 
lethally irradiated mice and these cells gave rise to all hematopoietic lineages for a 
lifetime (Spangrude et al., 1988). The isolation of a population enriched for human 
hematopoietic stem cells was reported five years later (Peault et al., 1993).  
2.2 The hematopoietic hierarchy 
From elaborate analysis of surface antigens, which characterize certain 
hematopoietic populations, and from functional capacities of these populations the 
hematopoietic hierarchy was deduced (Figure 1; Weissman, 2002). All blood and 
immune cells displayed can be stained with labeled antibodies and can be 
specifically isolated by FACS. The various effector cells on the lowest levels are 
fully differentiated and mediate specialized functions in the blood and immune 
system (Janeway, 2008). Cell types higher up in the hierarchy are immature 
progenitor cells, which can differentiate into the specialized cells mentioned 
before. These processes are regulated by intrinsic and extrinsic signals (Bain et 
al., 1994; Rieger et al., 2009). Of all cell types shown, only the long-term HSC (LT-
HSC) and the short term HSC (ST-HSC) are multipotent and can, upon certain 
signals, give rise to all other hematopoietic cells. The differentiaton between LT- 
and ST-HSCs is based on the finding that the lifespan of short-term HSCs is 
limited (Morrison et al., 1995b). Their capacity to form all cells within the hierarchy 
exhausts with time and their potential is gone about 4 months after transplantation 
(Morrison et al., 1995a). Although not shown yet, it is commonly assumed that only 
LT-HSCs have unlimited potential to undergo self-renewing divisions (Trumpp et 
al., 2010). A self-renewing division is defined as a cell division generating two 
daughter cells, on average, one of which will maintain the properties of the original 
cell. Thereby, the hematopoietic potential to generate billions of different blood 
cells every day can be maintained without exhaustion of the stem cell pool. 
Changes in stem cell properties are accompanied by changes in the displayed 
surface markers. Many studies have confirmed that long-term reconstitution 
potential of LT-HSCs is lost upon expression of CD34 in the mouse (Osawa et al., 
1996; Reya et al., 2001; Weissman et al., 2001). The limited self-renewal capacity 
in ST-HSCs is lost upon expression of Flt3 (Adolfsson et al., 2001), and when the 
multipotent progenitor (MPP) downregulates the expression of Sca1 (Stem cell 
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antigen 1; Uchida et al., 1996), it differentiates into a common myeloid progenitor 
(CMP; Figure 1). 
 
 
 
Figure 1: Hematopoiesis and bone marrow niche. Hematopoietic stem cells (HSC) 
give rise to mature blood cells and these processes are regulated by intrinsic and extrinsic 
factors in the bone marrow. Maturation of hematopoietic cells is accompanied by antigenic 
markers on their surface. These molecules are used for their isolation. HSCs reside in 
specialized microenvironments but the cellular composition remains undefined. HSCs 
localize to (1) osteoblasts at the inner bone surface, (2) endothelial cells of sinusoidal 
vessels and (3) mesenchymal stem cells (MSC) in the bone marrow. (Image was kindly 
provided by Terese Winslow) 
Since the first description of HSCs, which are negative for the Lineage markers of 
differentiated cells (Gr-1, Mac1, B220, CD4, CD8 and TER119), but express Sca1 
(stem cell antigen-1) and c-Kit (stem cell growth factor receptor), they were termed 
„KSL“ population (Lagasse et al., 2001). Researchers applied a lot of effort to 
identify additional ways to increase the frequency of LT-HSCs within the KSL 
population (Weissman, 2002; Wilson et al., 2008). It was demonstrated that upon 
single cell transplantation of the KSL population only one out of seven cells had 
long-term reconstitution potential (Wagers et al., 2002). To further purify this 
population alternative methods and new surface markers were discovered. 
Margaret Goodell established a method independent of expressed surface 
molecules. Upon incubation of whole bone marrow with Hoechst-dye every cell is 
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stained except for HSCs (Goodell et al., 1996). Due to the expression of unique 
ABC-transporters, HSCs can actively efflux the dye and remain unstained. Sean 
Morrison added the SLAM-family markers (CD48, CD150 and CD244) to increase 
the purity of HSCs (Kiel et al., 2005; Lin and Goodell, 2011). 
Although low numbers of LT-HSCs can be found in peripheral blood, spleen and 
thymus, data suggests that self-renewing divisions occur only in a specialized 
microenvironment, the hematopoietic stem cell niche (Lymperi et al., 2010; Seita 
and Weissman, 2010). Extramedullary hematopoiesis can sustain blood formation 
for up to months, but their potential exhausts over time and the stem cell pool 
depletes as shown by transplantation of splenic colonies (Schofield, 1978). 
2.3 The hematopoietic stem cell niche 
Hematopoietic cells depend on interaction with specialized stromal 
microenvironments. T cell development requires crosstalk with thymic stromal 
cells, which control their differentiation and proliferation (Pantelouris, 1968). 
Similarly, B cells cannot develop without interaction with stromal cells in the bone 
marrow (Nagasawa et al., 1996). Although claimed by Raymond Schofield 
(Schofield, 1978) already more than thirty years ago, the existence of a HSC niche 
has not been convincingly proven yet, mainly due to technical limitations (Lymperi 
et al., 2010). Within the following chapter, data will be discussed that provide 
strong evidence that the support of HSCs depends on different stromal cell types 
and the various cytokines produced by these niche cells.  
Upon injection of bone marrow cells from a donor into a congenic recipient, the 
transplanted cells can contribute to hematopoiesis. The degree of contribution, 
defined as chimerism, is an indicator for the level of engraftment. In 1987, 
Schofield and colleagues published that the level of chimerism depends on pre-
conditioning of the recipient (Massa et al., 1987). In this study, three experimental 
animal groups were injected eitherwise isopropyl methane sulfonate (IMS, 
randomly damages hematopoietic cells), or received busulfan (kills cycling 
hematopoietic cells) or  were irradiated (kills all hematopoietic cells) before they 
were transplanted with an equal number of reconstituting bone marrow cells. The 
degree of chimerism was measured for six months. Interestingly, IMS pre-
conditioned animals did not show any chimerism at all, while busulfan treated 
animals had a chimerism of 40-83% and the group of pre-irradiated recipients 
showed a chimerism ranging from 60-97%. They concluded that the transplanted 
HSCs need to engraft into a niche before they can actively contribute to 
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hematopoiesis. As niche space is limiting the niche is already occupied and 
without pre-conditioning the transplanted cells cannot engraft (Massa et al., 1987). 
Following the same concept, Li and colleagues were the first to show that 
osteoblastic cells in the bone marrow limit the number of HSCs. When they 
specifically deleted bone morphogenic protein receptor 1 (BMPR1) in bone marrow 
stromal cells, they found higher numbers of osteoblastic cells (Zhang et al., 2003). 
This led to increased bone formation rates and a reduction in marrow space and 
total cellularity. However, mice deleted for BMPR1 in bone marrow stromal cells 
showed a twofold increase in the frequency of LT-HSCs. The authors speculate 
that the deletion of BMPR1 in mesenchymal stem cells (MSCs) led to increased 
numbers of specialized spindle-shaped osteoblastic cells that express N-cadherin. 
Thereby, the niche size was extended, which resulted in increased HSC 
frequencies  (Zhang et al., 2003). 
In a different study, Scadden and colleagues generated a transgenic mouse strain 
overexpressing a constitutively active parathyroid-hormone receptor (PTH1R) in 
osteoblastic cells of the bone marrow (Calvi et al., 2003). They detected increased 
osteoblast activity, which resulted in increased bone formation and twofold higher 
KSL frequencies. Interestingly, hematopoietic progenitor populations were not 
increased, arguing that osteoblasts are specialized niche cells for HSCs (Calvi et 
al., 2003). 
Adipocytes are fat cells, specialized in the storage of energy, and are part of the 
bone marrow stroma. Their number increases with age and the amount of fat cells 
in the marrow inversely correlates with its hematopoietic activity. Although their 
function in hematopoiesis is only poorly understood, adipocytes are indicated to be 
negative regulators of hematopoiesis. The question whether adipocytes just fill up 
space in the marrow, or whether they actively contribute to hematopoietic 
regulation, was addressed by Daley and colleagues (Naveiras et al., 2009). When 
comparing mouse skeletal regions with differing adiposity, they found more stem 
and progenitor cells in regions with low adiposity (vertebrae of the thorax over 
vertebrae in the tail). These results were confirmed when transplanting wild type 
bone marrow into transgenic mice with inhibited adipogenesis. Overall, they found 
better engraftment and higher HSC frequencies in transgenic over control animals 
(Naveiras et al., 2009). However, the function of adipocytes and their contribution 
to hematopoiesis is poorly understood. 
Mesenchymal stem cells (MSCs) can give rise to various cell types found in bone 
marrow stroma, namely adipocytes, chrondrocytes, endothelial cells, osteoblasts 
and fibroblasts (Pittenger et al., 1999). Nestin positive cells display characteristics 
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of MSCs and are in direct cell-cell contact with HSCs (Mendez-Ferrer et al., 2010). 
In addition, they express cytokines important for their maintenance and regulation. 
The deletion of Nestin positive cells in transgenic animals resulted in rapid loss of 
HSCs. Furthermore, upon transplantation of labeled HSCs into irradiated 
recipients, the HSCs homed directly to Nestin positive cells in the bone marrow 
(Mendez-Ferrer et al., 2010). In summary, the bone marrow microenvironment for 
HSCs is made up by various stromal cell types regulating their homing, 
maintenance, number and activity (Figure 1; Mercier et al., 2012).  
While the previously cited studies demonstrated the importance of stromal cells in 
hematopoietic regulation by increase or ablation of these cells, the interaction of 
HSCs with their microenvironment has also been addressed on a molecular level. 
Osteoblasts produce molecules regulating major signaling pathways in 
hematopoietic cells. Through upregulation of parathyroid hormone 1 receptor 
(PTH1R) in osteoblasts, Notch signaling in HSCs can be induced, resulting in an 
increased stem cell pool (Calvi et al., 2003). Overexpression of the canonical Wnt 
inhibitor Dickkopf1 (Dkk1) in osteoblastic cells inhibited Wnt signaling in HSCs and 
resulted in increased proliferation and reduced reconstitution capacity of bone 
marrow cells in a transgenic mouse model (Fleming et al., 2008). Thrombopoietin 
(TPO) was identified as a molecule expressed by osteoblasts to regulate 
quiescence in HSCs. Quiescent HSCs express Mpl (TPO receptor) and localize to 
TPO-producing osteoblasts (Yoshihara et al., 2007). Upon inhibition of this 
signaling pathway, HSCs are released from their niche and the bone marrow in 
these animals can be engrafted without previous irradiation. Angiopoetin1 (Ang1) 
expressed by osteoblasts was identified as another molecule to induce quiescence 
in HSCs. Quiescent HSCs express the Ang1 receptor Tie-2 (TIE receptor tyrosine 
kinase 2) and localize to osteoblasts at the inner bone surface (Arai et al., 2004). 
Adiponectin, a growth factor expressed in adipocytes, was shown to induce 
proliferation in HSCs (express the adiponectin receptors 1 and 2). Interestingly, the 
immature state of HSCs was maintained (DiMascio et al., 2007). Although very 
difficult to study, varying oxygen levels are also implicated in HSC regulation and 
maintenance. Long-term HSCs have high levels of pimonidazole (PIM) indicating 
that these cells reside in hypoxic niches to preserve long-term self-renewal 
potential (Parmar et al., 2007; Simsek et al., 2010). High calcium levels are sensed 
via a calcium-receptor expressed by HSCs. Thereby, stem cells are retained in 
close proximity to osteoblasts at the inner bone surface (Adams et al., 2006).   
Two signaling molecules, which are of high relevance in terms of this thesis, will be 
discussed in a broader context now. Deletion of the chemokine stromal derived 
factor 1 (SDF-1) in mice results in prenatal death due to hematopoietic failure 
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(Nagasawa et al., 1996). The fetal liver is the primary organ of early hematopoiesis 
from E11.5-E12.5 until the first week after birth (Morrison et al., 1995a). 
Examination of fetal liver in SDF-1-/- mice showed normal levels of granulocytes 
and monocytes and fetal liver cells from these mice yielded normal numbers of 
colonies in colony forming assays (Nagasawa et al., 1996). However, the bone 
marrow cellularity in E17.5 SDF-1-/- mice is reduced and hematopoietic cells 
showed greatly reduced functionality in colony forming assays compared to wild 
type. SDF-1 is expressed in stromal cells of the bone marrow and although bone 
structures had formed normally, hematopoietic cells were almost absent. This 
indicates a function for SDF-1 during very early hematopoietic processes in the 
bone marrow (Nagasawa et al., 1996). Two years later, CXCR4 (C-X-C chemokine 
receptor type 4) deficient animals were reported to show the same phenotype as 
was observed in SDF-1-/- mice (Zou et al., 1998). CXCR4, which is expressed on 
HSCs, is the receptor for SDF-1 and 90% of wild type fetal liver cells were shown 
to migrate towards a SDF-1 gradient, while CXCR4-/- cells did not respond to the 
gradient (Zou et al., 1998). Finally, the interaction of CXCR4 and SDF-1 was 
shown to be responsible for the mobilization of HSCs to the peripheral blood upon 
G-CSF (granulocyte colony-stimulating factor) treatment (Petit et al., 2002). In 
human hematopoietic stem cell transplantation, the donor HSCs are mobilized and 
collected from the peripheral blood by administration of G-CSF. Lapidot and 
colleagues showed that this mobilization of HSCs from their niche is mediated by 
inactivation of SDF-1 due to cleavage by neutrophil elastase and cathepsin G 
secreted by neutrophils during G-CSF treatment (Petit et al., 2002). In summary, 
SDF-1 produced by bone marrow stromal cells is a strong chemoattractant for 
hematopoietic progenitor cells and mediates the switch from fetal liver to bone 
marrow based hematopoiesis. Moreover, inactivation of SDF-1 results in the 
mobilization of HSCs from the bone marrow to the peripheral blood.  
Matrix-metalloproteases are expressed by various stromal cells and shape the 
bone structure and morphology by remodeling the extracellular matrix (ECM; 
Kessenbrock et al., 2010). By release of membrane-bound chemokines like VEGF 
(vascular endothelial growth factor) they regulate angiogenesis and osteoclast 
activity in the bone marrow (Bergers et al., 2000; Engsig et al., 2000; Vu and 
Werb, 2000). Interestingly, matrix-metalloprotease-9 (MMP-9) deficient animals 
show no defects in hematopoiesis (Heissig et al., 2002). However, the authors 
show in the same study that when the bone marrow is challenged by 
administration of 5´Fluorouracil (5-FU, a pyrimidine analog that kills actively cycling 
cells), HSCs fail to repopulate and proliferate in their former niches and 72% of 
MMP-9-/- mice die while all control animals survive. When the levels of active 
MMP-9 were determined in supernatants of bone marrow from wild type animals 
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before and three days after 5-FU treatment, they were found elevated. The levels 
of soluble c-kit ligand (stem cell factor, SCF) were also found to be increased 
threefold in the same experiment. c-kit ligand is normally membrane bound 
(mKitL), but can be cleaved to soluble c-kit ligand (sKitL), which binds to c-Kit 
(stem cell growth factor receptor) expressed on HSCs. In an in vitro assay, the 
authors show that MMP-9 rapidly promoted sKitL release from mKitL expressing 
cells upon addition of MMP-9 to the cell culture medium. This release could be 
blocked by simultaneous addition of an MMP-9 inhibitor (Heissig et al., 2002). 
These data show that MMP-9 expressed by stromal cells is important to regulate 
the activity of HSC by releasing sKitL (SCF). 
2.4 EBF proteins 
2.4.1 Ebf protein family 
The protein family of Ebf (early B cell factor) transcription factors comprises four 
members, which are highly conserved amongst each other but also in evolution 
(Liberg et al., 2002). Via a zinc-finger motif within their DNA binding domain (DBD) 
they recognize regulatory DNA elements of genes and bind to these as homo- or 
heterodimers, thereby inducing or suppressing transcription (Dubois and Vincent, 
2001). Ebf1, the founding member of this protein family, plays an essential role in 
hematopoiesis. Deletion of Ebf1 in mice causes a complete block in B cell 
differentiation (Lin and Grosschedl, 1995). Since then, Ebf1 has been intensively 
studied and was shown to be part of huge regulatory network, important to 
determine and maintain the B cell state (Nutt and Kee, 2007). 
While Ebf1 is the only family member expressed in hematopoietic cells, a largely 
overlapping expression pattern of the different Ebfs is found in other tissues. Ebfs 
were shown to be simoultaneously expressed in neuronal cells (Corradi et al., 
2003; Malgaretti et al., 1997), olfactory epithelium (Wang et al., 1993), retina (Jin 
et al., 2010), adipocytes (Jimenez et al., 2007) and stromal cells of the bone 
marrow (Kieslinger et al., 2005). As all Ebf family members bind to the same DNA 
sequences, their activity in tissues with an overlapping expression pattern is 
probably redundant and a single deletion results in a hypomorphic phenotype. 
2.4.2 Ebf2 
Of the four Ebf proteins, most is known about the biological function of Ebf2, which 
displays more then 90% sequence homology with Ebf1 on protein level (Dubois 
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and Vincent, 2001). To study Ebf2 expression and function in the mouse, Ebf2-
LacZ animals were generated by gene targeting in murine ES cells (Corradi et al., 
2003). Ebf2-LacZ mice carry an in-frame insertion of the bacterial LacZ gene 
immediately downstream of the translation initiation site of the Ebf2 gene. At the 
same time, Ebf2-Gfp mice were generated in the laboratory of R. Reed applying 
the same strategy, but instead of the bacterial LacZ gene the animals carry an in-
frame insertion of the Gfp gene (Wang et al., 2004). Thereby, the reporter genes 
mentioned (LacZ and Gfp) are expressed under control of the endogenous Ebf2 
promotor while expression of the Ebf2 gene is disrupted.  
In the context of mouse neural development, Ebf2 regulates the migration of 
gonadotropin releasing hormone-synthesizing neurons (Corradi et al., 2003). The 
deletion of Ebf2 in these cells results in defects of the neuroendocrine axis leading 
to secondary hypogonadism. Due to the contribution of Ebf2 to neuronal 
development, Ebf2-LacZ-/- animals are mildly uncoordinated and walk with an 
unsteady and waddling gait. Furthermore, Ebf2-LacZ-/- animals exhibit a 
hunchback and show a strong reduction (>50%) in body weight (Corradi et al., 
2003; Croci et al., 2006). Interestingly, Ebf2 is abundantly transcribed in 
adipocytes and carries the potential to drive adipogenesis (Jimenez et al., 2007). 
However, a differentiation-block of adipocytes in Ebf2-LacZ mice was not reported. 
In the bone marrow, Ebf2 is expressed by a mixed population of stromal cells 
required for bone homeostasis (Kieslinger et al., 2005). Bones of Ebf2-LacZ-/- 
animals are reduced in size, mass and firmness, although bone formation rates 
and morphology are normal. Ebf2-expressing stromal cells are regulators of 
osteoclastogenesis and maintain bone homeostasis by acting upstream of RANKL 
signaling. Loss of Ebf2 results in increased osteoclast activity, which causes an 
osteopenia phenotype in young animals. Ebf2-expressing bone marrow stromal 
cells express relatively high levels of Runx2 and low levels of Sox9, alkaline 
phosphatase and bone sialoprotein (Kieslinger et al., 2005). Runx2 has been 
shown to be an essential transcription factor for the differentiation and maturation 
of osteoblasts from a mesenchymal progenitor (Komori et al., 1997). Alkaline 
phosphatase and bone sialoprotein are important for bone formation and are found 
to be expressed in mature osteoblasts, while Sox9 is required for determination of 
the chondrogenic cell lineage (Eames et al., 2004; Long, 2012). Noteworthy, Ebf2 
is not expressed in chondrocytes (Kieslinger et al., 2005). Therefore, it was 
concluded that Ebf2 is expressed in a bipotent progenitor with osteoblastic and 
chondrocytic potential. However, due to the abundant levels of Runx2 transcript 
the population was termed Immature Ebf2-expressing Osteoblasts (IEOs) 
(Kieslinger et al., 2010).  
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Ebf2-LacZ-/- animals show a strong reduction in the total cellularity of 
hematopoietic organs (bone marrow, spleen and thymus, Kieslinger et al., 2010). 
Noteworthy, Ebf2 is expressed in stromal cells of these organs, but not in 
hematopoietic cells. Bone marrow cells from Ebf2-LacZ-/- animals have greatly 
reduced potential to form colonies in methylcellulose and lymphoid lineages were 
found to be more severely affected than myeloid cells. More specifically, the 
frequency of hematopoietic stem cells is reduced two- to fourfold (Kieslinger et al., 
2010). This defect is cell nonautonomus because upon transplantation of Ebf2-
LacZ-/- bone marrow into irradiated wild type recipients the observed hematopoietic 
defects are gone. Furthermore, Ebf2-expressing bone marrow stromal cells can 
support HSCs in vitro in an Ebf2-dependent manner. Therefore, IEO cells 
represent hematopoietic niche cells that mediate stem cell homeostasis in a cell-
nonautonomous manner. Altogether, this complex phenotype results in premature 
death of Ebf2-deficient animals. We routinely find dead pups in litters from Ebf2-
LacZ heterozygous crossings and Ebf2-deficient survivors die roughly three to six 
weeks after birth for unknown reason.  
2.5 Mesenchymal Cre lines 
While signaling pathways involved in HSC homeostasis have been studied 
intensively, the role of transcription factors in this process remains relatively 
undefined (Lymperi et al., 2010). IEO cells represent a mixed population of stromal 
cells, which support HSCs (Kieslinger et al., 2010). However, their contribution at 
the cellular level is still unclear. To address this question within the course of this 
study, mice with a conditional Ebf2 allele shall be generated based on the Cre-
LoxP system. In 1988, Sauer and Henderson published to have site-specifically 
recombined DNA sequences in mammalian cells using Cre recombinase isolated 
from the bacteriophage P1 (Sauer and Henderson, 1988). Cre is a DNA 
recombinase that binds to 34 bp long LoxP sequences and recombines them while 
DNA elements in between are excised, leaving one LoxP sequence behind. The 
Flp-Frt system functions in an analogous way, however Frt sites are recombined 
by Flp recombinase originally isolated from S. cerevisiae (Chen and Rice, 2003). 
In 1993, Rajewsky was the first to report successful transfer of the Cre-LoxP 
system to mice studying DNA polymerase beta in T cells (Gu et al., 1993). A 
complete deletion of that gene resulted in a lethal phenotype, making it impossible 
to study the protein function in T cells. Therefore, mice carrying a floxed DNA 
polymerase beta allele were combined with a mouse strain where Cre is 
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expressed under control of a T cell specific promotor. Thus, deletion specifically 
took place in T cells only (Gu et al., 1993). 
Within the course of this study, mice with a conditional allele of Ebf2 shall be 
generated and combined with appropriate Cre lines to delete Ebf2 in certain Ebf2-
expressing stromal cell lineages. Thereby, the contribution of these lineages in 
Ebf2-mediated niche function for HSC homeostasis can be defined in vivo (Figure 
2). 
 
 
 
Figure 2: Schematic representation of stromal cell lineages expressing Ebf2. 
Differentiation scheme of multipotent MSCs maturating into specialized stromal lineages. 
Stages when Ebf2 is expressed are indicated. Dashed lines indicate timepoints when Ebf2 
expression is disrupted due to Cre expression using the Cre lines shown (AP2Cre, OsxCre, 
PrxCre). 
Ebf2 is expressed by MSCs, which give rise to osteoblasts, chondrocytes and 
adipocytes (Pittenger et al., 1999). Paired related homeobox protein 1 (Prx) has 
been shown to be expressed in MSCs (Martin et al., 1995). Prx-/- animals show 
defects in skeletogenesis, involving loss or malformation of craniofacial, limb and 
vertebral skeletal structures. PrxCre transgenic animals express Cre recombinase 
under control of Prx-derived regulatory elements (Logan et al., 2002) and have 
been successfully used to study skeletal development (Kimura et al., 2010; Seo 
and Serra, 2007). 
IEO cells can be differentiated into adipocytes in vitro (Kieslinger et al., 2005). To 
elucidate the function of Ebf2-expressing adipocytes in HSC homeostasis, Ebf2fl/fl 
animals shall be crossed with an adipocyte specific Cre line. Adipocyte protein 2 
(AP2) is a carrier for fatty acids and is expressed in brown and white fat tissue 
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(Hotamisligil et al., 1996). AP2Cre transgenic mice express Cre recombinase under 
control of the 5.4 kb promotor region of the AP2 gene  and have been successfully 
used in many studies to generate adipocyte specific deletions (He et al., 2003; 
Polak et al., 2008; Sabio et al., 2008). 
The differentiation of mesenchymal stem cells into an osteoblast is regulated by 
consecutive expression of transcription factors (Long, 2012). The initial 
differentiation of MSCs into an osteo-chondro progenitor is driven by the 
transcription factor Runx2 (Komori et al., 1997). Terminal differentiation of this 
bipotent progenitor into the osteoblastic lineage is mediated by the transcription 
factor Osterix (Osx; Nakashima et al., 2002). OsxCre transgenic mice express Cre 
recombinase under control of the osterix promotor, which is active at very early 
stages of osteoblast differentiation (Rodda and McMahon, 2006). 
2.6 T cell development in the thymus 
Unlike other hematopoietic lineage cells, T cells develop and mature in a 
specialized organ, the thymus. The importance of this organ came to light when 
Grist and colleagues in 1962 discovered the nude mouse (these animals lack hair 
and a thymus; Pantelouris, 1968). A random mutation had led to the disruption of 
the Forkhead box protein N1 (FOXN1) gene, which is essential to drive 
differentiation of mesenchymal cells into thymic epithelium (Nehls et al., 1994). 
This process is crucial for proper formation of the organ (Bleul et al., 2006). Nude 
mice lacked T cell dependent immunity like rejection of a transplant or killing of 
virus-infected cells (Janeway, 2008). A similar phenotype was observed, when the 
thymus from young wild type mice was dissected within twenty-four hours after 
birth. Finally, the phenotype could be rescued by transplantation of thymic stromal 
cells into nude mice. These early experiments clearly demonstrated the necessity 
of thymic stromal cells for T cell dependent immunity (Janeway, 2008). 
Since then, the architecture of this organ and the function of different epithelial 
cells therein have been intensively studied, creating the basis for a better 
understanding of T cell development (Klein, 2009). The thymus is a highly 
vascularized organ with an outer cortex and an inner medulla. Thymic epithelial 
cells comprise cortical epithelial cells (cTECs) and medullary epithelial cells 
(mTECs), which are located in the cortex and the medulla, respectively 
(Takahama, 2006). Both are derived from a common thymic epithelial progenitor 
and are important for early and late stages of T cell development (Bleul et al., 
2006; Rossi et al., 2006). 
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In the early stages of T cell development, lymphoid progenitors, which are double 
negative for CD4 and CD8 (DN), migrate through the cortex where they rearrange 
their T cell receptor (TCR) gene segments variable (V), diversity (D) and joining 
(J). Millions of different T cell receptors are generated during these processes, 
ensuring recognition of any foreign antigen (Janeway, 2008). The success of an in-
frame V, D, J gene rearrangement to form a functional TCR is then controlled by 
cTECs (Klein, 2009). Promoted by Notch-signals and signals from the IL-7 
pathway, which are mediated by cTECs, the CD4+ CD8+ double positive (DP) T 
cells are stimulated to interact with major histocompatibility complex (MHC) 
molecules expressed on cTECs (Peschon et al., 1994; Sambandam et al., 2005). 
Only thymocytes, that have generated a TCR that can interact with MHCI or MHCII 
molecules within a certain window of affinity will receive a survival signal (Starr et 
al., 2003). Without this signal they die, while survivors undergo massive 
proliferation (Rodewald et al., 1997; Staal et al., 2004). T cells interacting with 
MHCI become CD8+ single positive (SP) T cells, and those interacting with MHCII 
become CD4+ (SP) T cells (Anderson et al., 1994). 
The random nature of T cell receptor gene segment rearrangement bears a high 
risk that T cells may recognize own antigens and become self-reactive, leading to 
autoimmunity (Wing and Sakaguchi, 2010). To test for self-tolerance, positively 
selected T cells migrate from the cortex into the medulla, the inner region of the 
thymus (Klein, 2009). In the medulla, their unique TCR is tested regarding its 
tolerance towards self antigens (Derbinski et al., 2001). mTECs have the 
extraordinary ability to express several thousands of transcripts, which are 
normally restricted to specialized tissues. This phenomenon, described as 
promiscuous gene expression mainly depends on the transcription factor 
autoimmune regulator (AIRE; Anderson et al., 2002). By this mechanism, mTECs 
can ideally load the proteome on MHC molecules and present it to T cells. Any T 
cell that interacts with a presented antigen beyond a certain affinity threshold will 
be negatively selected (Starr et al., 2003). Thereby, mTECs ensure the tolerance 
of T cells to any self antigen they encounter in the periphery (Klein et al., 2009). 
After the process of negative selection mature T cells express G-protein receptor 
shingosine-1-phosphate receptor (S1P1), which is required for their egress from 
the thymus into the bloodstream (Matloubian et al., 2004). 
While the role and function of epithelial cells in the thymus is relatively well 
understood, much less is known about thymic endothelial cells and thymic 
fibroblasts (Takahama, 2006). These cells provide extracellular matrix 
components, which are essential for the maturation of early T cell progenitors in 
the thymus (Anderson et al., 1997; Rezzani et al., 2008). In another study, 
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embryonic mesenchyme was shown to produce Fibroblast growth factors (FGFs), 
which are essential for cTEC proliferation (Jenkinson et al., 2003). In mice, FGF-7 
was shown to be dispensable for T cell development, but to play an important role 
during thymic regeneration in irradiation and chemotherapy models (Alpdogan et 
al., 2006; van den Brink et al., 2004). Quite recently, a distinct population of thymic 
fibroblasts marked by the expression of the surface antigen MTS15+ was identified 
(Gray et al., 2007). Interestingly, these cells localize to the blood/thymus barrier 
and express FGFs and various cytokines (IL-7, SCF and SDF-1) indicating an 
important functional role in the complex interplay between thymocytes, epithelial 
cells and fibroblasts (Gray et al., 2007). 
2.7 Cancer 
While in 1900 the global average lifespan was just 31, it had increased to 48 years 
by mid-20th century and rose to 66 years in 2005. By 2030 the average life 
expectancy at birth will be around 85 years for the populations of the Western 
world (WHO, 2006). These dramatic improvements are mainly due to better 
nutrition and great advancements in control and prevention of infectious diseases 
(vaccination and antibiotics; Buchman et al., 2008). Beyond question, cancer is a 
genetic disease and the risk to develop a cancerous disease increases with age 
(Dunn, 2012). Therefore, the requirements to improve cancer treatment are vital. 
During treatment of leukemia and solid tumors, many patients go into remission 
but have a relapse with the same symptoms after a certain time (DeVita and 
Schein, 1973). This observation led scientists to postulate the Cancer Stem Cells 
(CSC) hypothesis (Bonnet and Dick, 1997; Reya et al., 2001; Visvader and 
Lindeman, 2008). By definition these cells have properties of normal stem cells, 
meaning they can infinitely sustain tumor growth (self-renewing divisions) and can 
regenerate all different cell types found within the heterogenous tumor 
(multipotent). In 1994, Dick and colleagues published the identification of cancer 
stem cells in acute myeloid leukemia (AML; Lapidot et al., 1994). Only upon 
transplantation of a CD34+CD38- (immature immunophenotype) population of 
human acute myeloid leukemia cells into immunocompromised NOD/SCID mice, 
these cells caused leukemia. Any other cell population transplanted did not cause 
leukemia. It was therefore concluded that CSCs probably derive from an immature 
hematopoietic progenitor (Bonnet and Dick, 1997). 
Since then, CSCs have been identified in cancers of blood, brain, breast, colon, 
ovary, pancreas, prostate, melanoma and multiple myeloma (Al-Hajj et al., 2003; 
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Bonnet and Dick, 1997; Li et al., 2007; Maitland and Collins, 2008; O'Brien et al., 
2007; Schatton et al., 2008; Singh et al., 2003; Zhang et al., 2008). It has been 
postulated that CSCs must not necessarily derive from a stem cell, but they have 
to acquire its characteristics (Bjerkvig et al., 2005). This might be achieved by an 
accumulation of mutations that lead to dedifferentiation and activation of pathways 
normally restricted to stem cells, Figure 3 (Rosen and Jordan, 2009). 
 
 
 
Figure 3: Cancer stem cells and normal stem cells are multipotent and can self-
renew. CSCs must not necessarily derive from a normal stem cell, but any cell may turn 
into a CSC upon activation of pathways, which are normally restricted to stem cells. 
(Image kindly provided by Terese Winslow) 
2.7.1 Leukemia 
Leukemia is a cancer of the blood and bone marrow (Kampen, 2012). It is 
characterized by uncontrolled proliferation of immature leukocytes. These 
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malignant cells accumulate first in the bone marrow and later in secondary 
hematopoietic organs like spleen and lymph nodes, but also in the liver. With 
disease progression, normal hematopoiesis is more and more suppressed by 
malignant cells (Dohner et al., 2010) and as a consequence patients suffer from 
anemia (lack of erythrocytes) and impaired immune function (Barberan et al., 
2011). 
Clinically and pathologically leukemia is classified into acute and chronic forms 
(Michiels et al., 2007). Acute leukemias are aggressive with fast proliferating cells. 
Therefore, they require immediate treatment. Chronic forms develop slowly and 
are normally just surveyed during the first months and years after diagnosis. When 
a certain concentration of leukemic cells in peripheral blood is reached, patients 
are treated by chemotherapy (Downing, 2008). 
2.7.2 B cell chronic lymphocytic leukemia (B-CLL) 
B-CLL is the most common type of leukemia in the Western world (Dores et al., 
2007). The median age of people newly diagnosed is above 50 years and the ratio 
between men and women is 2:1. Most patients are diagnosed during a routine 
blood test and show increased leukocyte numbers but no signs of sickness. 
Depending on the subtype of B-CLL, some patients die within months, while others 
do not need treatment throughout their lifetime. At present, B-CLL is not curable 
with conventional chemo- and radiation therapy. It is therefore necessary to 
identify new surrogate markers for a more detailed classification and prediction of 
the course of disease (Wadleigh and Tefferi, 2010). 
The accumulation of white blood cells (lymphocytosis) displaying a B-CLL cluster 
of differentiation (CD) phenotype on a complete blood count to more than 5000 
cells per µl is an indicator for leukemia (Harris et al., 2000; Rawstron et al., 2008). 
The accumulating B-CLL cells show surface expression of CD5, CD23, CD19 and 
CD20low (Lanasa, 2010). B-CLL is a clonal disease and all malignant cells in a 
patient are characterized by expressing either the lambda or kappa light chain. 
The malignant cells are slightly smaller than normal lymphocytes and tend to break 
when smeared onto a glass slide, reliably indicating leukemia by many broken 
cells (Schriever and Huhn, 2003). 
Evaluation of the number of mutations found in the DNA of the IgVH antibody gene 
region helps to distinguish high and low risk patients (Chiorazzi et al., 2005). A low 
mutation rate indicates a more immature B cell state, which correlates with a more 
rapid disease course. The presence of CD38 and zeta-chain-associated protein 
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kinase 70 (ZAP-70) on the malignant cells have also been correlated with a more 
aggressive disease course (Kay and Shanafelt, 2007; Malavasi et al., 2011). 
Genetic changes within the neoplastic cell population are determined by 
fluorescence in situ hybridization (FISH) during diagnosis (Nelson et al., 2007). In 
a study on 325 patients newly diagnosed with B-CLL, it was found that at least 
one, but up to three and more chromosomal aberrations, occur in more than 80% 
of the patients (Dohner et al., 2000). A sole 13q deletion (causes delayed 
development in children) was found in 36% of the patients and correlated with a 
median survival of 133 months. Patients (7%) with a 17p deletion (affecting the 
tumor suppressor p53) had a median survival of only 32 months (Dohner et al., 
2000). From this study, it can be concluded that B-CLL is characterized rather by 
prolonged survival of malignant B cells than by aggressive and invasive 
proliferation. Therefore, the cause of the disease is most likely a defect in 
apoptosis (Hallaert et al., 2007). 
Presumably, B-CLL cells depend on growth and survival factors provided by 
stromal cells in the bone marrow, as when cultured ex vivo, an apoptotic program 
is activated and the cells die within days (Collins et al., 1989). This is prevented 
when B-CLL cells are supported by a stromal feeder layer (Lagneaux et al., 1998). 
However, proliferation of B-CLL cells can be detected by in vivo labeling in 
patients, but the CD phenotype of these proliferating CSCs in the bone marrow 
remains undefined (Chiorazzi, 2007). From these observations and due to rarely 
observed invasive proliferation into other organs it can be assumed that B-CLL 
cells depend on factors produced by the bone marrow stromal microenvironment. 
2.7.3 B cell acute lymphocytic leukemia 
B-ALL is characterized by the accumulation of lymphoblasts with clonal origin in 
the bone marrow and peripheral blood (Cobaleda and Sanchez-Garcia, 2009; 
Onciu, 2009). Lymphoblasts are immature cells, which would normally differentiate 
into leukocytes, but instead proliferate in an uncontrolled manner in the bone 
marrow and aggressively infiltrate other organs. This form of leukemia is found 
mainly in children from 2-5 years and then peaks again in elderly people (>50 
years; Borkhardt et al., 1997). Because these immature cells proliferate quickly, 
patients require treatment within weeks after diagnosis (McGregor et al., 2012). 
Today, the overall cure rate with combined radiation- and multi chemotherapy is 
about 80% in children and 50% in adults (Gokbuget and Hoelzer, 2009; Yeoh et 
al., 2002). The diagnosis is based on a complete blood cell count and a blood 
smear. A bone marrow biopsy is a final proof. 
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The analysis of chromosomal translocations is routinely done in B-ALL diagnosis 
and serves as prognostic marker to identify patients who require more intense 
therapy (Harrison, 2009). The TEL-AML1 fusion t(12;21) is the most commonly 
detected chromosomal abnormality and found in 25% of patients (Zelent et al., 
2004). The TEL gene and the AML1 gene both encode transcription factors, which 
are essential for early hematopoietic development/stem cell maintenance (Ford et 
al., 2009). The TEL-AML1 translocation links the helix-loop-helix domain of TEL to 
the DNA binding and transactivation domains of AML1. Detection of this fusion is a 
favorable prognostic marker (Zelent et al., 2004).  
As part of an epidemiologic study, it was shown that the TEL-AML1 translocation 
could rarely be detected in neonatal blood spots (Greaves and Wiemels, 2003). 
Still, it took 5-10 years until leukemia was diagnosed in these children. Recurrent 
chromosomal translocations are a hallmark of B-ALL and are commonly found in 
TEL-AML1 leukemias, indicating that B-ALL develops from an immature cell 
accumulating additional mutations until it can drive leukemogenesis (Armstrong 
and Look, 2005). 
Fusion of the Abelson (ABL1) tyrosine kinase to the BCR (breakpoint cluster 
region) gene is a commonly found chromosomal translocation t(9;22)(q34;q11) in 
B-ALL (Nowell and Hungerford, 1960). The resulting Philadelphia chromosome  
encodes the constitutively active BCR-ABL tyrosine kinase, which drives 
tumorigenesis by increased cell division, inhibiting DNA repair mechanisms and 
providing anti apoptotic factors via constitutive STAT5 (Signal transducer and 
activator of transcription) signaling (Malin et al., 2010). The BCR-ABL fusion is 
found in 40% of adult patients and is associated with a poor prognosis (Gleissner 
et al., 2002).  
To this day, cancer stem cells have not been identified in B-ALL by a certain CD 
phenotype (Buss and Ho, 2011; Cox et al., 2009). However, their existence was 
functionally proven and their frequency can be defined using mouse models (Cox 
et al., 2004). To determine their frequency, patient derived cells are transplanted at 
limiting dilutions into immunocompromised mice. The CSC frequency is then 
calculated from the number of engrafted mice for each cell dose injected, using 
ELDA software (Hu and Smyth, 2009). 
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3 Aim of the study 
Hematopoietic stem cells (HSCs) have the unique ability to undergo self-renewing 
divisions. Thereby they maintain steady levels of hematopoiesis without depleting 
the stem cell pool. The balance between quiescence, proliferation and 
differentiation is regulated by intrinsic and extrinsic factors, provided by specialized 
microenvironments in the bone marrow. While HSCs themselves are well defined, 
the molecular and cellular composition of the niche they reside in is poorly 
understood. The transcription factor Ebf2 is expressed in stromal cells of the bone 
marrow and has been shown to regulate HSC homeostasis. Still, the underlying 
mechanisms and the contribution of Ebf2 on a cellular level remain undefined. 
The aim of this study was to examine whether all Ebf2-expressing bone marrow 
stromal cells contribute to Ebf2-mediated niche function for HSCs or whether this 
potential lies in a certain cell lineage. Therefore, mice carrying a conditional allele 
of Ebf2 were generated and combined with Cre lines to disrupt Ebf2-expression 
specifically in mesenchymal stem cells, adipocytes or osteoblasts. 
HSCs and leukemic Cancer Stem Cells (CSC) share certain characteristics. CSCs 
have the unique ability to propagate a heterogeneous disease upon 
transplantation of a single cell. Therefore, CSCs like HSCs are multipotent and can 
undergo self-renewing divisions. As IEO (immature Ebf2-expressing osteoblastic) 
cells support HSCs in vitro in an Ebf2-dependent manner, we addressed the 
question whether CSCs depend on the same Ebf2-mediated bone marrow niches. 
Therefore, co-culture experiments of human B-ALL and B-CLL leukemic cells with 
IEO cells and stromal cell lines were carried out. Thereby, the influence of Ebf2 on 
proliferation, survival and maintenance of CSCs was investigated. 
Finally, the role of Ebf2 in T cell development was studied. Ebf2-deficient mice 
show a strong reduction in thymic cellularity. In the thymus, Ebf2 is expressed by a 
small population of stromal cells at the boundary between the outer cortex and the 
inner medulla. Applying FACS, the nature of this cell population was characterized 
and we investigated whether different T cell types are equally affected by the loss 
of Ebf2 in thymic stromal cells. Furthermore, thymic embryonic lobes were 
transplanted into wild type recipients to determine whether the observed 
phenotype originates in the thymus or on the level of a bone marrow-derived T cell 
progenitor. 
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4 Results 
4.1 Ebf2 in normal hematopoiesis 
4.1.1 Generation of mice with a conditional Ebf2 allele 
Ebf2-LacZ-/- animals have a two- to fourfold reduction in HSC frequency, show a 
strong reduction in total cellularity of hematopoietic organs and die for unknown 
reasons at the age of roughly three to six weeks (Kieslinger et al., 2010). Most 
likely, various tissues and organs contribute to this complex phenotype leading to 
premature death. However, the underlying mechanisms, which cause the 
observed phenotype are poorly understood. To identify the Ebf2-expressing 
stromal cells responsible for the hematopoietic defects and to study their role in 
normal and malignant hematopoiesis, we generated a conditional knockout of 
Ebf2, based on the Cre-LoxP system. This strategy aimed at overcoming the 
premature death and at precisely defining the contribution of mesenchymal cell 
lineages expressing Ebf2, like MSCs, adipocytes and osteoblasts in Ebf2-
mediated niche function for HSCs. As a consequence of this tissue specific 
deletion, the animals are expected to be in a better health condition, which allows 
to perform transplantation experiments. 
4.1.2 Targeting strategy 
The introduction of LoxP sites into genes needs awareness. Their presence can 
result in alternative start codon usage, alteration of regulatory elements or 
expression of a truncated version of the protein. As a result, the generated mouse 
model might be useless. Thus, analyses of Ebf2 protein structure and bioinformatic 
approaches on the Ebf2 genomic locus were combined to minimize such risks. To 
fulfill their function as transcription factors Ebfs contain a DNA binding domain 
(DBD). Within their DBD lies a zinc-finger motif and for Ebf1 it was shown that 
each of the four central amino acids encompassing the zinc ion is essential for 
DNA binding (Hagman et al., 1995). Due to sequence homology of more than 90% 
at the protein level and 100% conservation of the four central zinc-finger amino 
acids between Ebf1 and Ebf2, we assumed that they are functionally indispensible 
in both proteins (Dubois and Vincent, 2001, Figure 4). Thus, exons which encode 
this structure are considered eligible targets. Upon Cre-mediated removal of DNA 
sequences encoding this zinc-finger, protein function should be disrupted. 
 
Results 23 
 
 
Figure 4: Schematic representation of the Ebf2 protein structure and its functional 
domains. The 575 amino acids comprise four different structural domains: a DNA binding 
domain (DBD), a transcription factor immunoglobulin domain (TIG), two helix-loop-helix 
domains (HLH) and a transactivation domain (TAD). The DBD contains a centered zinc 
finger motif, which is conserved between Ebf family members. For Ebf1, each of its four 
central amino acids (highlighted in bold letters) is essential for DNA binding (Hagman et 
al.,1995). The region coloured in blue is encoded by exons four to six. 
Ebf2 stretches over 196 kb on mouse chromosome 14 and consists of 17 exons. 
The zinc-finger motif is encoded by exon six and seven with an intron of seven 
kilobases (kb) in between. As the recombination efficiency starts to drop when the 
distance between two LoxP sites exceeds 400 bp (Ringrose et al., 1999; 
Schnutgen et al., 2006) and the success rate for homologous recombination for an 
insert of almost nine kb was considered rather low, just one of the two exons was 
targeted (exon six encodes 50% of the zinc finger). However, this approach carries 
the risk that due to alternative splicing mechanisms a truncated protein might be 
expressed. This truncated version might still interact with other Ebf proteins 
potentially altering their function and causing an undefined biological setting. 
Therefore, the targeting strategy was improved by making use of the non-sense 
mediated mRNA decay pathway (NMD; Ishigaki et al., 2001). Additional removal of 
exons four and five in addition to exon six, upon recombination of the LoxP sites, 
will cause an out-of-frame splice from exon three to exon seven. This frameshift 
generates an artificial stop codon in exon eight. As a consequence, the Ebf2 
mRNA encodes a truncated protein of only two hundred amino acids which lacks 
50% of its essential DBD. This should trigger NMD and result in degradation of the 
mRNA (Figure 5). 
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Figure 5: Schematic representation of the targeting strategy to generate mice 
carrying a conditional Ebf2 allele. The first seven exons of the Ebf2 wild type locus and 
the targeting construct are displayed. LoxP sites were introduced in front of exon four and 
after exon six. Flp or Cre recombinase activity leads to recombination and excision of DNA 
fragments in between Frt or LoxP sites, respectively. Probes and restriction sites used in 
southern blot experiments are shown. Primer pairs used to genotype the different genetic 
situations are indicated by filled arrows. The primer pair used to detect Ebf2 transcripts in 
RT-PCR reactions is shown by open arrows. 
Introns, although non-coding, can contain regulatory elements important for gene 
regulation (Banerji et al., 1983). Although LoxP sites are only 34 bps in size, they 
can influence gene expression and splicing. If these minor changes manifest in a 
phenotype, the mouse model becomes useless for conditional approaches. Most 
likely not only genes, but also their regulatory elements are conserved in evolution. 
Therefore, cross-species alignments between Ebf2 of C57BL/6 mice (set as 
reference), macaque, beagle and human were performed and regions of very low 
sequence homology within introns three and six were identified (Figure 6; 
Ovcharenko et al., 2004). These regions are unlikely to be of functional relevance 
and were therefore chosen for the placement of LoxP sites. 
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Figure 6: Cross-species alignment of the C57BL/6 Ebf2 genomic locus. The DNA 
sequences of various organisms were aligned with the Ebf2 genomic region of C57/BL6, 
set as reference. Arrowheads indicate two regions with low sequence homology, which 
qualify for the introduction of LoxP sites. 
pEZ FrtLox DT served as vector backbone (Figure 7). It contains a diphteria toxin 
A gene, whose expression is lethal and kills all ES cells that have randomly 
integrated the linearized plasmid into their genome. This greatly increases the 
frequency of correctly targeted ES cell clones and reduces screening efforts. 
Moreover, the vector contains a neomycin resistance cassette, which is flanked by 
two Frt sites. The neomycin cassette is required for selection of ES cell clones, 
which have correctly integrated the construct. The Frt sites have a length of 48 bp 
and are recognized by Flp recombinase that recombines Frt sites and excises the 
DNA fragment lying inbetween (Chen and Rice, 2003). Adjacent to Frt sites, the 
vector contains two LoxP sites between which the insert has to be cloned. At the 
outsides of these LoxP sequences, a left and right arm with homology to the 
targeted genomic region are required. These arms allow homologous 
recombination in ES cells. 
4.1.3 Cloning strategy 
Homologous recombination events can occur between two similar or identical 
stretches of DNA. The chance for such an event correlates directly with the level of 
identity. Therefore, the DNA fragments that mediate the recombination during 
gene targeting shall be identical to the targeted DNA sequence. To generate the 
targeting vector for Bruce4 and IDG3.2 ES cells, about 10 kb Ebf2 genomic DNA 
from C57BL/6 were needed comprising a 5.7 kb left arm of homology, a 1.7 kb 
insert and a 2.7 kb right arm of homology. To generate these fragments, a PCR 
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based approach using the „Phusion high fidelity DNA polymerase“ (Finnzymes) 
with an error rate of 4.4x10-7 was chosen. 
 
 
 
Figure 7: Vector backbone and completed construct used to target the Ebf2 locus. 
pEZ Frt LoxDT contains a Frt-flanked PGK-neomycin resistance cassette (PGK-neo), two 
LoxP sites and the diphteria toxin A gene (DTA). The insert was cloned in between the 
second Frt and LoxP site using the unique SalI restriction site. Left- and right arm of 
homology were cloned adjacent of the two LoxP sites. To clone the left arm of homology, 
ClaI and NotI were used. The right arm of homology was cloned using the indicated XhoI 
site. 
A BAC clone (RP23-148I22) from a C57BL/6 library served as template in the 
reactions. The generated blunt ended PCR products were cloned into pJet1.2/blunt 
and sequenced. Hereafter, they were consecutively subcloned into pEZ Frt LoxDT. 
Restriction sites used for cloning steps and restriction sites to identify ES cell 
clones with a targeted Ebf2 allele in southern blot analysis were introduced via 
primer overhangs on the oligonucleotides used in the PCR reactions. Newly 
introduced restriction sites, which were used for clonings are shown in Figure 7. In 
preparation for southern blot analyses we introduced a SpeI site at the 3´-end of 
the left arm of homology and a BglII site at the 5´-end of the right arm of homology 
(not shown). When the vector was complete as shown in Figure 7, restriction 
analyses with different enzymes were performed and the newly introduced DNA 
fragments were sequenced.  
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4.1.4 ES cell targeting and screening 
In this study, two different ES cell lines were manipulated. Bruce4, a pure C57BL/6 
ES cell line, was used to quickly achieve a congenic genetic background for 
transplantation experiments. IDG3.2, a F1 hybrid ES cell line derived from a 
crossing of 129/Sv x C57BL/6, was used because it is reported to be very robust 
and reliable in terms of germline transmission (personal communication with U. 
Zimber-Strobl and R. Kühn, HMGU).  
Bruce4 and IDG3.2 ES cells were electroporated and after selection with geneticin, 
500 Bruce4 ES cell clones and 400 IDG3.2 ES cell clones were isolated and 
analyzed by southern blot. In the first screen using the BglII probe, four Bruce4 ES 
cell clones (ES cell clone B5-36 is shown as an example in Figure 8 a) and three 
IDG3.2 clones gave a signal at the expected height of a recombined allele (4 kb, 
see Figure 8b). This corresponds to a targeting efficiency of 0.8% in both ES cell 
lines (supplementary Table 1). Those seven clones were then analyzed with the 
SpeI probe and all gave a signal at the expected height for a recombined allele (5 
kb, see Figure 8c). Correctness of LoxP sites was confirmed by sequencing and 
LoxP sites were functionally tested adding tat-Cre (Peitz et al., 2002) to cultured 
ES cells. Genomic DNA from tat-Cre treated cells was isolated and a recombined 
Ebf2 allele could be detected by PCR (Figure 5, data not shown). 
 
 
 
Figure 8: Embryonic stem cell clones cultured on mouse embryonic fibroblasts and 
southern blot analysis of the latter. (a) Brightfield image of Bruce4 ES cell clone B5-36 
just before injection into blastocysts. (b) Southern blot analysis of genomic ES cell DNA 
after cleavage with BglII showing a wild type (8 kb) and the targeted allele (4 kb, clone B5-
36). (c) Southern blot analysis of ES cell clones (B5-36 and B5-71) after cleavage with 
SpeI. Both clones show the correct integration of the construct (wt: 10 kb, targeted allele: 
5 kb). 
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Two clones of each ES cell type were then expanded for injection into blastocysts 
(Bruce4 clones: B5-36 and B5-71. IDG3.2 clones: I3-31 and I4-96). Blastocysts 
were isolated from three-week-old wild type C57BL/6 and Balb/C females by 
induced superovulation. Six days prior to isolation, 7.5 units of pregnant mare 
serum gonadotropin were injected intraperitoneally. Two days later, mice were 
injected with 7.5 units human chorionic gonadotropin and bred with males. Another 
3.5 days later, E3.5 blastocyts were harvested and 20-24 ES cells were injected 
each. Bruce4 ES cells were injected into Balb/C blastocysts (generates chimeras 
with black and brown coat colour) while IDG3.2 ES cells were injected into 
C57BL/6 blastocysts (generates chimeras with white and black fur colour). 
Thereafter, blastocysts were transplanted into Balb/C foster mothers. 
Overall, 15 chimeric animals showing a chimerism ranging from 5-90% were 
obtained (one female and no males from IDG3.2, five females and nine males from 
Bruce4). Male chimeras where crossed to C57BL/6 wild type females for germline 
transmission. In this breeding setup, animals with a black (sperms derive from 
Bruce4 ES cells injected into the blastocyst) or brown (sperms derive from the 
germline generated from cells of the fertilized Balb/C blastocyst) fur colour can be 
obtained. Due to heterozygosity of the injected ES cells (Ebf2+/neo-fl), the chance of 
successful inheritance of the transgene in an offspring with black fur colour is 50%. 
In two out of nine chimeras the engineered ES cells had contributed or completely 
formed the germline and the targeted Ebf2 allele was passed on to their progeny. 
One male, derived from clone B5-36 generated only black pups. This male is the 
founder animal of the new mouse strain. In addition to fur colour, genotypes were 
confirmed by PCR and southern blot analysis with the SpeI probe (data not 
shown). Ebf2+/neo-fl animals were then crossed with C57/BL6 FlpE females to 
remove the neomycin resistence cassette (Figure 5). This transgenic mouse strain 
expresses Flp recombinase under control of the human beta actin promotor which 
is active in all tissues (Rodriguez et al., 2000). Flp mediated recombination of the 
Frt sites leads to excision of the PGK-neomycin selection cassette in the mouse 
germline. Thereby, the PGK promotor, which might interfere with the endogenous 
Ebf2 promotor is removed. Offsprings from these breedings have the genotype 
Ebf2+/fl. Removal of the PGK-neomycin selection cassette was controlled by PCR 
(Figure 5, data not shown). 
4.1.5 Analysis of Ebf2Δfl/Δfl animals 
To evaluate the functionality of the newly generated mouse strain, it was crossed 
with DelCre transgenic animals, which express Cre recombinase in the germline 
(Schwenk et al., 1995). Cre mediated recombination of the two LoxP sites leads to 
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excision of Exons 4-6 (Figure 5). Offsprings from these breedings have the 
genotype Ebf2+/Δfl. Heterozygous progeny with one recombined Ebf2 allele 
(Ebf2+/Δfl) were then intercrossed to generate Ebf2Δfl/Δfl animals. Mice with this 
genotype carry two recombined Ebf2 alleles and their phenotype should 
recapitulate the phenotype of Ebf2-LacZ-/- animals. Recombination of LoxP sites 
was confirmed by PCR on genomic tail DNA as shown in Figure 9a. To control for 
a loss of Ebf2 transcript, thymic epithelium from Ebf2Δfl/Δfl animals was isolated and 
cDNA was synthesized from the extracted total RNA. In RT-PCR no Ebf2 
transcript could be detected (Figure 9b). 
 
 
 
Figure 9: Genotyping and RT-PCR to detect recombination of LoxP sites and loss of 
Ebf2 transcript in Ebf2Δfl/Δfl mice. (a) Heterozygous Ebf2+/Δfl animals were bred to 
generate Ebf2-deficient mice. A genotyping result is shown. (b) A reverse transcription 
reaction on cDNA from thymic stromal cells of wild type and Ebf2Δfl/Δfl animals failed to 
amplify the 77 bp product from Ebf2Δfl/Δfl cDNA. The shown HPRT product was used for 
normalization and serves as control for successful reverse transcription. (c) General 
appearance of a Ebf2Δfl/Δfl animal at the age of three weeks compared to a wild type 
littermate of the same age. (d) Three week old Ebf2Δfl/Δfl mice weight about 50% less 
compared to wild type littermates (n=3, p=0.0001). 
In Corradi et al. (2003), Ebf2-LacZ-/- knockin animals are described to show a 50% 
reduction in body mass compared to Ebf2-LacZ+/+ and Ebf2-LacZ+/- littermates, to 
be mildly uncoordinated and to walk with an unsteady and waddling gait. 
Furthermore, Corradi and colleagues report that Ebf2-LacZ-/- animals exhibited a 
hunchback and Ebf2Δfl/Δfl animals show the same behavioral disorders. When we 
determined the body weight of three-week-old Ebf2Δfl/Δfl mice we detected strong 
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reductions comparable to those previously reported for the Ebf2-LacZ mutation 
(Figure 9 c, d). 
 
 
 
 
At the age of three weeks, Ebf2Δfl/Δfl animals were sacrificed and total cellularity of 
thymus, spleen and bone marrow were found to be strongly reduced (Figure 10). 
The strongest reduction was found for thymus cellularity (sevenfold), followed by 
spleen (twofold) and bone marrow (twofold). Except for the reduction in spleen 
cellularity, which was reported to be decreased about fivefold at the age of three 
weeks, this data is comparable to the report on the Ebf2-LacZ-/- mutation 
(Kieslinger et al., 2010). 
Figure 10: Tibia, thymus and spleen of Ebf2Δfl/Δfl 
mice are reduced in size and cellularity 
compared to wild type controls. (a, b, c) 
Representative pictures and statistics of the latter 
organs from control and Ebf2Δfl/Δfl animals at the age 
of three weeks are shown (n=3, bone marrow 
p=0.0001, thymus p=0.0001, spleen p=0.002). 
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Ebf2-LacZ-/- animals have a two- to fourfold reduction in KSL (c-Kit+, Sca1+, Lin- 
cells, a population highly enriched for hematopoietic stem cells) frequency 
(Kieslinger et al., 2010). The KSL compartment in Ebf2+/+ and Ebf2Δfl/Δfl littermates 
was therefore analyzed and a sevenfold reduction could be detected (Figure 11). 
FACS gating strategy to determine the KSL frequency is shown in supplementary 
Figure S2. 
 
 
 
Figure 11: Ebf2Δfl/Δfl animals have reduced KSL frequencies. (a) Analysis of the KSL 
compartment in three-week-old animals by flow cytometry. Lymphocytes from the bone 
marrow were gated as living cells (PI-), lineage marker negative (Lin-) and were analyzed 
for the expression of Sca1 and c-Kit. (b) Ebf2-deficient animals show a sevenfold 
reduction in KSL frequency compared to control animals (n=3, p=0.0001). 
In summary, Cre-mediated recombination of LoxP sites leads to a loss of Ebf2 
transcript. Ebf2Δfl/Δfl animals fully recapitulate the phenotype of Ebf2-LacZ-/- mice 
(Corradi et al., 2003; Kieslinger et al., 2010). 
When we measured body weight, cellularity of hematopoietic organs and KSL 
frequencies in Ebf2fl/fl animals (not deleted in Ebf2), no differences compared to 
wild type littermates were detected (data not shown). Therefore, mice with a 
conditional allele of Ebf2 were successfully generated and the new mouse strain is 
applicable to investigate the function of Ebf2 in different stromal cell types by 
crossing Ebf2fl/fl animals with stromal cell type specific Cre lines. 
4.1.6 Analysis of PrxCreEbf2fl/fl animals 
To investigate whether Ebf2 expressed by MSCs is crucial for the support of HSCs 
in the bone marrow niche, Ebf2fl/fl animals were crossed with PrxCre transgenic 
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mice (Logan et al., 2002). Thus, Ebf2 is specifically deleted in MSCs. PrxCreEbf2fl/fl 
animals behave normally and do not show any signs of growth retardation. Their 
movement is ordinary and the animals are healthy. At the age of ten weeks, 
animals were sacrificed and primary and secondary hematopoietic organs were 
analyzed (Figure 12). 
 
 
 
Spleen and thymus were of normal size. Bones were normal in size and firmness 
(observation during preparation of bones). Bone weight was also unaffected by the 
loss of Ebf2 (data not shown). When the weight of spleen, thymus and bone 
marrow cellularity was determined, the organs from PrxCreEbf2fl/fl were not 
Figure 12: General appearance of PrxCreEbf2fl/fl 
animals at the age of ten weeks and analysis of body 
weight, tibia length and different hematopoietic 
organs. PrxCreEbf2fl/fl animals have normal body weight 
and bone length. Bone marrow cellularity and the weights 
of spleen and thymus were not distinguishable from 
control animals (n=3, body weight p=0.681, bone marrow 
p=0.659, thymus p=0.867, spleen p=0.804, tibia=NaN, 
n.s.=p>0.05). 
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distinguishable from control animals. Finally, the KSL compartment in PrxCreEbf2fl/fl 
animals was analyzed and found to be unchanged (Figure 13). We performed a 
genotyping PCR on genomic DNA (gDNA) isolated from bone marrow cells of 
PrxCreEfb2fl/fl animals to confirm that Cre expression resulted in successful deletion 
of Exons 4-6. Detection of a recombined Ebf2 conditional allele confirmed 
recombination of the LoxP sites at the Ebf2 locus by Cre recombinase 
(supplementary Figure S2). 
 
 
 
Figure 13: PrxCre-mediated deletion of Ebf2 does not affect HSC homeostasis. (a) 
Total bone marrow from ten-week-old PrxCreEbf2fl/fl animals and controls was analyzed by 
flow cytometry. Lymphocytes were gated as living cells (PI-), lineage marker negative 
(Lin-) and were analyzed for the expression of Sca1 and c-Kit. (b) Statistics on KSL 
frequencies measured in different experiments (PrxCreEbf2+/fl n=4, PrxCreEbf2fl/fl n=3, 
p=0.264, n.s.=p>0.05). 
 
4.1.7 Analysis of AP2CreEbf2fl/fl animals 
Adipocytes are part of the bone marrow stromal microenvironment for 
hematopoietic cells. Adiponectin, a secreted metabolic hormone, is exclusively 
produced by adipocytes and promotes proliferation of HSCs in the bone marrow 
(DiMascio et al., 2007). As Ebf2 is expressed in adipocytes (Jimenez et al., 2007) 
Ebf2fl/fl animals were crossed with AP2Cre transgenics, which express Cre under 
control of the adipocyte protein 2 (AP2) promotor to delete Ebf2 specifically in 
adipocytes (He et al., 2003). 
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Recombination of the LoxP sites of the conditional Ebf2 allele was confirmed by 
PCR on gDNA isolated from adipose tissue and flushed bone marrow cells of 
AP2CreEbf2fl/fl mice (supplementary Figure S3). AP2CreEbf2fl/fl animals developed 
normally and were not distinguishable from control animals (Figure 14). At the age 
of ten weeks body weight was determined and found to be unaltered and no 
reduction in subcutaneous fat was detected. Moreover, we did not observe a 
difference in bone firmness of AP2CreEbf2fl/fl animals compared to control mice 
(own observation during dissection of femur and tibia). Appearance of 
hematopoietic organs was ordinary and the weights of thymi and spleens were 
similar to those of control animals. Furthermore, the total bone marrow cellularity 
was not reduced and when the KSL frequency was determined by FACS, no 
difference to control animals was detected (Figure 15). 
Figure 14: Appearance of AP2CreEbf2fl/fl animals at 
the age of ten weeks and analysis of body weight, 
tibia length and weight of hematopoietic organs. 
AP2CreEbf2fl/fl animals have normal body weight and 
bone length. Bone marrow cellularity and weights of 
spleen and thymus were not distinguishable from 
control animals (n=3, body weight p=0.59, bone marrow 
p=0.455, thymus p=0.527, spleen p=0.866, tibia=NaN, 
n.s.=p>0.05). 
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Figure 15: Deletion of Ebf2 in adipocytes does not result in reduced KSL 
frequencies. (a) Analysis of KSL frequency in total bone marrow isolated from femurs 
and tibias of ten-week-old AP2CreEbf2fl/fl and control animals by flow cytometry. 
Lymphocytes were gated as living cells (PI-), lineage marker negative (Lin-) and were 
analyzed for the expression of Sca1 and c-Kit. (b) Bar chart and statistics on the detected 
KSL frequencies (n=3, p=0.938, n.s.=p>0.05). 
4.1.8 Analysis of OsxCreEbf2fl/fl animals 
Osteoblasts play a key role in regulating the hematopoietic stem cell niche and 
immature osteoblasts express Ebf2 (Kieslinger et al., 2010; Zhang et al., 2003). To 
investigate the role of Ebf2-expressing osteoblasts, Ebf2fl/fl animals were crossed 
with OsxCre transgenic animals, which express Cre recombinase under control of 
the osterix promotor (active during early osteoblast differentiation; Rodda and 
McMahon, 2006). OsxCreEbf2fl/fl pups were not distinguishable from control animals 
right after birth. However, at the age of one week OsxCreEbf2fl/fl animals started 
displaying developmental retardation and were smaller than littermates of other 
genotypes. The severity of this phenotype increased with age and OsxCreEbf2fl/fl 
animals had significantly reduced body weight at the age of four weeks (Figure 
16). 
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Figure 16: Deletion of Ebf2 in immature osteoblasts results in a time-dependent 
body mass reduction. At the age of four weeks OsxCreEbf2fl/fl animals have significantly 
reduced body weight while ten-week-old OsxCreEbf2fl/fl animals have relatively normal body 
weight compared to controls (four-week-old: n=3, body weight p=0.023; ten-week-old: 
n=3, p=0.447, n.s.=p>0.05).  
 
To reduce the extent of this phenotype to a minimum, the animals were fed pulp. 
Although this mildened the phenotype, OsxCreEbf2fl/fl mice still show reduced body 
mass. During the first weeks of life, OsxCreEbf2fl/fl animals were regularly observed. 
No behavioral disorders, like a waddling gait were detected. OsxCreEbf2fl/fl animals 
behaved comparable to control littermates, although displaying dwarfism they were 
in a better physical condition than Ebf2Δfl/Δfl animals. Due to the observed 
reduction in body mass, which is also detectable in Ebf2Δfl/Δfl animals, we decided 
to analyze hematopoietic organs and long bones of four-week-old OsxCreEbf2fl/fl 
animals (Figure 17). 
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The size of femur and tibia was reduced by about 20%. Although the bones were 
reduced in size, they were rather solid and firm like bones of control animals (own 
observation during dissection of femur and tibia). OsxCreEbf2fl/fl animals had about 
40% less bone marrow cells than control mice (non-significant). The weight of 
spleen and thymus was found to be significantly reduced, 2.5-fold for thymus and 
2.8-fold for spleen, see Figure 17.  
When the frequency of KSL cells in three- to four-week-old OsxCreEbf2fl/fl animals 
was determined by FACS analysis, we detected a two- to fourfold reduction 
(Figure 18). 
 
Figure 17: Photo of a four-week-old OsxCreEbf2fl/fl 
animal and an OsxCreEbf2+/fl littermate. Bar charts 
show significantly reduced body weight, tibia length and 
decreased weights of hematopoietic organs in 
OsxCreEbf2fl/fl animals compared to controls. Bone 
marrow cellularity was also reduced (non-significant) in 
OsxCreEbf2fl/fl animals (n=3, body weight p=0.023, bone 
marrow p=0.142, thymus p=0.016, spleen p=0.004, 
tibia=0.001, n.s.=p>0.05). 
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Figure 18: Deletion of Ebf2 in immature osteoblasts results in reduced KSL 
frequencies in three- to four-week-old OsxCreEbf2fl/fl animals compared to controls. 
(a) Analysis of total bone marrow from three- to four-week-old animals by flow cytometry. 
Lymphocytes were gated as living cells (PI-), lineage marker negative (Lin-) and were 
analyzed for the expression of Sca1 and c-Kit. (b) KSL frequencies in OsxCreEbf2fl/fl 
animals are reduced about 2.3-fold compared to controls (OsxCreEbf2+/fl n=4, OsxCreEbf2fl/fl 
n=5, p=0.009). 
Surprisingly, the body weight of OsxCreEbf2fl/fl animals increased rapidly from week 
four onwards. At the age of ten weeks, the body weight of OsxCreEbf2fl/fl animals 
had strongly increased and we could not detect a significant difference compared 
to controls (Figure 16). 
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When the weight of hematopoietic organs from ten-week-old mice was 
determined, a slight reduction in spleen size was detected, but thymic weight was 
found to be normal (Figure 19). The bone marrow cellularity was slightly reduced 
(non-significant). Further, long bones from OsxCreEbf2fl/fl animals were shorter 
(10%). Investigation of the stem cell compartment by FACS showed no reduction 
in KSL frequency (Figure 20). 
 
Figure 19: Photo of a ten-week-old OsxCreEbf2fl/fl 
animal and an OsxCreEbf2+/fl littermate. Body weight, 
tibia length and hematopoietic organs were analyzed. 
OsxCreEbf2fl/fl animals show a slight reduction in bone 
length compared to controls. Bone marrow cellularity 
and splenic weights were mildly reduced (non-
significant), but thymic weights were not distinguishable 
from control animals (n=3, body weight p=0.447, bone 
marrow p=0.117, thymus p=0.972, spleen p=0.169, 
tibia=0.029, n.s.=p>0.05). 
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Figure 20: OsxCre-mediated deletion of Ebf2 in osteoblasts does not result in 
decreased KSL frequencies in ten-week-old animals. (a) Total bone marrow of ten-
week-old OsxCreEbf2fl/fl and control animals was analyzed by flow cytometry. Lymphocytes 
were gated as living cells (PI-), lineage marker negative (Lin-) and were analyzed for the 
expression of Sca1 and c-Kit. Frequencies of KSL cells in the indicated gate were not 
reduced as shown in the diagramm (b), (n=3, p=0.958, n.s.=p>0.05). 
4.1.9 DNA microarray analysis of IEO-Ebf2+/- and IEO-Ebf2-/- cells 
Ebf2 is strongly expressed in adipose tissue. We and others speculated that Ebf2 
may be essential for steady state metabolic processes in fat cells. Loss of Ebf2 in 
this tissue is most likely the reason why Ebf2-deficient mice display dwarfism and 
show a strong reduction in body weight (Corradi et al., 2003). When we combined 
newly generated Ebf2fl/fl mice with AP2Cre and OsxCre transgenic mice we expected 
AP2CreEbf2fl/fl animals to recapitulate the body weight phenotype but AP2CreEbf2fl/fl 
animals had unchanged weights compared to control animals. Intriguingly, juvenile 
OsxCreEbf2fl/fl mice had reduced body weight but almost fully recovered from this 
reduction until the age of ten weeks. This observation links early mouse 
developmental processes to the transcription factor Ebf2 expressed in osteoblasts.  
To gain a better understanding of the observed phenotype in OsxCreEbf2fl/fl 
animals, the gene expression profiles of IEO-Ebf2+/- and IEO-Ebf2-/- bone marrow 
stromal cells were compared by DNA microarray analysis. Osteoblastic cell 
fractions were isolated from Ebf2-Gfp+/- and Ebf2-Gfp-/- embryos at the 
developmental stage E18.5 and Gfp positive IEO (Immature Ebf2-expressing 
Osteoblastic) cells were FACS sorted into trizol (sorting scheme and information 
on breeding procedures are shown in supplementary Figure S4). Prior to 
amplification and labeling of total RNA samples, an aliquot was run on a 
bioanalyzer for quality control. Finally, six samples of each genotype with high 
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RNA quality were amplified, labeled, hybridized and scanned using an Illumina 
DNA microarray plattform. The top 100 downregulated genes detected in IEO-
Ebf2-/- cells compared to IEO-Ebf2+/- cells are shown in table S 2. The complete list 
of deregulated genes can be found on the CD provided with this thesis. 
4.1.10 Characterization of Ebf2-expressing thymic stromal cells 
In the thymus, Ebf2 is expressed by a small stromal cell population at the 
boundary between cortex and medulla (Kieslinger et al., 2010). Nature and 
function of these cells is still unknown. Due to the strong decrease in thymic 
cellularity detected in Ebf2-deficient mice, these cells might have a functional role 
in homing and support of bone marrow derived common lymphoid progenitors 
(CLPs) in the thymus. In order to investigate which thymic stromal cells express 
Ebf2, single cell preparations from minced and collagenase/dispase digested 
thymi were analyzed by FACS. As beta-galactosidase does not fluoresce, it cannot 
directly be detected in FACS. Therefore, Ebf2-Gfp mice were used to characterize 
Ebf2-expressing thymic stromal cells. Ebf2-Gfp-/- animals were shown to have the 
same stem cell phenotype as published by Grosschedl and colleagues 
(Hiechinger, S., 2010) and fully recapitulate the phenotype of the Ebf2-LacZ 
mutation (Wang et al., 2004, own observation). 
Thymi from Ebf2-Gfp+/+ and Ebf2-Gfp+/- animals were isolated and single cell 
suspensions were stained with antibodies to identify stromal cell populations that 
express Ebf2-Gfp. DAPI was added to exclude dead cells. (1) Non-epithelial cells 
were identified as CD45-G8.8-Ly51-. Amongst this population a fraction of cells 
expresses Ebf2-Gfp. (2) cTECs were identified as CD45-G8.8intLy51+ and showed 
no Ebf2-Gfp expression. However, we identified Ebf2-expressing cells among the 
(3) mature mTEC population which was identified as CD45-G8.8+Ly51-CD80high. 
Hence, Ebf2-Gfp is expressed in a fraction of mature mTECs (Figure 21). 
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Figure 21: Ebf2 is expressed by mature CD80+ mTECs and a population of non-
epithelial cells. Cells were gated for living cells (DAPI-) and non-hematopoietic cells 
(CD45-). Next, cells were analyzed for Ly51 and G8.8 expression. (1) non-epithelial cells, 
(2) cTECs and (3) mTECs were identified and separately analyzed further. (1) A fraction of 
non-epithelial cells expresses Ebf2. (2) cTECs do not express Ebf2. (3) Within the mTEC 
population a fraction of mature mTECs expresses Ebf2. 
For a more in-depth analysis of the Ebf2-expressing cell population, markers for 
endothelial cells (CD31), subcapsular epithelial cells (gp38) and MTS15+ 
fibroblasts (MTS15) were tested in thymic cell preparations from Ebf2-Gfp+/+ and 
Ebf2-Gfp+/- animals. While Ebf2 is not co-expressed with CD31 and gp38 (data not 
shown) a population of MTS15/Gfp double positive cells could be identified (Figure 
22). Digested thymi were stained with DAPI, CD45, G8.8 and MTS15. To exclude 
dead and hematopoietic cells, gates on DAPI- and CD45- cells were set (not 
shown). Living stromal cells were then analyzed for G8.8 expression. Non-
epithelial cells were then examined for expression of MTS15 and Ebf2-Gfp and a 
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population of double positive cells was identified. Hence, Ebf2 is expressed in 
MTS15+ mesenchymal fibroblasts (Figure 22). 
 
 
Figure 22: Ebf2-expressing cells are positive for the fibroblast marker MTS15. To 
exclude dead and hematopoietic cells a gate for DAPI- and CD45- cells was set (not 
shown). To gate out epithelial cells (mTECs and cTECs) a gate on G8.8 negative cells 
was set. Finally, cells were analyzed for Ebf2 and MTS15. Within the MTS15 positive 
cells, a population of Ebf2-expressing Gfp positive cells shifts on the x-axis. The 
histogram shows that a fraction of MTS15+ cells is also Gfp positive. 
4.1.11 Ebf2 in T cell development 
Ebf2 is strongly expressed in thymic stromal cells and Ebf2-LacZ-/- animals show a 
strong decrease in thymus cellularity (Kieslinger et al., 2010). Since a distinct 
population of Ebf2-expressing mTECs and MTS15+ fibroblasts was identified, we 
addressed the question, whether loss of Ebf2 in thymic stromal cells affects T cell 
development. Therefore, the T cell profile of Ebf2-Gfp animals was analyzed. 
Investigating two to three-week-old Ebf2-Gfp-/- animals, we observed the same 
reduction in thymic cellularity as was published for Ebf2-LacZ-/- mice (Kieslinger et 
al., 2010; data not shown). A more in-depth analysis of the T cell profile, looking 
specifically at the percentage composition of DN, DP, CD4+ and CD8+ T cells, 
revealed a 1.6-fold reduction in the CD4+ single positive T cell compartment 
(Figure 23). 
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Figure 23: Ebf2-deficient animals show a reduction in CD4+ T cells. Cells were pre-
gated on DAPI- lymphocytes. Cells were then analyzed for expression of CD4 and CD8 as 
shown and CD4+ T cells were found to be reduced 1.6-fold (n=4, p=0.05). 
Since Ebf2 is not expressed in hematopoietic cells as previously reported 
(Kieslinger et al., 2005, data not shown), Ebf2-expressing stromal cells might be 
important regulators of T cell proliferation, maturation and differentiation. To 
exclude secondary effects of Ebf2-deficiency, resulting in a bad health condition or 
defects in other organs, transplantation experiments of thymic embryonic lobes 
from Ebf2-Gfp+/+, Ebf2-Gfp+/- (heterozygous mice are not distinguishable from wild 
type mice and were therefore used as controls) and Ebf2-Gfp-/- into wild type 
recipients were performed. 
Thymic embryonic lobes (E14.5) were isolated and cultured in complete IMDM 
medium supplemented with deoxyguanosine. This nucleotide analogon is 
incorporated into the DNA of rapidly replicating cells (hematopoietic cells) thereby 
killing them, while slowly replicating cells (stromal cells) remain unaffected. 
Thereafter, lobes were transplanted under the kidney capsule of six-week-old 
congenic wild type recipients (Figure 24). 
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Figure 24: Schematics showing the experimental design of transplantation 
experiments. Embryonic lobes were isolated from E14.5 embryos and cultured on 
floating filter paper in complete IMDM medium supplemented with deoxyguanosine for five 
days. Thereafter, lobes were transplanted under the kidney capsule of C57/BL6 wild type 
recipients. Three and six weeks later, lobes were isolated and analyzed by FACS. 
Host derived wild type CLPs repopulated the Ebf2-Gfp-/-, Ebf2-Gfp+/- and Ebf2-
Gfp+/+ lobes and T cells were analyzed at three and six weeks after transplantation 
to study T cell development at different time points. The results of these 
experiments are shown in Figure 25. CD8+, DN and DP T cell populations were 
found unaltered compared to control animals. The frequency of CD4+ T cells was 
also found unchanged at three and six weeks after transplantation. In summary, 
the reduction in thymus cellularity and CD4+ T cells is not transplantable. 
 
 
Figure 25: T cell development in transplanted Ebf2-/- thymic lobes is unchanged. 
Three and six weeks post transplantation thymic lobes were isolated and analyzed. The 
total cellularity was found unaltered. The percentage of CD4+, CD8+, DN and DP 
thymocytes in Ebf2-/- lobes is unchanged compared to controls (three weeks: wt n=7, Ebf2 
-/- n=10, six weeks: wt n=10, Ebf2-/- n=10, p=n.s. for all bar charts shown). 
Results 46 
4.2 Ebf2 in malignant hematopoiesis 
IEO cells support HSCs in vitro in an Ebf2-dependent manner (Kieslinger et al., 
2010). In view of the fact that the existence of CSCs was functionally proven in 
1997 (Bonnet and Dick, 1997), we investigated a potential role of Ebf2 in the 
maintenance of malignant B cells. Therefore, in vitro co-culture experiments were 
established and human B-CLL and B-ALL cells were co-cultured and analyzed by 
FACS or in vivo after transplantation into immunocompromised mice. 
4.2.1 The support of B-CLL cells is influenced by Ebf2 
Human B-CLL samples were taken from peripheral blood of patients, depleted for 
CD2/CD14 expressing cells (T cells, NK cells, macrophages, neutrophils and 
dendritic cells, frozen samples were provided by I. Ringshausen, TUM) and were 
seeded on different feeder layers. To characterize subtypes of B-CLL cells in the 
context of Ebf2, the patient samples used varied regarding their ZAP-70 status. 
Figure 26 shows the experimental setup. 
 
 
 
Figure 26: Schematic showing the experimental design of co-culture experiments. 
Human B-CLL cells were co-cultured on different stromal feeder layers for six days. 
Thereafter, cells were collected, stained with 7-AAD and AnnexinV and analyzed by 
FACS. 
The stromal cell lines EL08 and EL28 were isolated from the mouse aorta gonad 
mesonephros (AGM) region. Single cell clones were characterized regarding their 
capacity to maintain HSCs in vitro. While EL08 cells maintain HSCs in vitro for 
weeks, their counterpart EL28 does not carry this potential (Oostendorp et al., 
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2005). The same cell lines were characterized regarding their capacity to support 
human B-CLL cells. Interestingly, EL08 cells provide a better support than EL28 
cells, as was determined by lower apoptotic rates in co-cultures (Ingo 
Ringshausen, personal communication). Therefore, these cell lines served as 
positive and negative control. Due to reports that feeder cell line mediated support 
of HSCs correlates with the expression of Ebf proteins (Kieslinger et al., 2010), 
RNA levels of Ebf1, Ebf2 and Ebf3 in EL08 and EL28 cells were compared by 
quantitative real time PCR. Expression levels of Ebf1, 2 and 3 are at least 16-fold 
higher in the supporting EL08 cells than in non-supporting EL28 cells (Figure 27a). 
To investigate the importance of Ebf2, a gain of function experiment was carried 
out. EL28 cells were transduced with an Ebf2-IRES-Gfp or mock-IRES-Gfp (empty 
vector control) retrovirus to overexpress Ebf2. Any gain or loss of support in EL28 
Ebf2 cells compared to EL28 mock cells for human B-CLL cells would be mediated 
by Ebf2. Figure 27b shows successfully infected and non-infected control cells 
detected by FACS. Ebf2 protein levels in EL28 Ebf2 compared to EL28 mock were 
analyzed by western blot (Figure 27c). 
 
 
 
Malignant B-CLL cells were cultured on EL08 wt, EL28 mock and EL28 Ebf2 
transduced feeder layers. In parallel, B-CLL cells were cultured on mouse IEO 
cells isolated from Ebf2-Gfp+/- and Ebf2-Gfp-/- mice. Hence, a gain of function and 
a loss of function approach are tested simultaneously. With this experimental 
Figure 27: HSC supporting stromal cells express Ebfs. (a) 
Ebf1, 2 and 3 expression levels were compared by 
quantitative real time PCR. The diagramm shows in a 
logarithmic scale that all Ebfs are expressed to a higher extent 
in supporting EL08 cells than in non-supporting EL28 cells. (b) 
FACS analysis showing EL28 wt stromal cells infected with an 
Ebf2-IRES-GFP retrovirus or an empty vector control (mock-
IRES-GFP). (c) Western blot analysis showing Ebf2 
overexpression in EL28 Ebf2 cells while EL28 mock cells have 
no detectable Ebf proteins. 
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setup any support mediated by Ebf2 should increase cell survival in EL28 Ebf2 
over EL28 mock, while at the same time the level of support mediated by IEO-
Ebf2-/- cells compared to IEO-Ebf2+/- should decline. 
To determine the number of viable B-CLL cells after six days of co-culture, a 
quantitative FACS analysis using accucheck counting beads (Invitrogen) was 
established. A known volume of beads (type A and B beads) was added to a 
known volume of resuspended cells. When counting the beads along with cells, 
their numbers can be related. Furthermore, the beads contain two different 
fluorospheres in a known proportion. The accuracy of a measurement can 
therefore be determined by relating the counts for beads A and B. At the end of a 
co-culture experiment, all cells were harvested and transfered to FACS tubes for 
washing and staining. For analysis, beads were added and samples were 
measured by FACS. FSC/SSC were adjusted to have three separate populations: 
(1) FACS counting beads of type A and B in the upper left. (2) B-CLL cells in the 
lower center and (3) the majority of feeder cells scattered from center to the upper 
right (Figure 28). 
 
 
 
Figure 28: Gating scheme and experimental design to quantify the number of viable 
B-CLL cells after six days of co-culture by FACS analysis. In FSC/SCC a gate was 
set on FACS counting beads and a second gate on lymphocytes. Accuracy of the 
measurement was controlled by analysis of the ratio of the fluorescent beads A and B in 
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FL2/SSC. Gfp+ feeder cells were excluded and Gfp- lymphoid cells were analyzed with 7-
AAD and AnnexinV. The ratio between viable cells and beads was calculated as shown. 
To determine the number of FACS beads, they were gated and analyzed in 
SSC/FL2-H. The events counted within the gates for beads A and B were 
aggregated. For analysis of viable B-CLL cells a gate on lymphoid cells was set. 
To exclude Gfp-positive feeder cells a gate on Gfp-negative B-CLL cells was set. 
Finally, B-CLL cells were analyzed for AnnexinV (apoptotic cells) and 7-AAD (dead 
cells) and the events for living cells in the lower left quadrant were counted (Figure 
28).  
Figure 29 gives an overview on one representative experiment (patient sample 
V261), which was analyzed after six days of co-culture on the following feeder 
layers:  
(1) EL08 served as a positive control 
(2) No feeder layer served as negative control 
(3) EL28 mock are transduced with an empty vector and served as control for 
EL28 Ebf2 transduced cells 
(4) EL28 Ebf2 cells overexpress Ebf2 
(5) IEO-Ebf2-/- cells represent stromal cells deleted for Ebf2  
(6) IEO-Ebf2+/- cells represent stromal cells which express Ebf2 
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Figure 29: Representative analysis of co-cultered lymphocytes after six days under 
different conditions. EL08 cells and no feeder layer served as positive and negative 
control in co-culture experiments. EL28 feeder cells were transduced with an empty vector 
control (EL28 mock) and an Ebf2 encoding virus (EL28 Ebf2). Mouse stromal IEO-Ebf2+/- 
and IEO-Ebf2-/- cells were compared to determine the relevance of Ebf2. Events counted 
in the lower left quadrant are 7-AAD and AnnexinV negative and therefore considered 
viable cells. 
To detect Ebf2-mediated support, the ratio between beads and the number of 
living cells after six days of co-culture was determined. Finally, the measured 
values were normalized and then compared: EL28 Ebf2 was normalized to EL28 
mock and IEO-Ebf2-/- values were normalized to IEO-Ebf2+/-. 
A summarizing overview on the eight patient samples tested is given in Figure 30. 
The detected effects are shown in percent change after normalization. Overall, 
three out of eight samples showed a significant response to Ebf2 expression. 
Sample V 261 responded to Ebf2 under both experimental conditions. 
Overexpression of Ebf2 led to a significant increase in B-CLL cell survival (20% 
more viable cells) while the loss of Ebf2 in IEO-/- cells resulted in 50% fewer living 
B-CLL cells in comparison to IEO+/- cells. Patient sample V 128 behaved in a 
similar way. We detected 20% more viable cells upon overexpression of Ebf2 in 
EL28 Ebf2 cells compared to EL28 mock while the loss of Ebf2 in IEO cells 
resulted in a significant decrease in feeder layer-mediated support (30% fewer 
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living cells on IEO-/- cells compared to IEO+/- cells). A similar trend was observed 
for sample P 27. Finally, we detected significantly fewer living cells for patient 
sample D 14 when cultured on IEO-/- cells compared to IEO+/- cells. However, this 
sample did not respond to overexpression of Ebf2 in EL28 Ebf2 compared to EL28 
mock. Out of the eight samples tested, only V 147 patient cells showed slightly 
increased survival in the absence of Ebf2 (non-significant). These results show 
that Ebf2 can influence the survival of B-CLL cells. However, the ZAP70-status 
could not be correlated with Ebf2-mediated support. 
 
 
 
Figure 30: Increased survival of human B-CLL cells cultured on Ebf2-expressing 
stromal cells. A group of eight human patient samples with differing ZAP70-status were 
co-cultured for six days on mouse primary IEO-Ebf2+/- and IEO-Ebf2-/- cells as well as on 
Ebf2 over-expressing and control cells (EL28 mock). Columns show percent change of 
viable B-CLL cells on Ebf2-expressing feeder layers relative to control cell feeder layers 
(significant changes (p=<0.05) are indicated with asterisks). 
4.2.2 IEO cells support B-ALL CSCs in vitro 
B-ALL is highly invasive and characterized by quickly proliferating cells. In co-
culture experiments we addressed the question, whether the CSC frequency in a 
given B-ALL patient sample can be altered in an Ebf2-dependent manner. We 
isolated bone marrow stromal cells from Ebf2-Gfp+/- animals and sorted two cell 
populations: (1) bone marrow stromal cells depleted for Ebf2-expressing niche 
cells (non-IEO) and (2) Ebf2-expressing niche cells (IEO). These two cell 
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populations were cultured in vitro until 80% confluency was reached. Transgenic 
human B-ALL cells were isolated directly from the spleen of leukemic mice, 
counted and seeded on top of the different feeder layers. Transgenic human B-
ALL cells were generated by transducing primary human B-ALL patient cells with a 
Gaussia luciferase-IRES-Gfp encoding adenovirus. After transduction the cells 
were injected into immunodeficient mice. Upon signs of sickness the animals were 
sacrificed and human B-ALL cells were isolated from the spleen and analyzed for 
Gfp-expression by FACS. Gfp-positive transgenic human B-ALL cells were then 
FACS-sorted and re-injected into mice. This procedure was repeated until 96-99% 
of the cells isolated from the spleen of a leukemic mouse were Gfp-positive. 
Sample P199 was generated in this way and 1x107 cells were seeded on IEO and 
non-IEO feeder layers. After 30 days in vitro, B-ALL cells were harvested and 
counted. The number of B-ALL cells on non-IEO cells was roughly unchanged 
compared to the number initially seeded, while we detected a modest reduction 
(20%) on IEO cells. Next, the cells were washed, resuspended in PBS and 
injected into immunodeficient mice at different concentrations (Figure 31). 
 
 
 
Figure 31: Outline of the experiment performed. FACS sorted IEO and non-IEO cells 
were co-cultured with human B-ALL patient cells for 30 days in vitro. Thereafter, cells 
were counted, prepared in limiting dilutions and injected into mice. 
Engraftment and development of leukemic cells was then followed over time by 
imaging the animals with a CCD camera. Therefore, the animals were narcotized 
and injected with native coelenterazine and imaged on day 11, 21 and 34 post 
injection of leukemic cells. Coelenterazine serves as a substrate for Gaussia 
luciferase, which is expressed by the human B-ALL cells due to the stable 
integration of the gaussia luciferase encoding adenovirus. The chemiluminescence 
reaction can be detected with a CCD camera and signal intensities correlate with 
cell number (Figure 32). Animals who had received the highest dose of leukemic 
cells were detectably engrafted already 11 days after injection. In these mice, the 
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B-ALL cells engrafted femur and tibia first (scattered/weak signal from the thorax 
region is unspecific signal from the liver). 
 
 
 
 
Figure 32: IEO and non-IEO cells maintain human B-ALL CSCs for at least 30 days 
in vitro. Mice were imaged 11, 21 and 34 days post injection. On day 11, only mice who 
had received 1x106 leukemic cells were engrafted. 21 days after injection, animals of that 
group were full with leukemic cells and were sacrificed shortly after. 34 days post injection 
mice within all groups were engrafted. The pattern of engraftment always followed the 
same order: femur/tibia, sternum, lung/axillary lymph nodes and last in cervical lymph 
nodes. 
At 21 days, the leukemic cells in these mice had spread and infiltrated sternum, 
lungs, cervical and axillary lymph nodes. These animals were sacrificed shortly 
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after. Mice, which had been injected lower cell numbers, were not detectably 
engrafted at 11 days post injection (data not shown). At 34 days post injection, 
only animals, which had been injected the lowest cell number (3000 cells), were 
not engrafted throughout the experimental animal group. Only two out of three 
from the IEO group were engrafted, while just one out of three animals from the 
non-IEO group was detected positive. From these results it can be concluded that 
it requires about 3000 leukemic cells to successfully transplant the leukemia. 
Interestingly, the same cell number is at least needed to successfully transplant 
this human B-ALL patient sample directly from one mouse to another without in 
vitro culture. 
In summary, IEO and non-IEO stromal cells maintained B-ALL cells over 30 days 
in vitro. Although the CSC frequency was not altered in an Ebf2-dependent 
manner, the leukemic potential was entirely preserved. 
 
5 Discussion 
5.1 Generation of mice with a conditional allele of Ebf2  
Embryonic stem cell engineering enabeled researchers to study gene function in 
higher vertebrates. As certain biological processes or diseases are directly linked 
to single genes, mice deleted in this gene offer a powerful tool to investigate the 
underlying mechanisms. However, many phenotypes observed in knockout mice 
may be caused indirectly and result from complex physiological alterations in these 
mice. This can strongly diminish the conclusions drawn from the data obtained. 
The deletion of Ebf2 is a good example because its loss in different organs and 
tissues results in multiple/complex phenotypes that are probably interconnected. 
Most obvious is the strong reduction in body weight, which could be caused by an 
altered metabolism due to loss of Ebf2 in adipocytes. Deletion of Ebf2 causes 
disturbance of neuronal axon migration presumably resulting in a waddling gait 
and mildly uncoordinated movements. In addition, Ebf2-deficient animals display 
secondary hypogonadism and strongly reduced fertility (Corradi et al., 2003; Wang 
et al., 2004). Together with the juvenile osteopenia phenotype (Kieslinger et al., 
2005) and the observed hematopoietic defects (Kieslinger et al., 2010), Ebf2-
deficient animals are in a poor health condition, which is reflected by a high 
postnatal lethality observed amongst Ebf2Δfl/Δfl offspring (85% died after birth, only 
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15% reached the age of three weeks (supplementary Figure S5). The study of 
developmental processes like hematopoiesis or T cell development in these 
animals harbors risks, because T cell progenitors emerge in the bone marrow but 
differentiate in the thymus. Therefore, alterations observed in the thymus may 
originate from the bone marrow.  
In conclusion, Ebf2 conditional knockout animals were generated for the following 
reasons: (1) the deletion of Ebf2 can be restricted to hematopoietic organs, (2) 
Ebf2-mediated niche function for HSCs might be associated to a certain stromal 
subpopulation, and (3) if so, these mice shall be used to study malignant 
hematopoiesis in vivo (this is not possible in Ebf2-deficient animals, because they 
die from irradiation which is mandatory for transplantation experiments; personal 
communication Matthias Kieslinger). Furthermore, by use of certain Cre lines (e.g. 
inducible systems), Ebf2 can be deleted tissue specifically and at defined time 
points. 
While many laboratories use the BAC recombineering technology (Warming et al., 
2005) to generate their congenic targeting vectors, a PCR based strategy was 
applied here. The generation of the arms of homology with a high fidelity 
polymerase using a BAC clone as template was successful and unique restriction 
sites used for cloning and southern blot analysis were introduced via overhangs on 
the primers used in the PCR reactions. This approach circumvents constraints 
concerning endogenous restriction sites and greatly facilitated the design of an 
applicable southern blot strategy. Amongst all ES clones analyzed, seven scored 
positive for homologous recombination. This relatively low targeting efficiency was 
expected from a previous targeting of the same locus, although the constructs 
used are slightly different (Corradi et al., 2003). As Ebf2 is not expressed in ES 
cells (personal communication Silvia Hiechinger, HMGU Munich), the low 
efficiency most likely results from a closed chromatin structure at the Ebf2 locus. 
Of the seven mutant ES cell clones obtained, two Bruce4 and two IDG3.2 that 
formed uniform colonies with distinct borders and had normal proliferation rates 
were injected into blastocysts. Surprisingly, male chimeric mice (Bruce4 and 
IDG3.2 ES cells were generated from male animals) were only obtained from the 
two Bruce4 ES cell clones. This result was unexpected, because all four ES cell 
clones formed uniform, rotund colonies with distinct borders. This assessment was 
independently confirmed by our collaborators who injected the ES cells into 
blastocysts (personal communication, A. Tasdemir, HMGU Munich). However, at 
this point in time no conclusions can be drawn whether Bruce4 ES cells should be 
preferred over IDG3.2, as the number of experiments performed is too low. From 
breedings of male chimeras with wild type C57/BL6 females, we obtained offspring 
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with black fur color, which must derive from the injected Bruce4 ES cells. Together 
with the results obtained from southern blot analysis and genotyping PCR this led 
us to progress further and we crossed newly generated Ebf2+/fl animals with DelCre 
transgenic mice, which express Cre recombinase in all tissues including the 
germline. Heterozygous Ebf2+/Δfl animals were then intercrossed to generate 
Ebf2Δfl/Δfl mice, which should fully recapitulate the phenotypes observed in Ebf2-
LacZ-/- animals. We isolated RNA from thymic stromal cells of wild type and 
Ebf2Δfl/Δfl mice and were not able to amplifiy Ebf2 transcript on cDNA of Ebf2Δfl/Δfl 
animals while control reactions were successful. Although we did not analyze 
whether the chosen strategy led to activation of the NMD pathway, we assume 
that no truncated protein is expressed. This question could not be addressed 
experimentally, because an Ebf2 specific antibody is not available. 
Ebf2Δfl/Δfl animals move with a waddling gait, display reductions in body weight, 
bone size and bone firmness as reported for Ebf2-LacZ-/- mice (Corradi et al., 
2003; Kieslinger et al., 2005). When we analyzed the hematopoietic system of 
Ebf2Δfl/Δfl animals, we detected the previously described reduction in total 
cellularity of hematopoietic organs and KSL frequency for Ebf2-LacZ-/- and Ebf2-
Gfp-/- mice (Hiechinger, S., 2010; Kieslinger et al., 2010). Interestingly, some of the 
phenotypes observed in Ebf2Δfl/Δfl animals were slightly more severe than 
previously reported (e.g. KSL frequency and survival rates). In the first publication 
of Ebf2-LacZ animals, no juvenile mortality of Ebf2-deficient mice is mentioned 
(Corradi et al., 2003). In contrast, animals even reached the age of 2 years 
(personal communication G. G. Consalez, ISR Milan). Interestingly, the ES cells 
used in the reported gene targeting were derived from the 129Sv mouse strain and 
although offspring were bred with C57/BL6 animals for five generations, the 
studies were not performed in a pure genetic background (Corradi et al., 2003). 
Without control (SNP analysis) it takes about ten generations to achieve a clean 
genetic background. However, in 2002 Ebf2-LacZ mice were transferred to our 
laboratory and since then are further backcrossed onto a C57/BL6 background. 
While premature death was rarely observed during first generations of 
backcrossing (personal communication, Matthias Kieslinger), the frequency 
increased over the years and we rarely obtain Ebf2-deficient animals older than 
three weeks nowadays (own observation). More or less the same holds true for 
Ebf2-Gfp-/- mice for which R.Reed reported a 25% postnatal lethality rate (Wang et 
al., 2004). Remarkably, the Ebf1 deletion is not reported to be lethal neither (Lin 
and Grosschedl, 1995). However, the chances to obtain an Ebf1-/- animal in our 
laboratory and the laboratory of Harinder Singh (personal communication 
Chauncey Spooner, Genentech) on a pure C57/BL6 background are dramatically 
low. Therefore, we speculate that some phenotypes caused by the deletion of Ebf1 
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and Ebf2 are more severe in a pure C57/BL6 background. As Ebf2Δfl/Δfl animals 
were generated from pure C57/BL6 ES cells, this might explain the increased 
reduction in KSL frequency from two- to fourfold (Kieslinger et al., 2010) to the 
level of roughly sevenfold described here. It has to be mentioned here, though, 
that the number of animals analyzed was only three. Differences in litter sizes and 
different levels of parental care may influence the severity of some phenotypes. 
With regard to the high mortality rate it should also be kept in mind that animals 
that survived till the age of three weeks were most likely naturally pre-selected for 
a mild phenotype. 
In preparation of stromal cell type specific deletions, we analyzed the phenotype of 
Ebf2fl/fl animals. In this way, the functionality of the conditional allele of Ebf2 is 
controlled. Ebf2fl/fl animals have unchanged KSL frequencies (data not shown). 
They are born at the expected Mendelian ratios and they are indistinguishable 
from wild type littermates. Therefore, we conclude that the introduction of LoxP 
sites does not lead to phenotypic changes. 
In summary, the data discussed in this chapter led to the conclusion that we 
successfully generated mice carrying a conditional allele of Ebf2 because the 
phenotypes we observe after complete Cre-mediated deletion, but not before that, 
are comparable to those described for Ebf2-LacZ-/- and Ebf2-Gfp-/- mice (Corradi et 
al., 2003; Kieslinger et al., 2005; Hiechinger, S., 2010; Kieslinger et al., 2010). 
Bioinformatic analysis on the mouse genome indicates the presence of cryptic or 
pseudo LoxP sites with a frequency of 1.2 per megabase. Although these 
sequences are recombined by Cre recombinase with rather low efficiency 
compared to consensus LoxP sites, their recombination can result in DNA damage 
causing cell death or altered proliferation rates in Cre expressing cells. Therefore, 
expression of Cre recombinase alone may result in an in vivo phenotype (Schmidt-
Supprian et al., 2007). Due to these reports on Cre toxicity, we used Cre 
expressing littermates as controls.  
5.2 PrxCre driven deletion of Ebf2  
Mesenchymal stem cells were shown to constitute an essential component of the 
HSC niche (Mendez-Ferrer et al., 2010). We used PrxCre transgenic mice to delete 
Ebf2 specifically in MSCs for two reasons. First, these analyses provide new 
insights into the role of Ebf2 expressed by MSCs and second, the deletion in 
MSCs serves as a backup for osteoblast and adipocyte specific deletion 
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experiments because both cell types derive from MSCs. If adipocytes and 
osteoblasts equally contribute to HSC support in the bone marrow, deletion of Ebf2 
in only one of these cell types may result in a very mild phenotype. 
The observation that ten-week-old PrxCreEbf2fl/fl animals show a wild type 
phenotype was very surprising and unexpected. No alterations in body weight, 
bone size or hematopoietic organs were observed. PrxCre animals are widely used 
to study processes of skeletal development involving MSCs, chondrocytes and 
osteoblasts (Kimura et al., 2010; Seo and Serra, 2007). In the first report on PrxCre 
animals, Cre expression was characterized in whole mount stainings using LacZ-
reporter animals. Cre expression in E10.5 embryos was detected throughout the 
limbs, interlimb flanks and craniofacial mesenchyme (Logan et al., 2002). We 
concluded that Cre is expressed in MSCs and decided to use PrxCre animals to 
delete Ebf2 in every mesenchymal cell deriving from a MSC, including adipocytes 
and osteoblasts (Figure 2). Detection of a recombined Ebf2Δfl allele by PCR on 
gDNA isolated from bone marrow of tibia and femur proved the functionality of the 
conditional Ebf2 allele and the expression of Cre recombinase (supplementary 
Figure S2). However, PrxCre driven deletion of Ebf2 most likely resulted only in a 
partial deletion of Ebf2 in certain skeletal areas. Although all skeletal elements 
derive from MSCs, the Prx enhancer used to drive Cre expression is presumably 
not generally active in MSCs but mainly in MSCs of the lateral plate mesoderm 
(Martin et al., 1995). The lateral plate mesoderm forms the appendicular skeleton 
(pelvis, pectoral girdle and long bones of limbs) and Prx is expressed in these 
tissues. However, Prx seems expressed to a lesser extent (if at all) in paraxial 
mesoderm that forms the somites, which give rise to the axial skeleton. Therefore, 
Ebf2 is probably still expressed in the spinal cord and parts of the skull and rip 
cage of PrxCreEbf2fl/fl mice. These skeletal elements contribute to hematopoiesis. 
Although we cannot exclude that Ebf2 expressed by MSCs contributes to HSC 
niche function, results within this thesis show that Ebf2 expressed by osteoblasts 
is required for HSC homeostasis in three- to four-week-old OsxCreEbf2fl/fl mice. As 
osteoblasts derive from MSCs, Ebf2 should be deleted in osteoblasts of 
PrxCreEbf2fl/fl mice. As none of the previously described phenotypes observed in 
Ebf2-deficient animals was detected in PrxCreEbf2fl/fl mice, we speculate that the 
deletion efficiency within the IEO population is very low in PrxCreEbf2fl/fl animals. 
However, it requires analysis of additional mice and furthermore it is mandatory to 
study three- to four-week-old PrxCreEbf2fl/fl mice before any conclusion can be 
drawn. 
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To determine the deletion efficiency, we will combine the mouse strains available 
to generate PrxCreEbf2fl/Gfp mice. By FACS sorting of Gfp positive cells, we will 
determine the deletion efficiency within the IEO population by quantitative real time 
PCR. In a similar approach, one could use a reporter mouse strain carrying a LoxP 
flanked stop cassette in front of the human CD2 gene. PrxCre-mediated 
recombination of the LoxP sites would activate expression of hCD2 (which 
encodes a membrane bound surface molecule for which antibodies are available) 
and the analysis of stromal cells from hipbone, tibia and vertebrae would provide 
valuable information on the deletion efficiency. 
5.3 AP2Cre-mediated deletion of Ebf2 
Ebf2-deficient mice show a strong reduction in body weight and seem to have 
reduced subcutaneous fat (although we did not investigate this experimentally, 
supplementary figure S6). Ebf2 carries adipogenic differentiation potential 
(Jimenez et al., 2007) and we speculated that Ebf2 might play an important role in 
the metabolic function of adipocytes. Remarkably, AP2CreEbf2fl/fl animals were not 
reduced in body weight and had normal amounts of subcutaneous fat (own 
observation). These findings argue that Ebf2 is dispensable for the metabolic 
function of adipocytes. This assumption is supported by the detection of an Ebf2Δfl 
allele in gDNA isolated from adipose tissue of AP2CreEbf2fl/fl animals 
(supplementary Figure S3). Moreover, the numbers of IEO cells isolated from 
Ebf2-Gfp+/- and Ebf2-Gfp-/- animals are comparable, suggesting that the loss of 
Ebf2 does not result in a differentiation block of bone marrow adipocytes in Ebf2-
deficient mice. Furthermore, no difference between IEO-Ebf2+/- and IEO-Ebf2-/- 
cells is observed in cell culture and adipocytes are detected at similar frequencies 
(own observation). These thoughts and speculations are reinforced by the fact that 
we observed a strong body weight reduction in young OsxCreEbf2fl/fl animals 
arguing that the body weight reduction is not related to the function of Ebf2 in 
adipocytes. This assumption is supported further by the fact that OsxCreEbf2fl/fl 
mice had a normal body weight at the age of ten weeks. Although OsxCre mice are 
not reported to delete in adipocytes (Rodda and McMahon, 2006) we want to 
prove this by PCR on gDNA isolated from adipose tissue of OsxCreEbf2fl/fl mice. To 
draw final conclusions regarding the deletion efficiency in AP2CreEbf2fl/fl animals 
we will perform a quantitative PCR analysis on gDNA of sorted adipocytes from 
AP2CreEbf2fl/fl mice.  
Interestingly, Ebf1 and Ebf2 are described to carry an equal adipogenic potential 
(Jimenez et al., 2007). Due to relatively high expression levels of all Ebf family 
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members in this tissue, it is possible that redundancy among the family members 
can compensate for the loss of a single Ebf protein. Deletion of Ebf1 or Ebf2 might 
be compensated, resulting only in non-significant reductions of adipocyte numbers. 
Intercrossing Ebf1- and Ebf2-deficient mice to produce double deficient animals 
would be one possibility to address whether adipogenesis requires both 
transcription factors. 
When we examined hematopoietic organs and HSC frequencies in ten-week-old 
AP2CreEbf2fl/fl animals, they were comparable to those in control mice. In summary, 
we could not detect any of the phenotypes observed in three-week-old Ebf2Δfl/Δfl 
mice in the ten-week-old AP2CreEbf2fl/fl mice analyzed. However, we need to 
extend the number of animals analyzed before any conclusions can be drawn. 
Interestingly, adiponectin was amongst the most deregulated genes in our DNA 
microarray analysis on IEO cells isolated from Ebf2-Gfp+/- and Ebf2-Gfp-/- mice. 
Adiponectin is exclusively expressed by adipocytes and was shown to be 
important for HSC proliferation (DiMascio et al., 2007). Therefore, we plan to 
analyze three-week-old AP2CreEbf2fl/fl mice in the near future. 
5.4 OsxCre-mediated deletion of Ebf2 
Many of the cytokines mediating homing, proliferation, and quiescence of HSCs 
were shown to be expressed in osteoblasts (Lymperi et al., 2010) and the number 
of HSCs directly correlates to the number of osteoblasts in the bone marrow, 
indicating their importance in hematopoiesis (Calvi et al., 2003; Zhang et al., 
2003). OsxCre transgenic animals were crossed with Ebf2fl/fl mice to investigate the 
function of Ebf2 expressed by osteoblasts. Our observation that the deletion of 
Ebf2 in osteoblastic cells resulted in severe weight reduction was very surprising. 
Although this reduction was observed in Ebf2-deficient animals, the cause 
remained unclear and like others (personal communication, G. G. Consalez, ISR 
Milan) we speculated that the neuronal defects might lead to reduced food uptake 
by the animals. Moreover, the severe osteopenia phenotype and the displayed 
hunchback might be an indicator of pain during movement and stretching for food 
pellets in Ebf2-deficient animals. We detected a similar reduction in bone length in 
OsxCreEbf2fl/fl animals and counteracted the potentially reduced maneuverability by 
feeding the animals pulp and providing water via a long neck of bottle. However, 
the average body weight of OsxCreEbf2fl/fl animals was still decreased. There were 
exceptions of animals, which developed relatively normal. The reason may be low 
deletion efficiency. In summary, the fact, that OsxCreEbf2fl/fl animals are vivid and 
healthy but still show reduced body weight strongly suggests a direct connection 
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between Ebf2 expressed by osteoblasts and early corporal/physic development. 
Anyhow, as the role of Ebf2 in hematopoiesis is the main focus of this thesis we 
did not investigate this phenotype any further.  
The post-natal development of the hematopoietic system in the bone marrow is 
completed at the age of eight to ten weeks and this time point was, therefore, 
chosen as time point for analysis (Beerman et al., 2010; Warren and Rossi, 2009). 
When we determined the total bone marrow cellularity of ten-week-old 
OsxCreEbf2fl/fl mice, we detected a slight reduction compared to control animals 
(non-significant). Spleenic weights were mildly reduced (non-significant) while 
thymi remained unaffected. At the same time KSL frequencies in ten-week-old 
OsxCreEbf2fl/fl mice were not reduced compared to control animals. These results 
were very surprising, because three-week-old Ebf2-deficient animals show 
reduced KSL frequencies compared to controls and we assumed that the severity 
of the hematopoietic phenotype would increase over time. As IEO cells mainly 
display characteristics of osteoblasts, we expected the deletion of Ebf2 in 
osteoblasts would cause defects in HSC homeostasis. Anyhow, we could not 
detect a reduction in KSL cells and, moreover, the reductions in total bone marrow 
cellularity were minor. Although more animals need to be analyzed, our data 
indicate that in some way the relevance of Ebf2 for hematopoiesis is time point 
dependent. Interestingly, R.Reed and colleagues report that 50% of the Ebf2-Gfp-/- 
mutant mice died by P30 (Wang et al., 2004). However, animals that survived to 
adulthood grew to normal size. In the future, we want to follow hematopoietic 
development over time (with gradual gaps of two weeks) from the age of two to ten 
weeks. 
Ebf2-deficient and OsxCreEbf2fl/fl animals show a reduction in body weight during 
the first three to four weeks after birth. However, while Ebf2-deficient animals die 
at the age of roughly three to six weeks, the severity of the body weight phenotype 
observed in OsxCre deleted animals starts to decline from that age onwards. In 
consequence of this observation we decided to analyze three to four-week-old 
OsxCreEbf2fl/fl animals and detected a reduction in total bone marrow cellularity and 
a significant decrease in KSL frequencies. These results strongly indicate that the 
transcription factor Ebf2 expressed in osteoblastic lineage cells regulates HSC 
homeostasis.  
During embryogenesis, the sites of hematopoiesis change and at E13 the fetal 
liver carries the highest hematopoietic potential and serves as the primary 
hematopoietic organ (Morrison et al., 1995). The last step in hematopoietic 
development requires the switch from fetal liver- to bone marrow-based 
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hematopoiesis, which starts at E16-E18 and parallels the ossification of bones. 
The importance of osteoblastic cells for this process was shown in Runx2-deficient 
mice. Deletion of this transcription factor leads to a maturational arrest of 
osteoblastic differentiation at a very early stage (Komori et al., 1997). Runx2-/- 
animals have no functional osteoblasts and lack calcified bone. At E18.5, Runx2-
deficient mice show congenital lack of bone marrow, which causes excessive 
extramedullary hematopoiesis in spleen and liver. Remarkably, hematopoiesis in 
mutant embryos at E16 is normal (Deguchi et al., 1999). This data strongly 
indicates that factors expressed by osteoblasts are required to establish bone 
marrow based hematopoiesis. Ebf2 is expressed at sites of adult hematopoiesis 
(bone marrow, spleen and thymus), but not in the fetal liver. Interestingly, the 
development of B and T lymphocytes during embryogenesis of Ebf2-deficient 
animals shows no significant defects (Kieslinger et al., 2010). Therefore, we 
speculate that Ebf2 may affect the switch from fetal liver to adult bone marrow 
based hematopoiesis. During early hematopoietic development, fetal liver and 
bone marrow contribute to the formation of mature blood cells. Fetal liver HSCs 
(Lin-, Mac1+, Sca1+) have a different CD phenotype than adult HSCs (Lin-, Sca1+, 
c-Kit+), and when the frequencies of fetal liver HSCs were determined in three-
week-old Ebf2-deficient animals, they were found to be increased two- to threefold. 
At the same time the number of adult phenotype HSCs is decreased two- to 
fourfold (Kieslinger et al., 2010). These findings argue that hematopoiesis in three-
week-old Ebf2-LacZ-/- animals is maintained in part by fetal liver derived HSCs. 
Interestingly, the number of CAFCs (cobblestone-area-forming cells) of wild type 
KSL cells cultured on IEO cells isolated from Ebf2-LacZ+/- and Ebf2-LacZ-/- mice 
was reduced by 50% on the Ebf2-deficient feeder layer (Kieslinger et al., 2010). 
This indicates less proliferation in the absence of Ebf2. The observations 
presented in this thesis may partly be explained by the list of down regulated 
genes obtained from our DNA microarray experiment on IEO stromal cells isolated 
from Ebf2-Gfp+/- and Ebf2-Gfp-/- mice.  
Matrix metalloproteinases (MMP) remodel the extracellular matrix and are involved 
in the regulation of HSC activity through release of membrane-bound cytokines in 
the bone marrow. MMP-9, which was found to be downregulated in Ebf2-deficient 
IEO cells is required to release membrane bound VEGF, which stimulates 
hematopoiesis and hematopoietic cell mobilization (LeCouter et al., 2004). 
Interestingly, VEGF itself is also expressed in IEO cells and was detected to be 
downregulated in IEO-Ebf2-/- cells compared to IEO-Ebf2+/- cells (personal 
communication, Matthias Kieslinger). 
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Another MMP family member, MMP-13 (also downregulated in Ebf2-deficient IEO 
cells) was shown to play an important role during processes of angiogenesis via 
VEGF in tumor formation (Lederle et al., 2010). Remarkably, blood vessels in one 
Ebf2Δfl/Δfl animal analyzed seem less pronounced compared to the wild type 
littermate, which could result from the detected deregulation in MMPs 
(supplementary Figure S6). However, unchanged bone morphology, including 
bone marrow vasculature, in Ebf2-LacZ-/- animals strongly argue against this 
(Kieslinger et al., 2005). 
Deletion of the chemokine SDF-1 results in hematopoietic failure and premature 
death at E18.5 or postnatally (Nagasawa et al., 1996). The expression level of 
SDF-1 is reduced in IEO-Ebf2-/- cells compared to IEO-Ebf2+/- cells indicating that 
the transcription factor Ebf2 is involved in mediating the switch from fetal liver to 
bone marrow based hematopoiesis via SDF-1. This result is reinforced by the fact 
that SDF-1 is a direct target of Ebf2 (Lagergren et al., 2007). This data could be 
confirmed by quantitative real time PCR on IEO-Ebf2+/- and IEO-Ebf2-/- cells in our 
laboratory (personal communication, Bettina Groll, HMGU). While SDF-1 plays an 
important role in HSC homing to the bone marrow niche, SCF promotes HSC 
proliferation via the c-Kit receptor expressed on hematopoietic cells (Ikuta et al., 
1992; Miller et al., 1996; Miller et al., 1997). Under physiologic conditions, SCF is 
membrane bound and needs to be cleaved for signaling via c-Kit. This process is 
partly mediated by MMP-9 (Heissig et al., 2002), which was also found to be 
downregulated in Ebf2-deficient IEO cells in our DNA microarray experiment. This 
downregulation was independently confirmed on sorted IEO cells from Ebf2-Gfp+/- 
and Ebf2-Gfp-/- cells in our laboratory (personal communication, Johanna 
Knallinger, HMGU Munich). Hence, we speculate based on these results that IEO-
Ebf2-/- cells have a reduced capability to recruit HSCs to their bone marrow niche 
due to reduced SDF-1 expression levels. In addition reduced levels of MMP-9 
result in decreased amounts of SCF leading to reduced proliferation of HSCs in the 
bone marrow. This interpretation is supported by the observation that fetal liver 
HSCs proliferated three times less when co-cultured on IEO-Ebf2-/- compared to 
IEO-Ebf2+/- stromal cells (preliminary data, supplementary Figure S7). In summary, 
the observed phenotype in young OsxCreEbf2fl/fl is most likely a consequence of 
reduced homing to the bone marrow and delayed expansion of HSCs. Therefore, 
we presume that the establishment of adult hematopoiesis partly depends on 
signals mediated by the transcription factor Ebf2. 
In a set of experiments we want to further investigate the HSC phenotype by 
looking at more defined stem cell populations and investigate proliferative rates of 
these populations in OsxCreEbf2fl/fl mice. Our in vivo data shall be further confirmed 
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by using the Tet-Off gene expression system available in the OsxCre transgenic 
mice used in this study (Gossen et al., 1992; Rodda and McMahon, 2006). The 
expression of Cre recombinase will be inhibited by administration of doxycycline 
during embryonic and early postnatal development of OsxCreEbf2fl/fl animals. 
Thereby, the deletion of Ebf2 is prevented until withdrawal of doxycycline. Analysis 
of the KSL frequency in OsxCreEbf2fl/fl mice, who received doxycycline until 
different time points after birth will provide new insights. In another approach, we 
want to transplant fetal liver HSCs and adult HSCs into lethally irradiated young 
OsxCreEbf2fl/fl animals. This experiment may provide answers whether Ebf2 is 
differentially required by fetal liver and adult HSCs. We speculate that signals 
mediated by Ebf2 are important for the maturation of fetal liver derived HSCs and 
the establishment of adult bone marrow-based hematopoiesis. 
5.5 Ebf2 in T cell development 
Ebf2 is expressed at all sites of adult hematopoiesis (bone marrow, spleen and 
thymus; Kieslinger et al., 2010). While the nature of these stromal cells in the bone 
marrow is rather well defined, the role and function of Ebf2-expressing cells in 
spleen and thymus is unknown. Based on the overall reduction in thymic cellularity 
observed in Ebf2-Gfp-/-, Ebf2Δfl/Δfl and Ebf2-LacZ-/- animals (Kieslinger et al., 2010) 
we speculated that Ebf2 might be of functional relevance at all sites of adult 
hematopoiesis. Thus, we characterized which thymic stromal cells express Ebf2 
and investigated how they could be responsible for the observed phenotype.  
Medullary thymic epithelial cells (mTECs) promiscuously express genes from all 
tissues, a process that assures T cell tolerance to antigens normally not present in 
the thymus. This function is mainly mediated by the transcription factor AIRE. As a 
result, mTECs present an enormous repertoire of self-antigens to T cells on MHCI 
and MHCII molecules and thereby negatively select self-reactive T cells. We found 
that in particular the CD80high fraction expresses Ebf2. This population represents 
mature mTECs that also express AIRE. As a consequence Ebf2, expressed in 
these cells could simply represent a promiscuously expressed gene, which 
therefore would have no function in mTECs except tolerance induction. However, it 
has been shown that a single promiscuously expressed gene is present only in a 
very small fraction (1-3%) of mTECs (Derbinski et al., 2001). As we detected about 
6% Gfp positive cells within the mTEC population, it is most unlikely, that this cell 
population results from promiscuous gene expression. We think that this 
population of Ebf2-expressing mTECs represents a true distinct population with 
specific function. To address this question Gfp positive and Gfp negative mTECs 
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of Ebf2-Gfp+/- animals will be isolated by FACS sorting. Measurement of Ebf2 
transcript levels within the sorted populations will show whether Gfp expression 
correlates with Ebf2 expression and in case it does, Ebf2-expressing mTECs 
represent a true population. 
Ebf2 expression was also detected in thymic fibroblasts. The importance of thymic 
fibroblasts was demonstrated in a previous study, which showed that growth 
factors provided by these cells are important for thymic regeneration after 
chemically induced atropy (Alpdogan et al., 2006). Furthermore they support early 
T cell development by providing extracellular matrix components (Anderson et al., 
1997) but their precise functional role is still poorly understood. Interestingly, Ebf2-
expressing fibroblasts are positive for the surface marker MTS15, which is specific 
to a unique population of thymic fibroblasts (Gray et al., 2007). MTS15 expressing 
fibroblasts line blood vessels at the corticomedullary junction, which is the entry 
site for common lymphoid progenitors (CLPs) from the peripheral blood stream 
into the thymus. Unlike the bone marrow, the thymus has no self-renewing 
potential and depends on the constant migration of CLPs from bone marrow into 
the thymus. Upon immigration into this zone, CLPs reside here for up to ten days 
(Petrie et al., 2007). MTS15+ cells express high levels of cytokines, e.g. SCF, IL-7 
and IL-6 (Gray et al., 2007). Therefore, we speculated that Ebf2 could potentially 
not only play an important role for the support of hematopoiesis in the bone 
marrow, but also in the thymus. However, our analysis of T cell development were 
performed in compromised animals with a strong HSC phenotype. As T cell 
progenitors derive from the bone marrow the T cell phenotype could be secondary. 
Therefore we transplanted thymic lobes into wild type animals. 
Upon transplantation, we could not observe the same phenotype, namely the 
reduction in total cellularity and CD4+ T cells. Furthermore, no reduction in any of 
the early T cell stages (DN1-DN4) was observed (data not shown), also arguing 
against a functional role for Ebf2 in the thymus. However, these results might also 
be explained by the observation that mesenchymal stem cells (MSCs) from the 
periphery can invade the thymus (Chamberlain et al., 2007). By this mechanism 
Ebf2-deficient cells could be replaced with host derived MTS15+ cells. The fact that 
we could detect Gfp positive mTECs, but no MTS15/Gfp double positive cells (data 
not shown) after transplantation argues that these cells were replaced by host-
derived cells. 
Due to the fact that we observed a reduction of thymic weights in four-week-old 
OsxCreEbf2fl/fl mice (the osterix promotor is specific to osteoblasts; Rodda and 
McMahon, 2006), it is most likely that indeed the defect in T cell development is a 
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secondary phenotype and originates from the bone marrow. Similarly to the bone 
marrow phenotype, alterations in thymic weights were only detected in four-week-
old OsxCreEbf2fl/fl animals but not in ten-week-old OsxCreEbf2fl/fl mice. The fact that 
Ebf2 transcript could be detected in thymic stromal cells of OsxCreEbf2fl/fl mice 
(data not shown) argues against an essential role for Ebf2 in T cell development. It 
is more likely that the number of CLPs entering the thymus is decreased and 
therefore T cell development is affected. While this may explain the reduction in 
total cellularity it does not explain why CD4+ T cells were reduced to a stronger 
extent than other T cell lineages. As no fibroblast specific cre lines are available, 
Ebf2fl/fl mice cannot be used to address this question. It would require the 
transplantation of Ebf2-LacZ-/- thymic lobes into Ebf2-Gfp+/- mice to gain further 
insights whether Ebf2-expressing stromal cells can populate transplanted thymi. 
5.6 Ebf2 influences the survival of B-CLL cells 
The aim of this project was to determine the relevance of Ebf2 in the support of 
human B-CLL cells. B-CLL is characterized by the accumulation of malignant B 
cells in the bone marrow and peripheral blood. Over time, these cells start to 
outgrow normal hematopoietic cells, leading to decreased immune function and 
bone marrow failure. A striking feature of B-CLL is that unlike other leukemia, B-
CLL rarely infiltrates other organs, which is strong evidence that bone marrow 
derived factors are required for cell proliferation and survival. As Ebf2 supports 
normal hematopoietic cells and is expressed in bone marrow stromal cells, we 
established an in vitro approach to address the question whether B-CLL cells 
respond to Ebf2 expressed by different stromal cells. In the clinic, zeta-chain-
associated protein kinase 70 (ZAP70) serves as a prognostic marker and ZAP70+ 
B-CLL cases show a faster disease progression (Chiorazzi et al., 2005). Therefore 
we investigated patient samples with differing ZAP70 status to find out whether 
subtypes of B-CLL depend more or less on Ebf2 expressed by stromal cells.  
In the experiments performed we used two different feeder layers in a gain and 
loss of function approach. Bone marrow derived IEO-Ebf2+/- cells were compared 
to IEO Ebf2-/- cells (loss of function). In parallel the stromal cell line EL28 (Ebf2 
non-expressing) was compared to EL28 Ebf2, which were transduced to 
overexpress Ebf2 (gain of function). In this experimental setup, Ebf2-mediated 
survival should be detectable in either experiments. Because certain studies 
indicate that only a very small fraction of B-CLL cells in the bone marrow 
proliferate and that the number of malignant cells generated is marginal compared 
to the amount of normal hematopoietic cells emerging every day (Chiorazzi et al., 
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2007), we decided to measure the apoptotic rate of the bulk population instead of 
investigating cell proliferation. Apoptosis is often used as final read out in such 
experiments but bears the problem that it is a very fast event and occurs within 
hours (Elmore et al., 2007). Due to the fact that the co-culture experiments 
performed in this study lasted for several days, we decided to measure the number 
of living cells at the end of co-culture instead of counting apoptotic events as 
readout for Ebf2-mediated effects. To do so, we combined an AnnexinV/7-AAD 
apoptosis assay with a quantitative FACS analysis. Thereby, the experimental 
readout becomes time independent. In an ideal experimental setting, apoptosis 
should be determined consistently every 12-24 hours, but the patient material 
provided was not sufficient. 
Eight patient samples were tested under two conditions. Three human samples 
responded to Ebf2 expression with increased survival while just one sample 
survived slightly better on Ebf2-deficient stromal cells (non-significant). 
Interestingly, two out of eight samples responded under both experimental 
conditions. Taking into account that B-CLL is a very heterogeneous disease, our 
results show the trend, that Ebf2 plays a role in the support of B-CLL cells. 
Furthermore, our data indicate that a differing ZAP70 status does not change the 
dependency on Ebf2. However, more samples need to be tested in this assay to 
draw final conclusions. Furthermore these results should be confirmed using other 
cell lines (HSC supporting and non-supporting counterpart) and should be 
strengthened by knockdown experiments. 
B-CLL mouse models offer a great tool to study the nature of the disease and new 
ways of treatment (Pekarsky et al., 2007; Santanam et al., 2010). Newly generated 
OsxCreEbf2fl/fl animals may be used to study the function of Ebf2 in B-CLL 
progression. Therefore, one could transplant bone marrow from B-CLL mouse 
models into OsxCreEbf2fl/fl animals of different age to address the role of Ebf2 in 
vivo. 
5.7 Long-term culture of B-ALL cells 
While prolonged survival of malignant cells in peripheral blood and bone marrow is 
a hallmark of B-CLL, B-ALL is characterized by high proliferation rates and 
aggressive invasion of lung, liver and lymphoid tissues by lymphoblasts. In a co-
culture based experiment we addressed the following questions: (1) whether CSCs 
can be maintained in vitro, (2) if CSCs depend on the same specialized bone 
marrow niche cells like non-malignant immature hematopoietic cells do and (3) 
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how their frequency changes on Ebf2-expressing and non-expressing feeder 
layers. Therefore we used a well-characterized human B-ALL patient sample with 
a known CSC frequency (originally determined by directly transplanting the 
leukemic cells from a mouse into another without in vitro culture) and plated these 
cells on confluent IEO (express Ebf2) and non-IEO (whole bone marrow stromal 
cells depleted for Ebf2-expressing niche cells) feeder layers isolated from Ebf2-
Gfp+/- mice. These co-cultures were then run for one month. 
As the CD phenotype of CSCs in B-ALL is unknown, a FACS analysis would not 
provide all information needed and we decided to use an in vivo readout system. 
Therefore the human B-ALL cells were transplanted into NOD/LtSz-scid IL2Rγnull 
mice (NSG) mice (Shultz et al., 2005). In this animal model the polygenic 
NOD/ShiLtJ strain (Anderson and Bluestone, 2005) was combined with the severe 
combined immune deficiency (Prkdcscid) mutation (Blunt et al., 1995) and the 
targeted IL2 receptor gamma chain (Il2rgtm1Wjl) deficiency (Cao et al., 1995). As a 
consequence, NSG mice lack mature B and T cells and have almost no NK cells. 
Furthermore they have defects in innate immunity and cytokine signaling 
pathways. As human cells develop normally upon transplantation, this animal 
model is widely used in the studies of hematopoietic stem cells and human 
disease like HIV, EBV and various types of cancer. 
Co-cultures were examined under the microscope every week and no signs of cell 
death or proliferation were observed. Therefore, B-ALL cells were most likely 
resting in G0 phase during co-culture. After four weeks the total B-ALL cell number 
was determined. We detected a mild reduction in total cell numbers on the IEO 
feeder layer compared to the numbers initially seeded while the number of B-ALL 
cells cultured on non-IEO stromal cells were almost unchanged. This indicates that 
IEO cells do not support the main B-ALL cell population as well as non-IEO cells 
do. However, no conclusion regarding the CSC frequency can be drawn from this 
result. To determine the CSC frequency, the harvested B-ALL cells were 
transplanted at limiting dilutions into NSG mice. Disease progression is driven by 
CSCs and their frequency is indirectly determined at the threshold limit, where the 
transplanted cell number does not cause leukemia in NSG mice.  
11 days post injection, animals that had been injected the highest dose of 
leukemic cells were detectably engrafted in the bone marrow (fluorescent signal 
from the knee). Although the B-ALL cells were originally isolated from the spleen of 
leukemic mice, they home to the bone marrow first. This is the regular pattern of 
engraftment detected in FACS analysis on prepared organs from leukemic mice 
(personal communication, Catarina Alves, HMGU). This result suggests, that the 
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B-ALL cells are very potent and survive in the spleen, but preferably home to the 
bone marrow where they originate from. Interestingly, in those mice injected with 
higher cell numbers, B-ALL cells cultured on non-IEO cells engrafted slightly 
better, leading to faster disease progression. This argues, that either the CSC 
frequency was maintained better or their number even increased on non-IEO cells 
compared to IEO cells. However, at lower cell numbers non-significant differences 
were observed.  
At the lowest cell number not all mice were engrafted one-month post injection. 
Based on these results the CSC frequency was calculated (about one in 3x103 B-
ALL cells) and was found to be unchanged compared to the initial frequency of the 
sample without in vitro culture. These results implicate that B-ALL cells do not 
specifically depend on the support of IEO niche cells but can be maintained on 
whole bone marrow stromal cells. This argues that they do not depend on the 
same niches like normal HSCs but they can be maintained in these niches.  
The detection of an unaltered CSC frequency after one month in vitro is a very 
interesting finding and has not previously been reported in the literature. In future 
experiments, we want to use this experimental setup to study different types of 
feeder layers to elucidate the minimal needs of B-ALL cells. This will provide 
valuable information why B-ALL can aggressively infiltrate other organs. 
  
6 Outlook 
Within the course of this study, we applied gene targeting in murine embryonic 
stem cells to generate mice with a conditional allele of Ebf2. Functional testing of 
this mouse model proved its functionality and confirmed an important functional 
role for the transcription factor Ebf2 in hematopoietic stem cell homeostasis. 
Furthermore, our results obtained from stromal cell type-specific deletions 
implicate, that specifically Ebf2-expressing osteoblastic cells are required for HSC 
homeostasis. However, our data suggest that this support is required only at 
certain stages of development and at the present point in time the contribution of 
other cell types cannot be excluded. 
Therefore, we will breed Ebf2fl/fl mice with additional stromal Cre lines and analyze 
these animals at the age of three to four weeks. As we speculate, based upon our 
DNA microarray data, that Ebf2 is required specifically for the homing and 
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proliferation of hematopoietic cells, it may be worth to investigate the 
hematopoietic recovery in adult Ebf2 conditional knockout mice after bone marrow 
suppression with 5-fluorouracil (5-FU). 5-FU is a chemotherapeutic drug that kills 
actively cycling bone marrow cells resulting in a partial bone marrow ablation. The 
recovery from this challenge requires intensive proliferation of hematopoietic stem- 
and progenitor cells and this process may require Ebf2.  
Our results obtained from the B-CLL co-cultures show, that the transcription factor 
Ebf2 can induce or repress genes that affect the survival of malignant B-CLL cells. 
To identify molecules that mediate this increased survival and reveal pathways of 
communication between feeder and B-CLL cells, we will analyze the gene 
expression profiles of EL28 mock- and EL28 Ebf2-transduced cells by DNA 
microarray. This data shall then be combined with the results from the DNA 
microarray experiment performed on IEO-Ebf2+/- and IEO-Ebf2-/- cells. In-depth 
bioinformatic analysis will allow for the identification of the signals provided by 
Ebf2-expressing stromal cells and may help to identify new Ebf2 target genes. 
To extend our knowledge on the minimal needs of B-ALL cells, we plan to perform 
additional co-culture experiments to test more B-ALL patient samples and different 
feeder layers. Finally, we want to find out whether this co-culture system could be 
used in drug development. Therefore, we will add well-established B-ALL drugs 
into co-cultures and study their effect on B-ALL cell proliferation and apoptosis by 
FACS. Influences on the CSC frequency will be determined by transplanting B-ALL 
cells at limiting dilutions into immunocompromised mice. 
 
7 Material and Methods 
7.1 Material 
7.1.1 Chemicals 
Chemicals were purchased from the following companies: Applied Biosystems, BD 
Biosciences, Biochrom (Berlin, Germany), BioRad (Munich, Germany), Eppendorf 
(Hamburg, Germany), GE Healthcare, Invitrogen , MBI-Fermentas (Thermo 
Scientific Inc.), Merck, Roth (Karlsruhe, Germany), Roche Applied Science, Sigma-
Aldrich, Stratagene. 
Material and Methods 71 
7.1.2 Instruments and devices 
Device Manufacturer 
Agarose gel chambers Peqlab Biotechnologie GmbH 
Accuracy weighing machine CP2245, Sartorius AG 
Bacterial incubator B6120, Heraeus, Thermo Scientific 
Blotting chamber Trans-Blot Semi-Dry Transfer Cell, 
Biorad 
Blotting paper Whatman 3mm, Schleicher & Schuell 
GmbH 
Cell culture material various, Nunc GmbH & Co KG 
 verschiedene, Falcon 
Cell counter CASY TTC, Innovatis 
Centrifuges Rotina 38R, Hettich 
 
 
Micro 200R, Hettich 
 Eppendorf centrifuge, 5424, Eppendorf 
CO2-inkubator CB150, Binder 
Cryo-tubes Nunc GmbH & Co KG 
Cuvette Uvette, 220 nm, Eppendorf 
Film developer Cawomat 2000IR, Cawo 
Electroporation cuvettes Gene Pulser, Bio-Rad 
Electroporation system Gene Pulser, Bio-Rad 
FACS machines FACSCalibur, Becton Dickinson 
 FACSAriaIII, Becton Dickinson 
 FACSCanto, Becton Dickinson 
Glass ware Schott, Braun 
Heating block Thermomixer Compact, Eppendorf 
Ice machine Scotsman AF 200, Scotsman Icesytem 
Improved counting chamber  Karl Hecht GmbH&Ko KG 
Refrigerator and freezer Liebherr GmbH 
 Privileg, Quelle 
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Device Manufacturer 
Laminar flow Herasafe KS12, Heraeus 
Magnet stirer RCT basic safety control (IKA) 
Microwave Panasonic 
Microscope Axiovert25, Zeiss 
Nitrocellulose membrane Protran, Whatman 
PCR machine DNA Engine, Bio-Rad 
SDS-PAGE chamber Mini-Protean, Bio-Rad 
Spectro photometer BioPhotometer, Eppendorf 
Powersupply Power Pack, Bio-Rad 
Pipettes Gilson 
pH meter 763 Multi Calimolic, Knick 
Reaction vessels 0,2 ml PCR-reaction tube, Biozym 
Diagnostik 
 15 ml, 50 ml, Falcon 
 0,5 ml, 1,5 ml, 2 ml, Eppendorf  
Shakers Polymax 1040, Heidolph 
 Reax2, Heidolph 
Thermo cycler Light Cycler 480II, Roche 
UV-Crosslinker Stratalinker 1800, Stratagene 
UV-Transilluminator San Gabriel 
Vacuum pump BVC 21, Vacuubrand 
Vortexer Vortex Genius (IKA) 
Waterbath Sub6, Grant 
 
7.1.3 Software 
Adobe Photoshop CS5, Adobe Illustrator CS5, MacVector, CellquestPro, Endnote, 
FlowJo, Microsoft Excel, Microsoft Word 
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7.1.4 Statistics 
P-values were calculated using „complete one-way analysis of variance“ (ANOVA). 
If the calculated P-values are > 0.05 for the statistical comparison the graph is 
marked as n.s. (=non-significant). 
7.1.5 Enzymes 
Enzyme Manufacturer 
Collagenase typeIA Sigma-Aldrich 
Dispase II Roche 
Fire-Pol DNA polymerase Solis BioDyne 
Phusion DNA polymerase Finnzymes, Thermo Scientific 
Proteinase K Roth 
Restriction enzymes MBI Fermentas, New England Biolabs 
T4 DNA ligase Invitrogen 
Taq DNA polymerase Invitrogen 
 
7.1.6 Western blot antibodies 
Antibody Manufacturer 
Anti-β-actin antibody, clone AC-74 Sigma-Aldrich 
Anti-EBF antibody, clone 6G6 E. Kremmer, HMGU, R. Grosschedl 
Goat-anti-mouse IgG (Fc-spec.) 
peroxidase conjugated 
Sigma-Aldrich 
Goat-anti-rat peroxidase conjugated Jackson Immuno Research 
 
 
7.1.7 FACS antibodies 
Antigen Manufacturer Clone 
CD8a, FITC BD Biosciences clone 53-6.7 
CD4, FITC BD Biosciences rm4-5 
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Antigen Manufacturer Clone 
CD11b, FITC BD Biosciences M1/70 
Ter119, FITC BD Biosciences TER119 
Gr1, FITC BD Biosciences RB6-8C5 
B220, FITC BD Diosciences RA3-6B2 
G8.8 (EpCAM) Hybridoma supernatant 
(AG Klein) 
 
Sca1, PE BD Biosciences D7 
CD4, APC BD Biosciences cloneGK1.5 
c-Kit, APC BD Biosciences 2B8 
CD45 BD Biosciences A20 
Ly51 BD Biosciences BP-1 
CD80 BioLegend B7.1 
MTS15 Hybridoma supernatant 
(AG Boyd) 
 
 
7.1.8 Size markers 
Name Manufacturer 
1 kb Ladder (DNA) Fermentas 
100 bp Plus DNA Ladder, 100-3000 Fermentas 
Prestained SDS-PAGE Standard Fermentas 
 
7.1.9 Kits 
Name Manufacturer 
Plasmid Miniprep Kit Sigma-Aldrich 
Plasmid Plus Midi Columns Qiagen GmbH 
EndoFree Plasmid Maxi Kit Qiagen GmbH 
Wizard SV Gel and PCR Clean-Up 
System 
Promega 
Random Prime Labeling Kit Amersham Bioscience 
Illustra G-50 Micro Columns GE Healthcare 
Illumina RNA amplification Kit Illumina 
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Name Manufacturer 
CloneJET PCR Cloning Kit Fermentas 
Ki67 proliferation detection Kit BD Pharmingen 
 
7.1.10 DNA Microarray 
Name Manufacturer 
MouseWG v2.0 Expression Beadchip Illumina 
 
7.1.11 Plasmids and BAC clones 
Name Description 
MSCV-IRES-GFP 
(Dr. R. Moriggl) 
This vector encodes the murine stem 
cell virus and was used to generate 
retroviral packaging cell lines. 
pEZ FrtLox DT 
(Dr. M. Schmidt-Supprian) 
This plasmid contains 2x Frt and 2x 
LoxP sequences, a PGK-neomycin 
selection cassette and the diphteria 
toxin A gene to avoid random 
integration. This vector served as 
backbone for the Ebf2 targeting. 
pJET1.2/blunt 
(Fermentas) 
This vector was used for subcloning 
and sequencing of PCR products. 
RP23-148l22 
(imaGenes GmbH) 
C57BL/6 BAC clone containing region 
67.845.129-67.865.129 of chromosome 
14. Used as template in PCR reactions 
to generate left and right arm of 
homology, insert region and both 
southern blot probes. 
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7.1.12 Southern blot probes 
Name Application 
BglII probe 
(chr. 14: 67.861.329-67.861.550)  
Probe used in southern blot to identify 
ES cell clones positive for homologous 
recombination at the Ebf2 locus. The 
probe was generated by PCR. 
Hybridisation temperature: 56°C. 
Washing: 3x 10 minutes at 58°C with 
0.1% SSC, 0.5% SDS. 
SpeI probe 
(chr. 14: 67.850.279-67.850.624) 
Probe used in southern blot to identify 
ES cell clones positive for homologous 
recombination at the Ebf2 locus. The 
probe was generated by PCR. 
Hybridisation temperature: 58°C. 
Washing: 3x 10 minutes at 60°C with 
0.2% SSC, 0.5% SDS. 
 
7.1.13 Oligonucleotides 
7.1.13.1 Oligonucleotides used in quantitative real time PCR 
Name Sequence 
Actin Fw tgt ggt ggt gaa gct gta gc 
Actin Rw gac gac atg gag aag atc tgg 
Ebf1 Fw gtc acc aca agc atg aat gg 
Ebf1 Rw tct gac aac tgg tgc gaa ag 
Ebf2 Fw tgg aga atg aca aag agc aag 
Ebf2 Rw ggg ttt ccc gct gtt ttc aaa 
Ebf3 Fw aga gcc gaa caa cga gaa aa 
Ebf3 Rw gca cat ctc cgg att ctt gt 
GFP Fw gcc cga agg tta tgt aca gg 
GFP Rw tga tgc cat tct ttg gtt tg 
Material and Methods 77 
Name Sequence 
HPRT Fw tgc tgg tga aaa gga cct ctc g 
HPRT Rw tct ggg gac gca gca act ga 
 
7.1.13.2 Oligonucleotides used to genotype mice 
Name Sequence 
Cre Fw ccc acc gtc agt acg tga gat atc 
Cre Rw cgc ggt ctg gca gta aaa act atc 
Ebf2 GFP Fw ggc ctg ggt tgt agt aac cat 
Ebf2 GFP Ko ctg agc atg atc ttc cat cac 
Ebf2 GFP Rw ttc aga gct ggt cct ctt cc 
Ebf2 cko 1 caa ctc tga acc agg cgt tt 
Ebf2 cko 3 cag tcg ctg gga gag taa gc 
Ebf2 cko I ctg ttt taa ccg agc aaa gac t 
Ebf2 cko III gcc gca agc tta taa ctt cgt at 
Ebf2 LacZ Fw gag gcg gca gat ctg aag 
Ebf2 LacZ Rw cca atg ctg cca gca aat g 
Ebf2 LacZ Ko cat tca ggc tgc gca act gtt 
 
7.1.13.3 Oligonucleotides used for cloning 
Name Sequence 
BglII probe B2 Fw  tca gac tga gac cag ggc ttt 
BglII probe B2 Rw  gcc tct cct ccc tat gga atc 
Insert Fw gtc gac tgg ttg att ccg ttt tat g 
Insert Rw gtc gac aat gaa gcc tgg ccc aac 
LHR Fw atc gat aag gcc gac tgc tcc tct at 
LHR Rw gcg gcc gca act agt ccc ctg ccc tct tt 
RHR Fw ctc gag tta gat ctg gga cga ggg ctc 
RHR rw ctc gag gtc tag tca gcc aaa ctc cagc 
SpeI probe short Fw gag tta gtt gtg ggg tga ggg 
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Name Sequence 
SpeI probe short Rw gag tct cgc gtt cca tcc tcg 
 
7.1.13.4 Oligonucleotides used in RT-PCR 
Name Sequence 
Ebf2 cko RT Fw cct tta cag caa cgg tgt cc 
Ebf2 cko RT Rw tat ggg ctg ttt ggt gac ag 
 
7.1.14 Bacteria 
Name Genotype 
XL-1 blue Competent Cells recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F ́ proAB lacIqZ∆M15 
Tn10 (Tetr)], Stratagene. 
 
7.1.15 Cell lines 
Name Description 
Bruce4 C57BL/6 murine embryonic stem cells. 
(Kindly provided by PD Dr. U. Zimber-
Strobl, HMGU) 
EL08 Stromal cell line isolated from mouse 
AGM region. This cell line was used as 
a positive control in co-culture 
experiments. (Kindly provided by Dr. 
R.Oostendorp, TUM) 
EL28 Stromal cell line isolated from mouse 
AGM region. This cell line was used as 
a negative control in co-culture 
experiments. (Kindly provided by Dr. 
Material and Methods 79 
Name Description 
R.Oostendorp, TUM) 
GP+E86 This fibroblast cell line was used to 
produce retroviruses to infect murine 
stromal cell lines. 
HEK293T cells Modified from HEK293 cells, this cell 
line expresses the SV40 large T 
antigen. HEK293T cells were used to 
generate retroviruses to infect GP+E86 
cells. 
MEF Generated from pSV2 neo/PEP-IL 4 
C57BL/6 mice these mouse embryonic 
fibroblasts carry a neomycin resistenz. 
(Kindly provided by Dr. R.Kühn, HMGU) 
 
7.1.16 Mouse strains 
Name Description 
B6;SJL-Tg(ACTFLPe)9205Dym/J 
(Within this thesis we used the name: 
FlpE) 
Transgenic mouse strain expressing 
Flp recombinase under control of the 
human beta actin promotor. Flp 
recombinase is active in all tissues, 
including the germ line. 
B6.C-Tg(CMV-cre)1Cgn/J 
(Within this thesis we used the name: 
DelCre) 
Transgenic mouse strain expressing 
Cre recombinase under control of the 
minimal human cytomegalovirus 
promotor. Cre recombinase is active in 
all tissues, including the germ line. 
B6.Cg-Tg(Fabp4-cre)1Rev/J 
(Within this thesis we used the name: 
AP2Cre) 
Transgenic mouse strain expressing 
Cre recombinase under control of the 
fatty acid binding protein 4 promotor. 
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Name Description 
Cre recombinase expression is 
detected in brown and white gonadal 
and subcutaneous adipose tissue. 
B6.Cg-Tg(Prrx1-cre)1Cjt/J 
(Within this thesis we used the name: 
PrxCre) 
Transgenic mouse strain expressing 
Cre recombinase under control of the 
paired related homeobox 1 promotor. 
Cre recombinase expression is 
detected in early limb bud 
mesenchyme. 
B6.Cg-Tg(Sp7-tTA,tetOEGFP/cre)1-
Amc/J 
(Within this thesis we used the name: 
OsxCre) 
Transgenic mouse strain expressing 
Cre recombinase under control of the 
mouse Sp7 (formerly called osterix) 
promotor. Cre recombinase expression 
is detected in the osteoblast lineage. 
C57BL/6 (Charles River, WIGA) C57BL/6 wild type mice were used in all 
breedings. 
Ebf2+/neo-fl Transgenic mouse strain carrying 2 Frt 
sequences, 2 loxP sequences and a 
PGK-neomycin resistenz  cassette in 
one allele of the Ebf2 gene. 
Ebf2+/fl Transgenic mouse strain with one 
conditional allele of Ebf2 carrying 2 
loxP sites. 
Ebf2+/Δfl Transgenic mouse strain with 
recombined LoxP sites. Ebf2 encoding 
exons 4-6 were thereby deleted. 
Ebf2-Gfp+/- Transgenic mouse strain expressing 
Gfp under control of the endogenous 
Ebf2 promotor (Dr. R. Reed, JHMI 
Baltimore). 
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Name Description 
Ebf2-LacZ+/- Transgenic mouse strain expressing 
beta-galactosidase under control of the 
endogenous Ebf2 promotor (Dr. G. G. 
Consalez, ISR Milan). 
NOD.Cg‐Prkdcscid Il2rgtm1Wjl/SzJ NOD.Scid.IL2-receptor γ knockout. 
Mice show reduced dendritic cell 
function, defective macrophages, no 
mature T and B cells, blocked signaling 
from 6 distinct interleukins to prevent 
NK cell development and were used for 
xenograft transplants. 
 
7.2 Cell culture 
7.2.1 Generell cell culture techniques 
In context of this work human and murine primary cells and cell lines were 
cultured. Cells were kept in an incubator (Binder) at 37°C, 5% CO2 and 100% 
relative humidity. Cells were passaged when 80% confluency, being defined here 
as 80% of the cell culture dish surface being covered with cells, was reached. If 
not stated otherwise, cells were spun down at 250 g, for 6 minutes at room 
temperature. Any manipulation or treatment of cells was performed under a sterile 
laminar flow (Heraeus). All working steps were performed with sterile material 
according to sterile working practices. 
7.2.2 Cell culture media 
Primary osteoblastic cells 
500 ml   MEMalpha (Gibco) 
10% (50 ml)    FCS (PAA) 
1% (6 ml)    Glutamine (Gibco) 
1% (6 ml)    Penicillin/Streptomycin (10000 U/ml, 10000U/ml, Gibco) 
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Murine embryonic stem cells 
500 ml    DMEM (Dulbecco´s Modified Eagle´s Medium, Gibco) 
 12% (75 ml)   FCS (ES cell approved, PAA) 
 2% (12 ml)   HEPES (Gibco) 
1% (6 ml)    Sodium Pyruvate (Gibco) 
1.5 % (9 ml)   Glutamine (Gibco) 
50 mM   Beta-mercaptoethanol (Gibco) 
2000 Units    LIF (leukemia inhibitory factor) 
 
GP+E86 
500 ml    DMEM (Dulbecco´s Modified Eagle´s Medium, Gibco) 
10% (50 ml)   FCS (PAA) 
1% (6 ml)   Glutamine (Gibco) 
1% (6 ml)     Penicillin/Streptomycin (10000 U/ml, 10000U/ml, Gibco) 
 
Thymic embryonic lobes 
500 ml   IMDM (Iscove´s Modified Dulbecco´s Medium) 
10% (50 ml)   FCS (PAA) 
200 mM   Deoxyguanosine (Sigma-Aldrich) 
 
Murine embryonic fibroblasts 
500 ml   DMEM (Dulbecco´s Modified Eagle´s Medium, Gibco) 
10% (50 ml)   FCS (PAA) 
1% (6 ml)     Glutamine (Gibco) 
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Adherent cell lines (EL08, EL28) and co-cultures (B-CLL and B-ALL) 
500 ml    RPMI (Gibco) 
10% (50 ml)   FCS (PAA) 
1% (6 ml)     Glutamine (Gibco) 
1% (6 ml)     Penicillin/Streptomycin (10000 U/ml, 10000U/ml, Gibco) 
 
7.2.3 Passaging of cells 
Description of the general procedure for a 10 cm cell culture dish: culture medium 
was removed and cells were washed with 10 ml PBS. To detach the cells, 3 ml 
trypsin was added and the cells were transferred to a 37°C incubator for 5-10 
minutes (depends on cell type). After optical control with a microscope (all cells 
need to swim in medium) the reaction was stopped by addition of 7 ml of complete 
cell culture medium (7.2.2). Cells were then vigorously pipetted up and down to 
generate a single cell suspension, transferred to a falcon tube and harvested by 
centrifugation (250 g, 6 min at room temperature). The pellet was then 
resuspended in fresh medium and cells were plated onto a new culture dish. 
7.2.4 Cell countings 
Cells were counted with a CASY TTC cell counter (Innovatis) according to the 
manufacturer´s protocol. Briefly, an aliquot of 50 µl trypsinized cells was 
transferred to a 15 ml Falcon tube with 10 ml PBS. Tube was inverted a few times 
before measurement. Parameters on the device were adjusted specifically for 
each cell type and the final cell number was the average, calculated from three 
independent measurements. 
For ES cell culture the cells were counted under a microscope using an improved 
counting chamber (Hecht). 
7.2.5 Thawing and freezing of cells 
For long-term storage, cells were trypsinized and harvested as described (7.2.3). 
After centrifugation, 1x106 cells were resuspended in 1 ml freezing medium (90% 
FCS, 10% DMSO) and transferred to a cryo-tube. Immediatly afterwards, vials 
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were put into a pre-cooled freezing box (Nunc, Thermo Scientific) and moved to a -
80°C freezer. The next day cells were moved into a liquid nitrogen tank. 
To thaw cells, cryo-vials (Nunc, Thermo Scientific) were removed from liquid 
nitrogen and subsequently put in a 37°C waterbath until still partly frozen. Cells 
were then resuspended in 10 ml of complete medium and harvested. After 
centrifugation, cells were resuspended in fresh medium and plated. 
7.2.6 Mitotic inactivation of MEFs 
Prior to co-culture experiments with ES cells, MEFs were mitotically inactivated by 
incubation in 10 mg/ml Mitomycin C (Sigma-Aldrich) for 2 hours. After treatment, 
cells were washed 3 times with PBS and replated at a density of 2.5x106 cells per 
10 cm dish. ES cells were added at the earliest 6 hours after treatment. 
7.2.7 Co-cultures 
To maintain their pluripotency, murine embryonic stem (ES) cells were cultured on 
mouse embryonic fibroblasts. Therefore, MEFs were mitotically inactived by 
Mitomycin C treatment (7.2.6). Thereafter, 0.8x106 ES cells were added and 
provided with fresh ES cell medium every 24 hours. ES cells were passaged as 
described (7.2.3) when colonies reached a certain size and were round-shaped 
with distinct borders, using trypsin supplemented with 3% chicken serum (Gibco). 
Human ALL and CLL patient cells were cultured on mouse aorta-gonad-
mesonephros (AGM) derived adherent cell lines EL08 and EL28. Prior to co-
cultures cell lines were plated into 48-well plates (5x104 cells/well). On the next 
day ALL or CLL cells were added. Immature Ebf2 expressing osteoblastic (IEO) 
cells were plated at 2500 cells per 48-well and cultured till 80% confluency was 
reached before ALL or CLL cells were added. Cells were fed every 48 hours by a 
partial medium exchange (50%) and kept in culture for up to 30 days. 
7.2.8 Separation of blood leukocytes by Ficoll gradient 
B-CLL cells from frozen human peripheral blood samples were isolated by ficoll 
gradient centrifugation. Therefore, samples were thawed, cells were resuspended 
in 20 ml medium and transferred to a 50 ml falcon with 10 ml of ficoll. After 
centrifugation (490 g, 20 minutes at RT with the centrifuge´s brake disabled) cells 
were harvested from the intermediary phase with a 20 ml pipette. Residues of ficoll 
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were removed by two PBS washing steps before cells were harvested, 
resuspended in RPMI and used in co-cultures. 
7.2.9 Flow cytometry 
For fluorescence activated cell sorting, single cell suspensions were prepared. 
Unspecific antibody binding was inhibited by Fc-block (20 minutes pre-incubation 
of the cells with a monoclonal CD16/CD32 rat anti-mouse antibody at room 
temperature). Stainings were performed in FACS buffer (1x PBS, 1.5% FCS) for 
20 minutes at 4°C in the dark. Prior to analysis, cells were washed twice with cold 
FACS buffer and propidium iodide (10 µg/ml final concentration) was added just 
before measurement. For FACS sorting, a FACSAriaIII (Becton Dickinson) was 
used. All other experiments were recorded on a FACSCalibur (Becton Dickinson) 
and FACSCanto (Becton Dikinson). Software for recording was Cellquest (Becton 
Dickinson) and FACSDiva (Becton Dickinson). FlowJo 9.3 (Treestar) was used to 
analyze data. 
7.2.10 Detection of apoptosis 
Early apoptotic cells in co-culture experiments were detected with an AnnexinV 
apoptosis detection kit (Becton Dickinson). Experimental procedures were 
performed according to the manufacturer´s protocol. Briefly, cells were harvested 
by centrifugation and resuspended in 95 µl AnnexinV staining buffer supplemented 
with 5 µl AnnexinV and 5 µl 7-AAD. Tubes were vortexed and kept in the dark at 
RT for 15 minutes. Then 400 µl AnnexinV staining solution was added and 
samples were analyzed by flow cytometry. 
7.2.11 Quantitative flow cytometry 
To determine the number of living cells at the end of co-culture experiments, PCB 
100 Accu Check Counting Beads (Invitrogen) were used. Prior to FACS 
measurements 30 µl (1000 Beads per µl) of FACS beads were added to each 
sample. 
7.2.12 Transfection of ES cells 
To generate stably transfected ES cell clones, cells were grown to a density of 
about 0.7x107 ES cells per 10 cm dish on a MEF feeder layer (about 50% of MEFs 
are covered with ES cell clones).  Cells were harvested, washed and 1x107 cells 
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were resuspendend in 700 µl of RPMI without phenol red and transferred to an 
electroporation cuvette (Gene Pulser cuvette, 0.4 cm electrode, Bio-Rad). 20 µg of 
the linearized pEZ FrtLox DT Ebf2 cko plasmid were resuspended in 100 µl of 
RPMI without phenol red and were added to the cells. Transfection was performed 
with an electroporator (Gene Pulser, Biorad) at 230 V, 500 µF. Cells were plated 
on MEFs and 32-48 hours after transfection G418 (Gibco) was added to start 
selection. Concentrations of G418 were increased by 10 mg/ml every day (lowest 
180 mg/ml, highest 220 mg/ml). 
7.2.13 Isolation and expansion of stably transfected ES cell 
clones 
7-9 days after transfection, single ES cell colonies were transferred to round 
bottom 96-well plates with a 200 µl pipette. Therefore the ES cell medium was 
removed and replaced with PBS. Next, the plate was put under a microscope and 
each colony was isolated by scratching the colony from the plate with the pipette 
tip while simultaneously sucking the clone into the tip with 25 µl PBS. The decision 
on which clones to pick was based on two main criteria: size (all clones should 
have a similar size (this is important for later freezing)) and appearance (round 
shaped and distinct borders). Colonies were then trypsinized in 50 µl trypsin (3% 
chicken serum) at 37°C for 10 minutes and passaged on three 96-well plates 
(plate A, B and C) with MEFs (1.8x106 per 96-well plate). 2-3 days after picking, 
cells on plate A were frozen by trypsinisation and addition of freezing medium 
(final DMSO concentration was 10%). Plate B was frozen about 36 hours later. 
Cells on plate C were passaged on two gelatinized 96-well plates, grown to 
confluency and analyzed for homologous recombination by southern blot. 
7.2.14 Retroviral infection 
Retroviral producer cell lines were generated based on the murine stem cell virus 
(MSCV). HEK-293 cells were electroporated with MSCV-mock-IRES-GFP / MSCV-
Ebf2-IRES-GFP and a helper-Plasmid (encodes viral gag-, pol- env-genes) to 
generate retroviruses. On three consecutive days, supernatant of freshly 
transfected HEK-293 cells was transfered onto proliferating GP+E86 cells and 
polybrene (6 mg/ml, Millipore) was added to increase the infection rate. Next, cells 
were harvested and 300.000 highly GFP positive GP+E86 cells were FACS sorted 
and expanded on a new 10 cm dish till 80% confluency. This procedure was 
repeated three times. Finally, the supernatent of GP+E86 cells was passed 
through a 0.22 µm filter and was put on proliferating stromal cells. This procedure 
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was repeated every 12 hours on three consecutive days and polybrene (6 mg/ml, 
Millipore) was added each time to increase infection rates. 
7.3 Molecular biology 
7.3.1 Working with RNA 
7.3.1.1 Lysis of eukaryotic cells 
Adherent cells were harvested by trypsinisation and 1x106 cells were transferred to 
a 15 ml falcon and collected by centrifugation (250 g, 6 min at 4°C). After removal 
of the supernatant, cells were lysed in 2 ml peqGOLD Trifast. RNA was extracted 
as described (7.3.1.3). 
7.3.1.2 Lysis of primary cells after FACS sorting (DNA microarray) 
IEO cells were sorted right into a 1.5 ml tube containing 1 ml of peqGOLD Trifast 
and RNA was extracted as described (7.3.1.3). 
7.3.1.3 RNA extraction 
To 1 ml of peqGOLD Trifast, 0.2 ml chloroform were added. Samples were mixed 
vigorously and incubated at RT for 5 minutes. The organic and aqueous phases 
were seperated by centrifugation (12000 g, 5 min at 4°C). 0.5 ml of the upper 
aqueous phase were transferred into a new 1.5 ml tube and mixed with 0.5 ml 
chilled isopropanol and 1 µl of glycogen (Ambion). After incubtion for 30 minutes 
on ice, RNA was precipitated by centrifugation (12000 g, 15 min at 4°C). The 
supernatant was removed and the RNA pellet washed with 1 ml 70% (v/v) ethanol 
(DEPC water). After harvesting the RNA pellet by centrifugation (12000 g, 5 min at 
4°C), the supernatant was thoroughly removed and the pellet was dried for 1 
minute at 50°C. Right afterwards the RNA pellet was resuspended in 20 µl of 
RNAse free water. Samples were either directly used in a downstream application 
or frozen on dry ice for storage at -80°C. 
7.3.1.4 RNA processing for DNA microarray experiments 
RNA samples were prepared as described (7.3.1.3). Prior to amplification the RNA 
quality was determined using the Bioanalyzer 2100 plattform (Agilent 
Technologies) and an „Agilent RNA 6000 Nano Kit“ (Agilent Technologies). 
Thereafter, a RNA amplification- and labeling step was performed using Illumina® 
TotalPrepTM-96 RNA Amplification Kit (Illumina) according to the manufacturer´s 
protocol. Genexpression profile analyses were performed using MouseWG v2.0 
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Expression Beadchips (Illumina). Arrays were scanned using an iScan System 
(Illumina) and data was analyzed using BeadStudio Data Analysis Software 
(Illumina).  
7.3.1.5 cDNA synthesis from total RNA 
cDNA was synthesized according to the manufacturer´s protocol for first strand 
cDNA synthesis, using Superscript II (Invitrogen). First, the RNA was dissolved in 
10 µl water. Next, 1 µl oligo dT primer (500 µg/ml, Fermentas) and 1 µl of 10 mM 
dNTPs were added. The mixture was incubated at 65°C for 5 minutes, cooled to 
4°C before 4µl first strand synthesis buffer, 1 µl of 0.1 mM DTT and 1 µl of RNAsin 
were added. The solution was incubated at 42°C for 2 minutes. Right afterwards 1 
µl of Superscript II RT was added and cDNA was synthesized during incubation at 
42°C for 50 minutes. Heat inactivation of the enzyme was secured by a 15 minute 
incubation step at 70°C. 
7.3.1.6 Quantitative real time PCR 
Gene expression analyses were performed according to the manufacturer´s 
protocol for the Lightcycler 480 Real Time PCR System (Roche). Oligonucleotides 
were designed to be intron spanning using tools provided on the manufacturer´s 
website. Measured values were normalized to hypoxanthine guanine 
phosphoribosyl transferase 1 (Hprt1) expression levels. Each experiment was 
performed in technical triplicates. The average and standard deviation were 
calculated based on the Cp values of the triplicates.  
7.3.2 Working with DNA 
7.3.2.1 Plasmid DNA isolation 
For cloning purposes plasmid DNA was isolated from bacterial cultures using 
GenElute Plasmid Miniprep Kit (Sigma-Aldrich). Isolation was performed according 
to the manufacturer´s protocol. 
7.3.2.2 Extraction of genomic DNA for genotyping 
Mouse-tails were suspended in 100 µl tailbuffer (1x Fire Polymerase Buffer, Solis 
BioDyne) supplemented with 50 mg/ml proteinase K and incubated at 56°C O/N. 
After heat-inactivation at 95°C for 15 minutes on the next day, 1 µl of the solution 
was used in PCR reactions. 
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7.3.2.3 Extraction of genomic DNA from ES cell clones (96-well format) 
Confluent ES cell clones were lysed by addition of 50 µl ES cell lysis buffer (10 
mM Tris pH 7.4, 10 mM EDTA, 10 mM NaCl, 0.5% SDS, 1 mg/ml proteinase K) 
and O/N incubation at 56°C in a humidified atmosphere. On the next day, DNA 
was precipitated with 100 µl ice-cold pure ethanol. After ethanol removal and two 
washing steps with 70% ethanol, the DNA was air dried and resuspended in 30 µl 
water. 
7.3.2.4 Extraction of genomic DNA from ES cell clones (10 cm dish) 
For ES cell clone sequencing purposes, clones were grown till confluency on 10 
cm plates, washed twice with 10 ml PBS and lysed in 5 ml ES cell lysis buffer 
(7.3.2.3). After transfer to a 50 ml falcon tube, cells were incubated at 56°C O/N. 
DNA was precipitated (7.3.2.6) and used in PCR reactions. 
7.3.2.5 Extraction of DNA 
1 volume of phenol/chloroform (1:1) was added to the DNA sample, mixed 
vigorously and centrifuged (14000 rpm, 10 min at 4°C). The upper aqueous phase 
was transferred to a new tube and 1 volume of chloroform was added. After 
centrifugation (14000 rpm, 15 min at 4°C) the upper aqueous phase was 
transferred to a new tube and DNA was precipitated (7.3.2.6). 
7.3.2.6 Precipitation of DNA 
DNA was precipitated by the addition of 1/10 volume of sodium acetate (3 M, pH 
5.2) and 2 ½ volumes of pure Ethanol. After mixing, the solution was incubated on 
ice for 30 minutes. DNA was harvested by centrifugation (14000 g, 30 min at 4°C) 
and the DNA pellet was washed in 70% ethanol and once again centrifuged 
(14000 g, 30 min at 4°C). The supernatant was discarded and the DNA pellet was 
air dried and dissolved in 100 µl water. 
7.3.2.7 Restriction analysis of DNA 
For cloning and southern-blot analysis, DNA was cut with restriction enzymes. If 
not stated otherwise, reactions were performed according to the manufacturer´s 
protocol. 
7.3.2.8 Restriction analysis of genomic DNA (96-well plate) 
In context of southern-blot analysis, genomic DNA was cut in 96-wells (prepared 
as described 7.3.2.3). For this purpose, dissolved DNA was supplemented with 1 
mM spermidin, 1 mM DTT, 100 mg/ml RNAse, 5 µl 10x restriction buffer and 50 
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units of the desired restriction enzyme. After sealing the plate with parafilm, 
reactions were incubated O/N at 37°C. 
7.3.2.9 Agarose gel electrophoresis 
DNA fragments derived from PCR reactions and restriction reactions were 
separated on gels: 1xTAE buffer (40 mM Tris/HCl, 20 mM Acetate, 1 mM EDTA, 
pH 8.5) supplemented with 0.8-3% Agarose. 1x TAE buffer served as running 
buffer. Separation was performed at 42-180 V for 0.5-16 hours. To detect DNA 
fragments 10 µl ethidium bromide (5 mg/ml) per 100 ml gel were added. A size 
marker supplemented with bromphenolblue was used for orientation. 
7.3.2.10 Southern blot analysis 
DNA was separated by agarose gel electrophoresis (7.3.2.9). Next, gel slices were 
shaken in 0.25 M HCl for 20 minutes, were briefly washed with water and 
subsequently incubated in alkaline transfer buffer (0.4 M NaOH, 0.6 M NaCl). 
Blotting of DNA from the gel onto a nylon membrane (Immobilon, Millipore) was 
performed overnight from top to bottom by capillary pressure of the transfer buffer. 
The next day, slots were marked directly on the membrane using a soft pencil. 
Thereafter, the basic membrane was neutralized in 2x SSC (0.3 M NaCl, 0.03 M 
sodium citrate, pH 6.5) for 20 minutes at RT. DNA crosslinking was performed with 
UV-light (Stratalinker, Stratagene) according to the manufacturer´s protocol. 
Prior to hybridization with a radioactively labeled probe, membranes were pre-
hybridized by incubation in warm (56°C) Church buffer (0.4 M Na2HPO4, 0.1 M 
NaH2PO4, 7% SDS, 0.1 mM EDTA). 50-100 ng of a specific probe were 
radioactively labeled using Amersham Ready-To-Go DNA labeling Beads (GE 
Healthcare) according to the manufacturer´s protocol. Non-incorporated 
radioactivity was removed using illustra sephadex G-50 DNA grade columns (GE 
Healthcare). Prior to hybridization, probes were denaturated by incubation at 95°C 
for 4 minutes, followed by subsequent quenching at 4°C for 2 minutes. Probes 
were pipetted directly into the hot Church buffer and were hybridized (7.1.12) with 
the membranes over night. The next day, the buffer was removed and membranes 
were washed (7.1.12). 
7.3.2.11 Polymerase chain reaction (PCR) 
DNA fragments were amplified in PCR reactions for genotyping, cloning, 
sequencing, RT-PCR and southern-blot purposes. Except for clonings and 
sequencing all experiments were performed with FirePol DNA polymerase (Solis 
BioDyne). Phusion High-Fidelity DNA polymerase (Thermo Scientific) was used for 
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PCR reactions related to sequencing and cloning. Experiments were performed 
according to the guidelines given in the manufacturer´s protocols. Annealing 
temperature was adjusted to the oligonucleotides used. Elongation time was 
adjusted to product lengths. Oligonucleotides used are listed under (7.1.13). 
7.3.3 Protein methods 
7.3.3.1 Protein extraction 
1x106 cells were harvested, washed and resuspended in 200 µl lysis buffer (50 
mM tris/HCl, pH 8; 150 mM NaCl; 1 % NonidetTM P 40 substitute (Sigma)). 
Thereafter, lysates were incubated on ice for 40 min. To prevent protein 
degradation complete, mini, EDTA-free tablettes (Roche) were added according to 
the manufacturer´s protocol. Finally, lysates were centrifuged (18600 g, 5 min at 
4°C) and supernatants were used in downstream applications or were shock 
frozen in liquid nitrogen. 
7.3.3.2 Western blot analysis 
Protein concentrations were determined with a BCA protein Assay Kit (Pierce) 
following the instructions given in the manufacturer´s protocol. Briefly, reagent A 
and B were mixed (50:1). To generate a calibration curve, BSA (PAA laboratories) 
was added at different concentrations (0, 2, 4, 8, 10 and 15 µg/µl) to a total volume 
of 400 µl of reagent A/B. Protein concentration in cell lysates was determined by 
addition of 1 µl lysate to 399 µl reagent A/B . After incubation (30 min at 37°C) the 
optical absorbance at a wavelength of 562 nm was determined. 
For protein separation according to their molecular weight up to 20 µg protein 
lysates were mixed with 5x Laemmli sample buffer (4% SDS; 20% glycerin; 250 
mM tris, pH 6.8; 5% beta-mercaptoethanol; 0.01% bromophenolblue). Prior to 
separation in SDS polyacrylamide gels, samples were boiled (10 min at 95°C). 
Thereafter, proteins were loaded onto a SDS polyacrylamide gel comprising of a 5 
% stacking gel (250 mM tris/HCl pH 6.8, 0.1% SDS, 5% acrylamide; 0.1% APS; 
0.004% TEMED) and a 10-12% resolving gel (375 mM tris/HCl pH 8.8, 0.1% SDS, 
10-12% acrylamide; 0.1% APS; 0.004% TEMED). Prestained Protein Ladder 
(Fermentas) was used as size marker. Separation of proteins was performed in a 
Bio-Rad electrophoresis chamber for 20 minutes at 100 V and then for 1 h at 160 
V. 1xTris-Glycine SDS running buffer (25 mM tris; 1% SDS; 192 mM glycin) was 
used as the electrophoresis buffer during the stacking and resolve process. 
Subsequently, proteins in the resolving gel were transferred to a Hybond-P 
nitrocellulose membrane (Amersham) using 1x blotting buffer (20% EtOH, 80% 1x 
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SDS running buffer) and a Trans-Blot SD semi dry chamber (Bio-Rad) by applying 
an electric force of 11 V, 300 mA for 1 h. Efficient transfer and equal protein 
loadings were verified with a Ponceau S (0.1% w/v Ponceau S, 5% acetic acid) 
staining. Prior to incubation with specific antibodies, membranes were incubated in 
5% milk-powder buffer (1x PBS, 5% (w/v) non-fat milk powder, 0.2% (v/v) Tween) 
for 30 minutes. For immuno detection primary antibodies were incubated with 
membranes in 5% milk-powder solution at 4°C O/N at moderate rolling. After 
washing (3x, 10 min in 15 ml 5% milk-powder solution) membranes were 
incubated with the secondary antibody in 5% milk-powder solution (moderate 
rolling for 1 hour at RT). After washing (3x, 10 min in 15 ml 5% milk-powder 
solution) the membrane was incubated with ECL (GE Healthcare) and 
chemiluminescence was detected with a photosensitive Hyperfilm (GE 
Healthcare). 
7.4 Mice 
All mice used in this study were housed under specific pathogen-free conditions 
and were used in accordance with institutional, state and federal guidelines. All 
strains were maintained or backcrossed to a pure C57BL/6 background.  
7.4.1 Mouse breedings 
Male chimeras were bred with C57BL/6 females for germline transmission. 
Offspring carrying the targeted mutation were used for breeding with either 
B6;SJL-Tg(ACTFLPe)9205Dym/J females for recombination of Frt sites to 
generate Ebf2+/fl or with B6.C-Tg(CMV-cre)1Cgn/J females for recombination of 
LoxP sites to generate Ebf2+/Δfl mice. B6.Cg-Tg(Fabp4-cre)1Rev/J, B6.Cg-
Tg(Prrx1-cre)1Cjt/J and B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J strains were 
used in combination with Ebf2fl/fl animals for cell type-specific deletions. Animals 
were sacrificed at 3-10 weeks of age, and unless otherwise stated, at least 3 
animals were analyzed per experiment while Cre-expressing Ebf2+/fl littermates 
served as controls. 
7.4.2 Transplantation of thymic epithelial cells 
Thymic embryonic lobes (E14.5) from animals of the respective genotypes were 
placed on Isopore membrane filters (Millipore), floating on 3 ml IMDM with 1.35 
mM deoxyguanosine and were cultured for 6 days. Lobes were washed with PBS 
and transplanted under the kidney capsule of 8-12 week old C57BL/6 mice. 
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7.4.3 Transplantation of ALL cells 
Transgenic human ALL cells used in this study were kindly provided by Dr. 
Catarina Alves, (laboratory of PD Dr. Irmela Jeremias, HMGU). To report briefly, 
primary ALL cells were transduced over night with an extGLuc virus (encodes a 
membrane-bound Gaussia luciferase). The next day, infected cells were 
intravenously injected into NOD.Cg‐Prkdcscid Il2rgtm1Wjl/SzJ mice (The Jackson 
Laboratory) for expansion. When showing symptoms of sickness, mice were 
sacrificed and human transgenic ALL cells were isolated from the spleen as 
discribed (7.4.3.4).  
For co-culture experiments, 1x106 ALL cells were plated on confluent IEO and 
non-IEO stromal feeder layers in a 48-well format. Cells were cultured as 
described (7.2.7). After 1 month, cells were collected by trypsinization, washed 
and intravenously injected into NOD/scid IL-2Rgammanull mice. The following 
dilutions were injected into 3 mice each: 3x103, 3x104, 6x104, 1.3x105, 2.5x105, 
5x105, 1x106. 
7.4.3.1 In vivo imaging of B-ALL cells 
To monitor engraftment and development of B-ALL cells, mice were imaged using 
a CCD camera. To this end, aminals were anesthetized using isoflurane and each 
mouse was intravenously injected with 100 µg of native coelenterazine (Synchem 
OHG, Germany) and imaged using the IVIS Lumina II Imaging System (Caliper 
Life Sciences). Data were analyzed with Living Image Software 4.0 (Caliper Life 
Sciences) and LIC frequency was calculated using poison statistic – ELDA 
software (Hu and Smyth, 2009). 
7.4.3.2 Isolation of total bone marrow 
Total bone marrow was isolated by flushing femur and tibia with ice cold PBS. 
Single cell suspensions were generated by vigorous up and down pipetting before 
cells were passed through a 70 µm cell strainer (Falcon). 
7.4.3.3 Isolation of IEO cells from Ebf2-Gfp animals 
Hindlegs from E18.5 embryos were isolated and skin and flesh were cut away 
leaving all bones intact. The remaining tissue was removed with 2 consecutive 
incubation steps in DMEM (0.1% collagenase, Sigma-Aldrich and 0.2% dispaseII, 
Roche) for 20 minutes at 37°C in a rotating incubator. Peeled bones were washed 
with PBS and swiped clean to remove all cells from the bone surface. Thereafter 
bones were cut open with scissors and incubated 3 times for 30 minutes at 37°C in 
the described medium in a rotating incubator. Supernatants were collected. For 
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FACS sorting, stromal cells were collected by centrifugation, resuspended in FACS 
buffer and kept on ice. 
7.4.3.4 Isolation of primary lymphocytes 
Thymus and spleen were taken out as whole organs. To generate single cell 
suspensions, the organs were passed through a 70 µm cell strainer (Falcon). 
7.4.3.5 Isolation of thymic epithelium 
Thymi were taken out as whole organs and connective tissue and fat were 
removed. Using scissors, thymi were cut into very small pieces and transferred to 
1 ml dissociation medium (IMDM supplemented with 0.2% collagenase (Roche) 
and 0.2% DispaseI (Roche), 2% FCS, 25 mM HEPES (Gibco) and 25 µg/ml 
DNAse I (Roche). Next, cells were dissociated out of the extracellular matrix by 
incubation at 37°C for 50 min in a FACS tube while pipetting the solution 
vigorously up and down every 10 min. The reaction was stopped with EDTA (final 
concentration: 5 mM). Cells were filtered with a 100 µm cell strainer (Falcon), 
washed in 1x PBS, resuspended in PercollTM (GE Healthcare) and transferred to 
a FACS tube. Next, a layer of Percoll (p 1.055) and a third layer of FACS buffer 
were carefully added on top. The gradient was centrifuged (1350 g, 30 min at 4°C) 
without acceleration and brake. Cells were harvested from the upper interphase 
with a 1 ml pipette and stained as described (7.2.9). 
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Table S2: Gene expression profiles of IEO cells from Ebf2-Gfp+/- and Ebf2-Gfp-/- animals were compared by DNA microarray analysis. 
Top downgulated genes with biological relevance for the observed phenotypes are shown (downregulation is shown in -fold, values for Ebf2-Gfp+/- 
and Ebf2-Gfp-/- are average signal intensities detected for n=6 each). 
Rank Probe Symbol Ebf2-Gfp+/- Ebf2-Gfp-/- Fold change Gene name and biological function Secreted 
Trans-
membrane 
1 ILMN_2757966 Cxcl4 5977,386 1043,154 5,730108881 C-X-C motif chemokine 4, interacts with integrins, promotes blood coagulation +   
2 ILMN_1241001 Eif2s3y 1374,429 250,0238 5,497192667 Eukaryotic translation initiation factor 2, essential for spermatogenesis    
3 ILMN_1259174 Scin 2611,352 550,4852 4,743727897 Scinderin, fibroblast motility, actin remodeling    
4 ILMN_2436424 Igl-5 1684,717 375,1085 4,49127919 Immunoglobulin Lambda Like Polypeptide 5 (IGlL5)    
5 ILMN_2776603 Ccl9 1356,672 306,6503 4,424166551 Chemokine (C-C motif) ligand 9, cytokine, activates osteoclasts through CCR1 +   
6 ILMN_2599233 Scrg1 4102,959 1036,546 3,958299005 Stimulator of chondrogenesis 1, associated with the secretory pathway    
7 ILMN_2609590 Cpa3 1204,255 317,3775 3,794393112 Carboxypeptidase A3, expressed in mast cells    
8 ILMN_3160137 Aldoc 1082,401 295,9504 3,657372992 Aldolase C, expressed in hippocampus and purkinje cells    
9 ILMN_2737685 Mmp13 7804,528 2257,042 3,457856788 Collagenase 3, extracellular matrix remodeling factor +   
10 ILMN_1226525 H2-Ab1 1332,837 394,7888 3,376076018 Histocompatibility 2 class II antigen A beta 1   x 
11 ILMN_1251248 Ebf2 1346,926 409,7955 3,28682477 Early B cell factor 2, transcription, multicellular organismal development    
12 ILMN_2617468 Chac1 4082,72 1261,296 3,23692456 Cation transport regulator-like 1, pro-apoptotic component of the unfolded protein response pathway    
13 ILMN_2711075 Mmp9 5317,391 1687,816 3,150456566 Matrix Metalloproteinase 9, extracellular matrix remodeling factor +   
14 ILMN_2721052 Panx3 5974,231 1896,88 3,149503922 Pannexin 3, gap junction protein, target of Runx2, bone development   x 
15 ILMN_2883606 Ebf2 1950,457 619,8492 3,146663737 Early B cell factor 2, transcription, multicellular organismal development    
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16 ILMN_2991799 Cpa3 807,1603 271,0061 2,97838425 Carboxypeptidase A3, expressed in mast cells    
17 ILMN_1219686 Esd 6177,165 2075,97 2,975556005 Esterase D, formylgluthatione hydrolase, possibly involved in recycling of sialic acids    
18 ILMN_2678421 Pcolce2 1647,099 574,4349 2,86733797 Procollagen C-endopeptidase enhancer 2, extracellular matrix remodeling factor +   
19 ILMN_2565942 B930011A14Rik 972,8411 351,8075 2,76526538 Uncharacterized     
20 ILMN_2940568 Epyc 4780,46 1731,87 2,760288012 Dermatan sulfate proteoglycan 3, extracellular matrix remodeling factor +   
21 ILMN_2738082 Adipoq 1911,28 711,1412 2,68762378 Adiponectin, fat metabolism and insulin sensitivity, HSC proliferation +   
22 ILMN_2965669 Xlr4a 5993,713 2269,566 2,640907116 X-linked lymphocyte-regulated 4A, uncharacterized     
23 ILMN_1222219 2610528A11Rik 724,238 274,9014 2,634537329 Uncharacterized     
24 ILMN_2597332 1700123O20Rik 3191,948 1216,086 2,624771603 Uncharacterized     
25 ILMN_2498263 Hspa1b 999,5281 381,4258 2,620504696 Heat shock 70 kDa protein 1B, protein stabilization    
26 ILMN_2967037 Gpr1 790,0399 302,8622 2,608578753 G protein-coupled receptor 1, Receptor for the inflammation-associated RARRES2    x 
27 ILMN_2472730 Zfp533 2100,802 820,4057 2,560686743 DNA binding protein, expressed in cardiomyocytes    
28 ILMN_2742861 Serpina3f 844,4957 331,9901 2,543737599 Serine (or cysteine) peptidase inhibitor clade A member 3F +   
29 ILMN_1231274 Cmtm5 1380,55 559,494 2,467497417 CKLF-like MARVEL transmembrane domain containing 5, chemokine-like factor   x 
30 ILMN_1227663 Sgms2 1990,848 815,4755 2,441333921 Sphingomyelin synthase 2, phosphatidylcholine metabolism, cell-signaling   x 
31 ILMN_1251748 Pscdbp 1109,768 457,7377 2,424462744 Cytohesin 1 interacting protein, modulates the activation of ARF genes    
32 ILMN_2613601 2010001M09Rik 683,9405 285,2767 2,397463585 Uncharacterized     
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33 ILMN_2485323 Trf 781,2725 331,5245 2,35660562 Telomeric repeat binding factor, inhibitor of telomerase    
34 ILMN_2848906 Rlbp1 521,5691 223,1512 2,337290142 Retinaldehyde binding protein 1, soluble retinoid carrier    
35 ILMN_2753342 Hapln1 3705,211 1603,295 2,310997664 Hyaluronan and proteoglycan link protein 1, extracellular matrix remodeling factor +   
36 ILMN_2917280 Efcab1 1563,575 677,7128 2,307135117 EF-hand calcium binding domain 1, possibly calcium ion binding     
37 ILMN_1250001 4930583H14Rik 3901,56 1698,32 2,297305573 Uncharacterized     
38 ILMN_2613878 Prg2 1576,918 692,7039 2,276467622 Proteoglycan 2, immune response, defense response to bacterium +   
39 ILMN_2788223 Kng1 1109,352 491,8 2,255697438 Kininogen 1, inhibitor of thiol proteases +   
40 ILMN_2944824 Hp 1981,691 882,7574 2,24488744 Haptoglobin, combines with free plasma hemoglobin to prevent damage +   
41 ILMN_2625377 Rgs1 450,0417 201,1044 2,237851086 Regulator of G-protein signaling 1, signal transduction   x 
42 ILMN_1218240 Cd69 555,3282 249,3483 2,227118452 CD69 molecule, calcium dependent lectin superfamily type II transmembrane receptor   x 
43 ILMN_1257051 Glt25d2 1004,469 451,8425 2,223051174 Glycosyltransferase 25 domain containing 2, extracellular matrix remodeling factor +   
44 ILMN_2607675 LOC641240 786,2088 355,908 2,209022556 Uncharacterized     
45 ILMN_3006123 Asns 1239,171 567,0882 2,185146861 Asparagine synthetase, uncharacterized     
46 ILMN_2988143 Plac8 2548,588 1192,105 2,13788886 Placenta-specific 8    
47 ILMN_2913716 H2-Ab1 537,9681 253,126 2,125297678 Histocompatibility 2, class II antigen A, beta 1   x 
48 ILMN_2749037 Ndg2 1097,461 525,4182 2,088738076 Coiled-coil-helix-coiled-coil-helix domain containing 10, uncharacterized     
49 ILMN_1241695 Ms4a6d 535,6003 256,5482 2,087718019 Membrane-spanning 4-domains, subfamily A, member 6E, signal transduction   x 
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50 ILMN_2846485 Vpreb1 1597,234 771,2458 2,070979187 Pre-B lymphocyte 1, associates with the Ig-mu chain    
51 ILMN_2772845 Cat 887,3517 428,8466 2,069158762 Catalase, defense against oxidative stress    
52 ILMN_2548302 2210017A09Rik 541,1469 261,5438 2,069048855 Uncharacterized     
53 ILMN_1227907 Gmfg 639,8651 310,062 2,063668234 Glia maturation factor gamma, nerve growth factor, possibly involved in angiogenesis    
54 ILMN_2827729 Calb2 429,2529 208,4879 2,058886391 Calbindin 2, message targeting and intracellular calcium buffering    
55 ILMN_2703182 Lgals7 2172,209 1064,097 2,04136371 Lectin galactoside-binding soluble 7, cell-cell and/or cell-matrix interactions   x 
56 ILMN_2866856 H2-DMa 945,5711 464,325 2,036442363 Histocompatibility 2 class II locus Dma, antigen presenting cell function   x 
57 ILMN_2787257 Coro1a 1003,122 497,3518 2,016926449 Coronin actin binding protein 1A, possibly a component of the cytoskeleton    
58 ILMN_2627546 LOC677369 500,382 248,5185 2,013459763 Uncharacterized     
59 ILMN_1227240 Cdkn2b 797,5409 396,5067 2,01141847 CDKN2B antisense RNA 1, uncharacterized     
60 ILMN_2737302 Cxcl12 1805,92 900,9241 2,004519582 Chemokine (C-X-C motif) ligand 12, SDF-1, chemokine +   
61 ILMN_2754940 LOC100047808 664,4418 331,8748 2,002085726 Uncharacterized     
62 ILMN_3158250 Cxcl12 1253,633 631,1554 1,98625093 Chemokine (C-X-C motif) ligand 12, SDF-1, chemokine +   
63 ILMN_2440194 5330423I11Rik 687,5683 346,9864 1,981542504 Uncharacterized     
64 ILMN_1225528 Trib3 2921,41 1476,323 1,978842028 Tribbles homolog 3, putative protein kinase that is induced by NF-kappaB    
65 ILMN_1221146 Cytl1 2962,408 1499,702 1,975331099 Cytokine-like 1, putative cytokine expressed in bone marrow cells +   
66 ILMN_2613832 Mgst2 1296,353 657,7356 1,970933305 Microsomal glutathione S-transferase 2, eicosanoid and glutathione metabolism    
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67 ILMN_3007428 Sox9 2445,267 1252,027 1,95304654 SRY, transcription factor required for normal skeletal development    
68 ILMN_2609813 Chi3l1 1706,275 874,1982 1,951817105 Chitinase 3-like 1, possibly involved in inflammation and tissue remodeling +   
69 ILMN_2725927 Serpina3g 4443,392 2294,676 1,936391891 Serpin peptidase inhibitor, clade A member 3, inhibits neutrophil cathepsin G +   
70 ILMN_1222471 Gmfg 556,176 287,7134 1,93309036 Glia maturation factor, gamma, uncharacterized     
71 ILMN_2855310 Mpl 461,7367 239,0909 1,93121821 Myeloproliferative leukemia virus oncogene, receptor for thrombopoietin   x 
72 ILMN_1229301 LOC676779 1539,94 798,1091 1,92948558 Uncharacterized     
73 ILMN_2523169 Treml1 506,7372 263,2628 1,924834044 Triggering receptor expressed on myeloid cells-like protein 1, calcium signaling   x 
74 ILMN_1221526 LOC100041516 995,4444 517,3671 1,924058178 Uncharacterized     
75 ILMN_1240728 Sh3tc2 444,1233 231,3192 1,919958655 SH3 domain and tetratricopeptide repeats 2, expressed in brain and spinal cord    
76 ILMN_2538597 LOC386405 1049,396 546,7166 1,919451504 Uncharacterized     
77 ILMN_2954824 Ppp1r1b 1168,207 609,2021 1,917601729 Protein phosphatase 1 regulatory (inhibitor) subunit 1B, signal transduction -   
78 ILMN_2734097 Btc 755,3676 394,0275 1,917042846 Betacellulin, ligand for EGF receptor  +   
79 ILMN_1217849 Laptm5 9898,646 5180,909 1,910600244 Lysosomal protein transmembrane 5, receptor associated with lysosomes     
80 ILMN_1230680 D130057F13Rik 1930,368 1014,34 1,903077863 Uncharacterized     
81 ILMN_2723965 Edn2 477,9507 251,3001 1,901912096 Endothelin 2,  initiate intracellular signaling events through endothelin receptors    x 
82 ILMN_1259069 F730003H07Rik 6085,027 3200,338 1,901370105 Uncharacterized     
83 ILMN_1215877 Extl1 628,6032 331,4048 1,896783631 Exostoses (multiple)-like 1, alpha 1,4- N-acetylglucosaminyltransferase -   
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84 ILMN_1247592 Casp1 461,491 246,292 1,873755542 Caspase 1, apoptosis- and inflammation-related cysteine peptidase -   
85 ILMN_1229397 Slc1a1 852,5682 457,7504 1,862517652 Solute carrier family 1, transport of L-glutamate and also L- and D-aspartate  -   
86 ILMN_2695199 St3gal6 5493,285 2955,622 1,85858848 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 -   
87 ILMN_2730311 2610017I09Rik 593,4163 319,7457 1,855900799 Uncharacterized     
88 ILMN_2889899 Glt25d2 504,2467 272,9079 1,847680848 Glycosyltransferase 25 domain containing 2, extracellular matrix remodeling factor +   
89 ILMN_2716389 Smpd3 887,7005 483,4326 1,836244597 Sphingomyelin phosphodiesterase 3, bone and dentin mineralization +   
90 ILMN_2653132 Clec7a 522,2294 285,4149 1,829720172 C-type lectin domain family 7 member A, type II membrane receptor   x 
91 ILMN_2610822 Cd79b 547,951 301,2274 1,819060949 CD79b molecule, Ig-beta protein of the B-cell antigen component   x 
92 ILMN_2627013 Zfp710 637,1771 350,8797 1,81594176 Zinc finger protein 710, uncharacterized     
93 ILMN_2874084 Car9 2668,724 1471,358 1,813782913 Carbonic anhydrase IX, calcification and bone resorption   x 
94 ILMN_2728729 Sdc4 3925,287 2164,892 1,813156037 Syndecan 4, proteoglycan that functions in intracellular signaling + x 
95 ILMN_2643513 Asns 4651,297 2566,063 1,812619955 Asparagine synthetase,     
96 ILMN_1251713 Car12 3459,468 1918,224 1,803474464 Carbonic anyhydrase 12, calcification and bone resorption   x 
97 ILMN_1257987 Slc7a3 727,1462 404,3141 1,798468567 Solute carrier family 7 member 3, mediates arginine uptake   x 
98 ILMN_2578681 C130080K17Rik 1193,022 664,4159 1,795595199 Uncharacterized +   
99 ILMN_2630852 Il7 444,9789 247,8374 1,795446934 Interleukin 7, essential role in lymphoid cell survival +   
100 ILMN_2538242 LOC386144 11278,48 6286,563 1,794061397 Uncharacterized     
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8.2 Supplementary figures 
 
 
 
Figure S2: PCR analysis of gDNA, isolated from bone marrow cells of PrxCreEbf2fl/fl 
mice. Long bones of two ten-week-old PrxCreEbf2fl/fl mice were flushed with PBS and flesh 
on the bone surface was thoroughly removed using scissors and a scalpel. Next, the 
empty bones were crushed and cells from the inner bone surface were lyzed in 1 ml tail 
buffer at 56°C overnight. Thereafter, a PCR was performed (35 cycles) and the Ebf2 
recombined allele (a), Ebf2 conditional allele (b) and the Cre recombinase gene (c) could 
be detected on a 2% agarose gel (- = empty lane, pc = positive control, wt = wild type, H20 
= water). 
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Figure S3: PCR analysis of gDNA, isolated from bone marrow cells or adipose 
tissue of AP2CreEbf2fl/fl mice. Long bones of two ten-week-old AP2CreEbf2fl/fl mice were 
flushed with PBS and cells were harvested by centrifugation. Next, cells were 
resuspended and lyzed in 1 ml tail buffer at 56°C overnight. Meanwhile, small pieces of 
subcutaneous fat were isolated from the mouse neck and waist region and the tissue was 
lyzed in 1 ml tail buffer at 56°C overnight. Thereafter, a PCR was performed (35 cycles) 
and the Ebf2 recombined allele (a, b), Ebf2 conditional allele (c) and the Cre recombinase 
gene (d) could be detected on a 2% agarose gel (- = empty lane, pc = positive control, wt 
= wild type, H20 = water). 
 
 
 
Figure S4: FACS sorting of IEO cells. Generally, timed matings between Ebf2-Gfp+/- 
animals were setup. Males and females were put together on afternoons. Plugs were 
checked the next morning. Eighteen days later (E18.5) pregnant females were sacrificed 
and osteoblastic cell fractions were isolated as described elsewhere (7.4.3.3). For FACS 
sorting, cells were gated on stromal cells in FSC/SSC. Doublets were excluded in 
FSC/SSC-H (not shown). IEO cells are Gfp positive and were sorted into reaction tubes 
with medium or trizol. 
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Figure S5: Ebf2Δfl/Δfl animals were born at very low frequencies. To test the newly 
generated mouse model, breedings of Ebf2+/Δfl mice were set up to generate Ebf2Δfl/Δfl 
animals. From 13 litters, 98 animals were born. Many pups were found dead after birth. In 
total, 3 Ebf2Δfl/Δfl animals reached the age of three weeks. 
 
 
 
Figure S6: Indication of reduced angiogenesis and subcutaneous fat in Ebf2Δfl/Δfl 
animals. Upper images were taken from a wild type littermate, lower images show an 
Ebf2Δfl/Δfl animal. Left fotos were taken from the rip cage. Right images show ventral view 
on pelvis. Red arrowheads point to subcutaneous fat, black arrowheads point to absent or 
reduced blood vessels (analysis was performed once). 
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Figure S7: Fetal liver HSCs proliferate more on Ebf2-expressing IEO cells. Fetal liver 
HSCs (Lin-, Mac1+, Sca1+) from wild type mice were FACS sorted and cultured in RPMI 
(10% FCS, 1% Glutamine) without addition of cytokines with IEO-Ebf2+/- and IEO-Ebf2-/- 
cells for 10 days. Cells were counted using a CASY Cell counter (experiment was 
performed once). 
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